薬生薬審発 0418 第１号
令 和 ４ 年 ４ 月 １８ 日

各都道府県衛生主管部（局）長　殿

厚生労働省医薬・生活衛生局医薬品審査管理課長
（　　公　　印　　省　　略　　）

医薬品の一般的名称について

標記については、「医薬品の一般的名称の取扱いについて（平成 18 年３月 31 日薬食発第 0331001 号厚生労働省医薬食品局長通知）」等により取り扱っているところです。今般、我が国における医薬品の一般的名称（以下「JAN」という。）について、新たに別添のとおり定めたので、御了知の上、貴管下関係業者に周知方よろしく御配慮願います。

（参照）
「日本医薬品一般的名称データベース」https://jpdb.nihs.go.jp/jan/Default.aspx
（別添の情報のうち、JAN 以外の最新の情報は、当該データベースの情報で対応することとしています。）

別添


（別表２）INN に収載された品目の我が国における医薬品一般的名称


（平成 18 年 3 月 31 日薬食審査発第 0331001 号厚生労働省医薬食品局審査管理課長通知に示す別表２）

登録番号　303-1-B6


JAN（日本名）：ジルコプランナトリウム

JAN（英　名）：Zilucoplan Sodium







NMeAsp




Tle



AzaTrp



Chg



Lys*(EG$_{24}$-Glu*-Palm)

* 酸性基を持つアミノ酸残基．1つの酸性基にはプロトン化されたアルギニン側鎖が結合し，
4つの酸性基にはナトリウムイオンがそれぞれ1つずつ結合している．

$C_{172}H_{274}N_{24}Na_4O_{55}$

ジルコプランナトリウムは，ジルコプランの四ナトリウム塩である．ジルコプランは化学修飾された合成環状ペプチドで，ヒト補体 C5 に結合する．ペプチド部分は 15 個のアミノ酸残基からなり，15 番目の Lys 残基は修飾されている．化学名は以下の通りである．

N^2-アセチル-L-リシル-L-バリル-L-α-グルタミル-L-アルギニル-L-フェニルアラニル-L-α-アスパルチル-*N*-メチル-L-α-アスパルチル-3-メチル-L-バリル-L-チロシル-3-(1*H*-ピロロ[2,3-*b*]ピリジン-3-イル)-L-アラニル-L-α-グルタミル-L-チロシル-L-プロリル-(2*S*)-2-シクロヘキシルグリシル-*N*^{6}-(3-{ω-[(*N*-ヘキサデカノイル-L-γ-グルタミル)アミノ]テトラコサキス(オキシエチレン)-α-イル}プロパノイル)-L-リシン　(6→1^6)-ラクタム　四ナトリウム塩


Zilucoplan Sodium is tetrasodium salt of Zilucoplan. Zilucoplan is a chemically modified synthetic cyclic peptide that binds to human complement C5. The peptide moiety consists of 15 amino acid residues, and Lys residue at position 15 is modified. Chemical name is as follows:

Tetrasodium salt of N^2-acetyl-L-lysyl-L-valyl-L-α-glutamyl-L-arginyl-L-phenylalanyl-L-α-aspartyl-*N*-methyl-L-α-aspartyl-3-methyl-L-valyl-L-tyrosyl-3-(1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-L-alanyl-L-α-glutamyl-L-tyrosyl-L-prolyl-(2*S*)-2-cyclohexylglycyl-N^6-(3-{ω-[(*N*-hexadecanoyl-L-γ-glutamyl)amino]tetracosakis(oxyethylene)-α-yl}propanoyl)-L-lysine (6→1^6)-lactam

登録番号　303-3-B3

JAN（日本名）：レナカパビルナトリウム

JAN（英　名）：Lenacapavir Sodium



$C_{39}H_{31}ClF_{10}N_7NaO_5S_2$


[4-クロロ-7-{2-[(1*S*)-1-{2-[(3b*S*,4a*R*)-5,5-ジフルオロ-3-(トリフルオロメチル)-3b,4,4a,5-テトラヒドロ-1*H*-シクロプロパ[3,4]シクロペンタ[1,2-*c*]ピラゾール-1-イル]アセトアミド}-2-(3,5-ジフルオロフェニル)エチル]-6-[3-(メタンスルホニル)-3-メチルブタ-1-イン-1-イル]ピリジン-3-イル}-1-(2,2,2-トリフルオロエチル)-1*H*-インダゾール-3-イル](メタンスルホニル)アザニド一ナトリウム

Monosodium [4-chloro-7-{2-[(1*S*)-1-{2-[(3b*S*,4a*R*)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1*H*-cyclopropa[3,4]cyclopenta[1,2-*c*]pyrazol-1-yl]acetamido}-2-(3,5-difluorophenyl)ethyl]-6-[3-(methanesulfonyl)-3-methylbut-1-yn-1-yl]pyridin-3-yl}-1-(2,2,2-trifluoroethyl)-1*H*-indazol-3-yl](methanesulfonyl)azanide

登録番号　303-3-B4

JAN（日本名）：ボクロスポリン

JAN（英　名）：Voclosporin



$C_{63}H_{111}N_{11}O_{12}$

シクロ{[(2*S*,3*R*,4*R*,6*E*)-3-ヒドロキシ-4-メチル-2-(メチルアミノ)ノナ-6,8-ジエノイル]-L-2-アミノブタノイル-*N*-メチルグリシル-*N*-メチル-L-ロイシル-L-バリル-*N*-メチル-L-ロイシル-L-アラニル-D-アラニル-*N*-メチル-L-ロイシル-*N*-メチル-L-ロイシル-*N*-メチル-L-バリル}

Cyclo{[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl]-L-2-aminobutanoyl-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl}

登録番号　303-3-B5

JAN（日本名）：ダトポタマブ　デルクステカン（遺伝子組換え）

JAN（英　名）：Datopotamab Deruxtecan (Genetical Recombination)

アミノ酸配列及びジスルフィド結合

H鎖


```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW    50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG   100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV   150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ   200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK   250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY   300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP   350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP   400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG   450
K                                                        451
```

L鎖


```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS    50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ   100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV   150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG   200
LSSPVTKSFN RGEC                                          214
```

H鎖 Q1：部分的ピログルタミン酸；H鎖 C224，H鎖 C230，H鎖 C233，L鎖 C214：薬物結合可能部位；
H鎖 N301：糖鎖結合；H鎖 K451：部分的プロセシング
H鎖 C224－L鎖 C214，H鎖 C230－H鎖 C230，H鎖 C233－H鎖 C233：ジスルフィド結合

主な糖鎖の推定構造



デルクステカン部位の構造式



n は平均 4 である

*抗体部分のシステイン残基の硫黄原子

$C_{6464}H_{9984}N_{1708}O_{2016}S_{44}$（タンパク質部分，4 本鎖）

H 鎖 $C_{2199}H_{3392}N_{580}O_{674}S_{16}$

L 鎖 $C_{1033}H_{1604}N_{274}O_{334}S_{6}$


ダトポタマブ　デルクステカンは，抗体薬物複合体（分子量 : 約 152,000）であり，遺伝子組換えモノクローナル抗体の平均 4 個のシステイン残基に，カンプトテシン誘導体とリンカーからなるデルクステカン（(3*RS*)-1-[(10*S*)-10-ベンジル-1-{[(1*S*,9*S*)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1*H*,12*H*-ベンゾ[*de*]ピラノ[3',4':6,7]インドリジノ[1,2-*b*]キノリン-1-イル]アミノ}-1,6,9,12,15,18-ヘキサオキソ-3-オキサ-5,8,11,14,17-ペンタアザトリコサン-23-イル]-2,5-ジオキソピロリジン-3-イル基（$C_{52}H_{57}FN_9O_{13}$；分子量 : 1,035.06））が結合している．抗体部分は抗細胞表面糖タンパク質 Trop-2 モノクローナル抗体であり，その相補性決定部はマウス抗体に，その他はヒト IgG1 に由来し，CHO 細胞により産生される．タンパク質部分は，451 個のアミノ酸残基からなる H 鎖（γ1 鎖）2 本及び 214 個のアミノ酸残基からなる L 鎖（κ 鎖）2 本で構成される糖タンパク質（分子量 : 約 148,000）である．

Datopotamab Deruxtecan is an antibody-drug-conjugate (molecular weight: ca. 152,000) consisting of deruxtecan ((3*RS*)-1-[(10*S*)-10-benzyl-1-{[(1*S*,9*S*)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1*H*,12*H*-benzo[*de*]pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl group ($C_{52}H_{57}FN_9O_{13}$; molecular weight: 1,035.06)), which is composed of camptothecin derivative and linker, attached to an average of four cysteine residues of a recombinant monoclonal antibody. The antibody moiety is an anti-cell surface glycoprotein Trop-2 monoclonal antibody, the complementarity-determining regions of which are derived from mouse antibody and other regions are derived from human IgG1 and produced in CHO cells. The protein moiety is a glycoprotein (molecular weight: ca. 148,000) composed of 2 H-chains (γ1-chains) consisting of 451 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

登録番号　303-3-B6

JAN（日本名）：インスリン　イコデク（遺伝子組換え）

JAN（英　名）：Insulin Icodec (Genetical Recombination)



$C_{280}H_{435}N_{71}O_{87}S_6$（修飾を含む，2本鎖）

A鎖　$C_{95}H_{151}N_{25}O_{36}S_4$

B鎖　$C_{185}H_{288}N_{46}O_{51}S_2$（修飾を含む）


インスリン　イコデクは，遺伝子組換えヒトインスリン類縁体であり，3個のアミノ酸残基（A鎖：Y14E，B鎖：Y16H，F25H）が置換され，B鎖C末端のT30は除去され，B鎖K29のε-アミノ基が(22*S*)-22,42-ジカルボキシ-10,19,24-トリオキソ-3,6,12,15-テトラオキサ-9,18,23-トリアザドテトラコンタン-1-オイル基でアシル化されている．インスリン　イコデクは，21個のアミノ酸残基からなるA鎖及び29個のアミノ酸残基からなるB鎖から構成される修飾ペプチドである．

Insulin Icodec is a recombinant human insulin analogue, in which amino acid residues are substituted at 3 positions (A-chain: Y14E, B-chain: Y16H, F25H), C-terminal T30 of B-chain is deleted, and the ε-amino group of K29 of B-chain is acylated with (22*S*)-22,42-dicarboxy-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazadotetracontan-1-oyl group. Insulin Icodec is a modified peptide composed of an A-chain consisting of 21 amino acid residues and a B-chain consisting of 29 amino acid residues.

登録番号　303-3-B7

JAN（日本名）：ザヌブルチニブ

JAN（英　名）：Zanubrutinib



$C_{27}H_{29}N_5O_3$


(7*S*)-2-(4-フェノキシフェニル)-7-[1-(プロパ-2-エノイル)ピペリジン-4-イル]-4,5,6,7-テトラヒドロピラゾロ[1,5-*a*]ピリミジン-3-カルボキシアミド

(7*S*)-2-(4-Phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

登録番号　303-3-B8

JAN（日本名）：マリバビル

JAN（英　名）：Maribavir



$C_{15}H_{19}Cl_2N_3O_4$


5,6-ジクロロ-2-(プロパン-2-イルアミノ)-1-β-L-リボフラノシル-1*H*-ベンゾイミダゾール

5,6-Dichloro-2-(propan-2-ylamino)-1-β-L-ribofuranosyl-1*H*-benzimidazole

登録番号　303-3-B9

JAN（日本名）：ペグセタコプラン

JAN（英　名）：Pegcetacoplan



nは約800~1100である.

$C_{170}H_{248}N_{50}O_{47}S_4$（ペプチド部分）

ペグセタコプランはPEG化ペプチド（分子量：約43,500）であり，補体C3に結合する2本の同一の合成ペプチドが，C末端リシンアミドのε-アミノ基を介してポリエチレングリコール（分子量：約39,600）の両端にそれぞれ結合している．ペプチド部分は15個のアミノ酸残基からなる．化学名は以下の通りである．

O,*O*'-ビス[(S^2,S^{12}-シクロ{*N*-アセチル-L-イソロイシル-L-システイニル-L-バリル-1-メチル-L-トリプトフィル-L-グルタミニル-L-α-アスパルチル-L-トリプトフィルグリシル-L-アラニル-L-ヒスチジル-L-アルギニル-L-システイニル-L-スレオニル-2-[2-(2-アミノエトキシ)エトキシ]アセチル-L-リシンアミド})-$N^{6\,15}$-カルボニル]ポリエチレングリコール


Pegcetacoplan is a PEGylated peptide (molecular weight: ca. 43,500) in which two identical synthetic peptides that bind to complement C3 are bound to each terminal of polyethylene glycol (molecular weight: ca. 39,600) via ε-amino group of C-terminal lysine amide. The peptide moiety consists of 15 amino acid residues. Chemical name is as follows:

O,*O*'-Bis[(S^2,S^{12}-cyclo{*N*-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-α-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-L-lysinamide})-$N^{6\,15}$-carbonyl]polyethylene glycol

登録番号　303-3-B10

JAN（日本名）：プラルセチニブ水和物

JAN（英　名）：Pralsetinib Hydrate



$C_{27}H_{32}FN_9O_2 \cdot H_2O$


cis-*N*-{(1*S*)-1-[6-(4-フルオロ-1*H*-ピラゾール-1-イル)ピリジン-3-イル]エチル}-1-メトキシ-4-{4-メチル-6-[(5-メチル-1*H*-ピラゾール-3-イル)アミノ]ピリミジン-2-イル}シクロヘキサン-1-カルボキシアミド　一水和物

cis-*N*-{(1*S*)-1-[6-(4-Fluoro-1*H*-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide monohydrate

登録番号　303-3-B11

JAN（日本名）：ベルズチファン

JAN（英　名）：Belzutifan



$C_{17}H_{12}F_3NO_4S$


3-{[(1*S*,2*S*,3*R*)-2,3-ジフルオロ-1-ヒドロキシ-7-(メタンスルホニル)-2,3-ジヒドロ-1*H*-インデン-4-イル]オキシ}-5-フルオロベンゾニトリル

3-{[(1*S*,2*S*,3*R*)-2,3-Difluoro-1-hydroxy-7-(methanesulfonyl)-2,3-dihydro-1*H*-inden-4-yl]oxy}-5-fluorobenzonitrile

登録番号　303-4-B1

JAN（日本名）：シボピキサント

JAN（英　名）：Sivopixant



$C_{25}H_{22}ClN_5O_5$

(2*S*)-3-[(4*E*)-3-[(4-クロロフェニル)メチル]-2,6-ジオキソ-4-({4-[(ピリジン-2-イル)オキシ]フェニル}イミノ)-1,3,5-トリアジナン-1-イル]-2-メチルプロパン酸

(2*S*)-3-[(4*E*)-3-[(4-Chlorophenyl)methyl]-2,6-dioxo-4-({4-[(pyridin-2-yl)oxy]phenyl}imino)-1,3,5-triazinan-1-yl]-2-methylpropanoic acid

登録番号　303-4-B2

JAN（日本名）：チスレリズマブ（遺伝子組換え）


JAN（英　名）：Tislelizumab (Genetical Recombination)

アミノ酸配列及びジスルフィド結合

H 鎖




L 鎖



H 鎖 Q1：部分的ピログルタミン酸；H 鎖 N295：糖鎖結合；H 鎖 K445：部分的プロセシング

H 鎖 C132－L 鎖 C214，H 鎖 C224－H 鎖 C224，H 鎖 C227－H 鎖 C227：ジスルフィド結合

主な糖鎖の推定構造



$C_{6410}H_{9890}N_{1686}O_{2012}S_{40}$（タンパク質部分，4 本鎖）

H 鎖　$C_{2166}H_{3353}N_{567}O_{670}S_{14}$

L 鎖　$C_{1039}H_{1596}N_{276}O_{336}S_{6}$

チスレリズマブは，遺伝子組換え抗 PD-1 モノクローナル抗体であり，その相補性決定部はマウス抗体に由来し，その他はヒト IgG4 に由来する．H 鎖の 6 個のアミノ酸残基が置換（S226P，E231P，F232V，L233A，D263A，R407K）されている．チスレリズマブは，CHO 細胞により産生される．チスレリズマブは，445 個のアミノ酸残基からなる H 鎖（γ4 鎖）2 本及び 214 個のアミノ酸残基からなる L 鎖（κ 鎖）2 本で構成される糖タンパク質（分子量：約 147,000）である．

Tislelizumab is a recombinant anti-PD-1 monoclonal antibody, the complementarity-determining regions of which are derived from mouse antibody and other regions are derived from human IgG4. In the H-chain, the amino acid residues are substituted at 6 positions (S226P, E231P, F232V, L233A, D263A, R407K). Tislelizumab is produced in CHO cells. Tislelizumab is a glycoprotein (molecular weight: ca. 147,000) composed of 2 H-chains (γ4-chains) consisting of 445 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

※　JAN 以外の情報は、参考として掲載しました。

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 84

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–1117) and Recommended (1–78) International Nonproprietary Names can be found in *Cumulative List No. 17, 2017* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 84

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la *Liste récapitulative No. 17, 2017* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 84


De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en *Cumulative List No. 17, 2017* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acidum aligomanuxicum

aligomanuxic acid	*O*-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]-(1→3)-D-mannaric, -(1→2)-D-arabinaric, -(1→3)-D-arabinaric, (1→2)-D-erythraric, -(1→2)-D-threaric, and -(1→2)-glyceraric acids, produced from alginates of brown seaweeds by acid-catalysed partial hydrolysis, isolation of oligomannuronans and oxidation of the reducing end group
acide aligomanuxique	acides *O*-[oligo-(1→4)-β-D-mannopyranuronan-β-osyl]-(1→3)-D-mannarique, -(1→2)-D-arabinarique, -(1→3)-D-arabinarique, (1→2)-D-érythrarique, -(1→2)-D-thréarique, et -(1→2)-glycérarique, produits à partir d'algues brunes par hydrolyse partielle par catalyse acide, isolation des oligomannuronanes et oxydation du groupe réducteur terminal
ácido aligomanúxico	ácidos *O*-[oligo-(1→4)-β-D-manopiranuronan-β-osil]-(1→3)-D-manárico, -(1→2)-D-arabinárico, -(1→3)-D-arabinárico, (1→2)-D-eritrárico, -(1→2)-D-treárico, y -(1→2)-glicerárico, producido a partir de algas pardas por hidrólisis parcialmente por catálisis ácida, aislamiento de los oligomanuronanos y oxidación del grupo reductor terminal


$(C_6H_8O_6)_n\ (CH_2O)_{m+m'}\ C_3H_4O_5$



acidum norucholicum

norucholic acid	3α,7β-dihydroxy-24-nor-5β-cholan-23-oic acid
acide norucholique	acide 3α,7β-dihydroxy-24-nor-5β-cholan-23-oïque
ácido norucólico	ácido 3α,7β-dihidroxi-24-nor-5β-colan-23-oico

$C_{23}H_{38}O_4$




acoramidisum

acoramidis — 3-[3-(3,5-dimethyl-1*H*-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid

acoramidis — acide 3-[3-(3,5-diméthyl-1*H*-pyrazol-4-yl)propoxy]-4-fluorobenzoïque

acoramidis — ácido 3-[3-(3,5-dimetil-1*H*-pirazol-4-il)propoxi]-4-fluorobenzoico

$C_{15}H_{17}FN_2O_3$



adebrelimabum #

adebrelimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], monoclonal antibody;
gamma4 heavy chain (1-446) [VH (*Homo sapiens* IGHV1-46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), hinge 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfide with kappa light chain (1'-218') [V-KAPPA (*Mus musculus* IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

adébrélimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal;

chaîne lourde gamma4 (1-446) [VH (*Homo sapiens* IGHV1-46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), charnière 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA (*Mus musculus* IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

adebrelimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal;
cadena pesada gamma4 (1-446) [VH (*Homo sapiens* IGHV1-46*01 (89.8%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1-119) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (120-217), bisagra 1-12 S10>P (227) (218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA (*Mus musculus* IGKV3-5*01 (84.8%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV4-1*01 (68.3%) -IGKJ2*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dímero (225-225":228-228")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMHWVRQA PGQGLEWMGR  50
IGPNSGFTSY NEKFKNRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGG 100
SSYDYFDYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAS LAVSPGQRAT ITCRASESVS IHGTHLMHWY QQKPGQPPKL  50
LIYAASNLES GVPARFSGSG SGTDFTLTIN PVEAEDTANY YCQQSFEDPL 100
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	260-320	366-424
	22"-96"	146"-202"	260"-320"	366"-424"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (CH1 10-CL 126)	133-218'	133"-218'"		
Inter-H-H (h 8, h 11)	225-225"	228-228"		

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

afamitresgenum autoleucelum #

afamitresgene autoleucel	Autologous CD4+ and CD8+ T cells obtained by leukapheresis, transduced with an HIV-derived self-inactivating (SIN) lentiviral vector, encoding an enhanced-affinity T cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE family member A4, antigen MAGE A4) HLA-A*02 peptide driven by the elongation factor 1 alpha (EF1α) promoter. Cells express lymphonode-homing markers CCR7 and CD62L, CD45 isoforms CD45RA and CD45R0, co-stimulatory markers CD27 and CD28, IL-7 receptor CD127, and chemokine receptor CXCR3. Cells secrete interleukin 2 (IL-2), tumor necrosis factor α (TNF-alpha, TNFα), interferon gamma (interferon γ, IFN-gamma), granzyme, interleukin 4 (IL-4), interleukin 13 (IL-13) and interleukin 17 (IL-17) upon activation.
afamitresgène autoleucel	Lymphocytes T CD4+ et CD8+ autologues obtenus par leucophérèse, transduits par un vecteur lentiviral auto-inactivant (SIN), dérivé du virus de l'immunodéficience humaine (VIH), codant pour un récepteur de lymphocytes T (TCR) à affinité augmentée spécifique du peptide HLA-A*02 de l'antigène du mélanome humain A4 (membre A4 de la famille MAGE, antigène MAGE-4), sous le contrôle d'un promoteur du facteur d'élongation alpha 1 (EF1α). Les cellules expriment les marqueurs de migration des ganglions lymphatiques CCR7 et CD62L, les isoformes CD45RA and CD45R0 du CD45, les marqueurs co-stimulateurs CD27 et CD28, le récepteur CD127 de l'interleukine 7 (IL-7) et les récepteurs de chimiokines CXCR3. Les cellules secrètent de l'interleukine 2 (IL-2), facteur de nécrose tumorale α (TNF-alpha, TNFα), interféron gamma (interféron γ, IFN-gamma), granzyme, interleukine 4 (IL-4), interleukine 13 (IL-13) et l'interleukine 17 (IL-17) au moment de leur activation
afamitresgén autoleucel	Linfocitos T CD4+ y CD8+ autólogos obtenidos por leucoaféresis, transducidos con un vector lentiviral auto inactivante derivado del HIV, que codifica para un receptor de linfocitos T (TCR) con afinidad aumentada, específico para el péptido del antígeno de melanoma humano A4 (MAGE A4) presentado por HLA-A*02, dirigido por un promotor del factor de elongación 1 alfa (EF1α). Las células expresan los marcadores de migración a ganglios linfáticos CCR7 y CD62L, las isoformas CD45RA y CD45R0 de CD45, los marcadores coestimuladores CD27 y CD28, el receptor de IL-7 CD127, y el receptor de quimoquinas CXCR3. Las células secretan interleukina 2 (IL-2), factor de necrosis tumoral (TNF-alfa, TNFα), interferón gamma (interferón γ, IFN-gamma), granzima, interleukina 4 (IL-4), interleukina 13 (IL-13) e interleukina 17 (IL-17) tras su activación.

alsevalimabum #

alsevalimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* VTCN1 (V-set domain containing T cell activation inhibitor 1, B7-H4, B7H4)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-59.98-109) (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (96.8%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (229-229":232-232")-bisdisulfide, produced in Chinese hamster ovary (CHO-FUT8$^{-/-}$) cells, glycoform alfa

alsévalimab

immunoglobuline G1-kappa, anti-[*Homo sapiens* VTCN1 (inhibiteur 1 de l'activation des cellules T contenant un V-set domain, B7-H4, B7H4)], anticorps monoclonal *Homo sapiens*;
chaîne lourde gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-59.98-109) (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO-FUT8$^{-/-}$), glycoforme alfa

alsevalimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* VTCN1 (inhibidor 1 de la activación de las células T que contiene un dominio V-set, B7-H4, B7H4)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma1 *Homo sapiens* (1-450) [VH (*Homo sapiens* IGHV4-39*01 (96.0%) -(IGHD) - IGHJ5*02 (93.8%)) CDR-IMGT [10.7.12] (26-35.53-59.98-109) (1-120) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (229-229":232-232")-bisdisulfuro, producido por células ováricas de hamster chino (CHO-FUT8$^{-/-}$), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QLQLQESGPG LVKPSETLSL TCTVSGGSIK SGSYYWGWIR QPPGKGLEWI  50
GNIYYSGSTY YNPSLRSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
GSYPNQFDPW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YHSFPFTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	147-203	264-324	370-428
	22"-97"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	223-214'	223"-214'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados

C-terminal lysine clipping

H CHS K2:
450, 450"


amcenestrantum

amcenestrant — 8-(2,4-dichlorophenyl)-9-(4-{[(3*S*)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5*H*-benzo[7]annulene-3-carboxylic acid

amcénestrant — acide 8-(2,4-dichlorophényl)-9-(4-{[(3*S*)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phényl)-6,7-dihydro-5*H*-benzo[7]annulène-3-carboxylique

amcenestrant — ácido 8-(2,4-diclorofenil)-9-(4-{[(3*S*)-1-(3-fluoropropil)pirrolidin-3-il]oxi}fenil)-6,7-dihidro-5*H*-benzo[7]anuleno-3-carboxílico

$C_{31}H_{30}Cl_2FNO_3$




amdakefalinum

amdakefalin — [6-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]acetic acid

amdakéfaline — acide [6-(D-phénylalanyl-D-phénylalanyl-D-leucyl-D-lysyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]acétique

amdakefalina — ácido [6-(D-fenilalanil-D-fenilalanil-D-leucil-D-lisil)-3,6-diazabiciclo[3.1.1]heptan-3-il]acético

$C_{37}H_{53}N_7O_6$




aramisulpridum

aramisulpride — 4-amino-5-(ethanesulfonyl)-*N*-{[(2*R*)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxybenzamide

aramisulpride — 4-amino-5-(éthanesulfonyl)-*N*-{[(2*R*)-1-éthylpyrrolidin-2-yl]méthyl}-2-méthoxybenzamide

aramisulprida — 4-amino-5-(etanosulfonil)-*N*-{[(2*R*)-1-etilpirrolidin-2-il]metil}-2-metoxibenzamida

$C_{17}H_{27}N_3O_4S$



autogenum cevumeranum #

autogene cevumeran — A 5'-capped single-stranded messenger RNA (mRNA) construct for the expression of patient-specific tumour neoantigens comprising a 5'-cap, a 5'-untranslated region derived from human alpha-globin mRNA, an optimised Kozak sequence, sequences encoding a secretory signal peptide ($sec_{2.0}$), transmembrane and cytoplasmic domains of a major histocompatibility complex (MHC) Class I molecule (MITD), a 3'-untranslated region (FI) and a poly(A)-tail; sequences encoding patient specific antigens are inserted between the secretory signal peptide and the transmembrane/cytoplasmic encoding domains.

autogène cévuméran — ARN messager (ARNm) de simple brin coiffé en 5' construit pour l'expression de néoantigènes tumoraux spécifiques du patient comprenant une coiffe en 5', une région en 5' non-traduite dérivée de l'ARNm de la globine alpha humaine, une séquence optimisée Kozak, et les séquences codant pour un peptide signal ($sec_{2.0}$), les domaines transmembranaire et cytoplasmique du complexe majeur d'histocompatibilité de groupe I (CMH1) (MITD), une région non traduite en 3' (FI) et une queue poly(A) ; Les séquences codant les antigènes spécifiques du patient sont insérées entre celles codant le peptide signal et les domaines transmembranaire et cytoplasmique.

autogén cevumerán

Un constructo de RNA mensajero (mRNA) de cadena sencilla y caperuza en 5', para la expresión de neoantígenos tumorales específicos de cada paciente, que contiene una caperuza 5' (5'-cap), una región 5' no traducida derivada del mRNA de la globina alfa humana, una secuencia optimizada Kozak, y las secuencias codificantes para el péptido señal ($sec_{2.0}$), los dominios transmembrana y citoplásmico de complejo mayor de histocompatibilidad de grupo I (CMHI) (MITD), una región non-traducida en 3' (FI) y una cola poly(A); las secuencias que codifican los antígenos específicos del paciente se insertan entre las del péptido señal y de los dominios transmembrana y citoplásmico.

Sequence / Séquence / Secuencia

```
GGGGCGAACU AGUAUUCUUC UGGUCCCCAC AGACUCAGAG AGAACCCGCC     50
ACCAUGAGAG UGAUGGCCCC CAGAACCCUG AUCCUGCUGC UGUCUGGCGC    100
CCUGGCCCUG ACAGAGACAU GGGCCGGAAG CNAUCGUGGG AAUUGUGGCA    150
GGACUGGCAG UGCUGGCCGU GGUGGUGAUC GGAGCCGUGG UGGCUACCGU    200
GAUGUGCAGA CGGAAGUCCA GCGGAGGCAA GGGCGGCAGC UACAGCCAGG    250
CCGCCAGCUC UGAUAGCGCC CAGGGCAGCG ACGUGUCACU GACAGCCUAG    300
UAACUCGAGC UGGUACUGCA UGCACGCAAU GCUAGCUGCC CCUUUCCCGU    350
CCUGGGUACC CCGAGUCUCC CCCGACCUCG GGUCCCAGGU AUGCUCCCAC    400
CUCCACCUGC CCCACUCACC ACCUCUGCUA GUUCCAGACA CCUCCCAAGC    450
ACGCAGCAAU GCAGCUCAAA ACGCUUAGCC UAGCCACACC CCCACGGGAA    500
ACAGCAGUGA UUAACCUUUA GCAAUAAACG AAAGUUUAAC UAAGCUAUAC    550
UAACCCCAGG GUUGGUCAAU UUCGUGCCAG CCACACCGAG ACCUGGUCCA    600
GAGUCGCUAG CCGCGUCGCU AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA    650
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA    700
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA              740
```

Feature		Position
Capping structure :	phosphorothioate stabilized cap analogue	1-2
hAG-Kozak :	human α-globin - Kozak region	3-53
$sec_{2.0}$:	secretion signal sequence	54-131
N :	indicates location of insertion of patient-specific sequences	132
MITD :	transmembrane and cytoplasmic domains of MHC class I molecule	133-303
FI :	sequence element derived of the amino terminal enhancer of split RNA (F) and from the mitochondrially encoded 12S RNA (I)	304-620
A120 :	poly(A) tail of 120 nucleotides	621-740

azemiglitazonum

azemiglitazone

rac-(5*R*)-5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione


azémiglitazone

rac-(5*R*)-5-({4-[2-(3-méthoxyphényl)-2-oxoéthoxy]phényl}méthyl)-1,3-thiazolidine-2,4-dione

azemiglitazona

rac-(5*R*)-5-({4-[2-(3-metoxifenil)-2-oxoetoxi]fenil}metil)-1,3-tiazolidina-2,4-diona

$C_{19}H_{17}NO_5S$



and enantiomer
et énantiomère
y enantiómero

belzupacapum sarotalocanum #

belzupacap sarotalocan

a modified human papillomavirus (HPV) type 16-derived empty nanoparticle, 55 nm in diameter conjugated to approximately 200 molecules of a phthalocyanine-based photosensitizer (*sarotalocan* group). Each nanoparticle is comprised of 72 capsomeres, made of 5 molecules of modified viral capsid protein L1 [P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S] and one molecule of viral capsid protein L2;
human papilloma virus type 16 (HPV16) capsid, a spherical shell of 72 self-assembling pentagonal $(L1)_5(L2)_1$ capsomere units comprising the recombinant viral capsid proteins L1 ([P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S]-modified) and L2, conjugated to approximately 200 *sarotalocan* groups (near infrared absorbing dye) at N^6 of lysine residues;
produced by human embryonic kidney 293 (HEK293) cells

belzupacap sarotalocan

nanoparticle vide dérivée du virus du papillomavirus humain 16 (HPV) modifié, 55nm de diamètre, conjuguée à approximativement 200 molécules d'un photosensibilisant à base de phthalocyanine (groupe *sarotalocan*). Chaque particule est composée de 72 capsomères, faits de 5 molécules de protéine de capside virale L1 modifiée [P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S] et d'une molécule de protéine de capside virale L2;
capside du virus du papillomavirus humain 16 (HPV16), une coquille sphérique de 72 unités de capsomère pentagonal $(L1)_5(L2)_1$ s'auto-assemblant comprenant les protéines recombinantes de capside virale L1 ([P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S]-modifiée) et L2, conjuguées à environ 200 groupes *sarotalocan* (colorant absorbant les proches infra-rouges) en N^6 des résidus lysine ;
produite par des cellules rénales embryonnaires humaines (HEK293)

belzupacap sarotalocán

nanopartícula vacía derivada del virus del papilomavirus humano 16 (HPV) modificado, 55nm de diámetro, conjugado con aproximadamente 200 moléculas de un fotosensibilizante a base de ftalocianina (grupo *sarotalocán*). Cada partícula se compone de 72 capsómeros, hechos de 5 moléculas de proteína de cápside viral L1 modificada [P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S] y de una molécula de proteína de cápside viral L2;
cápside del virus del papilomavirus humano 16 (HPV16), una cavidad esférica de 72 unidades de capsómero pentagonal $(L1)_5(L2)_1$ que se autoensamblan abarcando las proteínas recombinantes de cápside viral L1 ([P^{78}>R, T^{176}>N, D^{273}>T, N^{285}>T, S^{288}>N, T^{353}>P, T^{389}>S]-modificada) y L2, conjugadas aproximadamente a 200 grupos *sarotalocán* (colorante absorbente infrarrojo cercano) en N^6 de los residuos de lisina ;
producido por las células renales embrionarias humanas (HEK293)

Sequence / Séquence / Secuencia
major capsid protein L1:

```
MSLWLPSEAT VYLPPVPVSK VVSTDEYVAR TNIYYHAGTS RLLAVGHPYF   50
PIKKPNNNKI LVPKVSGLQY RVFRIHLRDP NKFGFPDTSF YNPDTQRLVW  100
ACVGVEVGRG QPLGVGISGH PLLNKLDDTE NASAYAANAG VDNRECISMD  150
YKQTQLCLIG CKPPIGEHWG KGSPCNNVAV NPGDCPPLEL INTVIQDGDM  200
VDTGFGAMDF TTLQANKSEV PLDICTSICK YPDYIKMVSE PYGDSLFFYL  250
RREQMFVRHL FNRAGAVGEN VPTDLYIKGS GSTATLANSN YFPTPSGSMV  300
TSDAQIFNKP YWLQRAQGHN NGICWGNQLF VTVVDTTRST NMSLCAAIST  350
SEPTYKNTNF KEYLRHGEEY DLQFIFQLCK ITLTADVMSY IHSMNSTILE  400
DWNFGLQPPP GGTLEDTYRF VTSQAIACQK HTPPAPKEDP LKKYTFWEVN  450
LKEKFSADLD QFPLGRKFLL QAGLKAKPKF TLGKRKATPT TSSTSTTAKR  500
KKRKL                                                   505
```

cyclic pentamer (175-428',175'-428",175"-428"',175"'-428"",175""-428)-disulfide, with further intermolecular disulfide bridges of unknown position linking the 72 pentamers together


minor capsid protein L2:

```
MRHKRSAKRT KRASATQLYK TCKQAGTCPP DIIPKVEGKT IAEQILQYGS   50
MGVFFGGLGI GTGSGTGGRT GYIPLGTRPP TATDTLAPVR PPLTVDPVGP  100
SDPSIVSLVE ETSFIDAGAP TSVPSIPPDV SGFSITTSTD TTPAILDINN  150
TVTTVTTHNN PTFTDPSVLQ PPTPAETGGH FTLSSSTIST HNYEEIPMDT  200
FIVSTNPNTV TSSTPIPGSR PVARLGLYSR TTQQVKVVDP AFVTTPTKLI  250
TYDNPAYEGI DVDNTLYFSS NDNSINIAPD PDFLDIVALH RPALTSRRTG  300
IRYSRIGNKQ TLRTRSGKSI GAKVHYYYDL STIDPAEEIE LQTITPSTYT  350
TTSHAASPTS INNGLYDIYA DDFITDTSTT PVPSVPSTSL SGYIPANTTI  400
PFGGAYNIPL VSGPDIPINI TDQAPSLIPI VPGSPQYTII ADAGDFYLHP  450
SYYMLRKRRK RLPYFFSDVS LAA                               473
```

intramolecular disulfide bridge: 22-28

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
None / aucune / ninguna

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales




belzutifanum

belzutifan — 3-{[(1*S*,2*S*,3*R*)-2,3-difluoro-1-hydroxy-7-(methanesulfonyl)-2,3-dihydro-1*H*-inden-4-yl]oxy}-5-fluorobenzonitrile

belzutifan — 3-{[(1*S*,2*S*,3*R*)-2,3-difluoro-1-hydroxy-7-(méthanesulfonyl)-2,3-dihydro-1*H*-indèn-4-yl]oxy}-5-fluorobenzonitrile

belzutifán — 3-{[(1*S*,2*S*,3*R*)-2,3-difluoro-1-hidroxi-7-(metanosulfonil)-2,3-dihidro-1*H*-indén-4-il]oxi}-5-fluorobenzonitrilo

$C_{17}H_{12}F_3NO_4S$



bepranemabum #

bepranemab	immunoglobulin G4-kappa, anti-[*Homo sapiens* MAPT (microtubule-associated protein tau, tau)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-445) [VH (*Homo sapiens* IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-118)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
bépranémab	immunoglobuline G4-kappa, anti-[*Homo sapiens* MAPT (protéine tau associée aux microtubules, tau)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-445) [VH (*Homo sapiens* IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-118) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-219')-disulfure avec la chaîne légère kappa humanisée (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (224-224":227-227")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
bepranemab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* MAPT (proteína tau asociada a los microtúbulos, tau)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-445) [VH (*Homo sapiens* IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-118) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-219')-disulfuro con la cadena ligera kappa humanizada (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (224-224":227-227")-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCTVSGFSLT SNDIAWIRQP PGKGLEWMGT  50
IWTDGSTNYN TAVQSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARHRL 100
YYGAFDYWGQ GTMVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLE YSDGYTYLEW YLQKPGQSPQ  50
LLIYEVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQATHNP 100
YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	145-201	259-319	365-423
	22"-95"	145"-201"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (CH1 10-CL 126)	132-219'	132"-219'"		
Inter-H-H (h 8, h 11)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


bersacapavirum

bersacapavir — *N*-(3-cyano-4-fluorophenyl)-1-methyl-4-{[(2*S*)-1,1,1-trifluoropropan-2-yl]sulfamoyl}-1*H*-pyrrole-2-carboxamide

bersacapavir — *N*-(3-cyano-4-fluorophényl)-1-méthyl-4-{[(2*S*)-1,1,1-trifluoropropan-2-yl]sulfamoyl}-1*H*-pyrrole-2-carboxamide

bersacapavir — *N*-(3-ciano-4-fluorofenil)-1-metil-4-{[(2*S*)-1,1,1-trifluoropropan-2-il]sulfamoil}-1*H*-pirrolo-2-carboxamida

$C_{16}H_{14}F_4N_4O_3S$



bexmarilimabum

bexmarilimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], humanized monoclonal antibody;
gamma4 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) -IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfide with kappa light chain humanized (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

bexmarilimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticorps monoclonal humanisé;
chaîne lourde gamma4 humanisée (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfure avec la chaîne légère kappa humanisée (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

bexmarilimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* STAB1 (stabilin 1, STAB-1, CLEVER-1, FEEL-1, FELE-1, FEX1, SCARH2)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 humanizada (1-449) [VH (*Homo sapiens* IGHV2-5*09 (91.8%) -(IGHD) - IGHJ4*01 (100%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (123-220), bisagra 1-12 S10>P (230) (221-232), CH2 L1.2>E (237) (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfuro con la cadena ligera kappa humanizada (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (80.2%) -IGKJ2*01 (100%)) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLKESGPT LVKPTQTLTL TCSFSGFSLS TSGMGIGWIR QPPGKALEWL  50
AHIWWDDDKR YNPALKSRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARH 100
YGYDPYYAMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFEGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCTASSSVS SSYLHWYQQK PGKAPKLLIY  50
RTSNLASGVP SRFSGSGSGT DYTLTISSLQ PEDFATYYCH QYHRSPPTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	149-205	263-323	369-427
	22"-97"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	136-215'	136"-215'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

bomedemstatum

bomedemstat

N-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1*H*-1,2,3-triazol-1-yl)benzamide


bomédemstat

N-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorophényl)cyclopropyl]amino}-1-(4-méthylpipérazin-1-yl)-1-oxopentan-2-yl]-4-(1*H*-1,2,3-triazol-1-yl)benzamide

bomedemstat

N-[(2*S*)-5-{[(1*R*,2*S*)-2-(4-fluorofenil)ciclopropil]amino}-1-(4-metilpiperazin-1-il)-1-oxopentan-2-il]-4-(1*H*-1,2,3-triazol-1-il)benzamida

$C_{28}H_{34}FN_7O_2$



cevostamabum #

cevostamab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FCRL5 (Fc receptor like 5, FCRH5, IRTA2, BXMAS1, CD307e)] and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific tetravalent;
gamma1 heavy chain anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma1 heavy chain anti-CD3 (1"-449") [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1"-119") -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120"-449")], (222"-219"')-disulfide with kappa light chain anti-CD3 (1"'-219"') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1"'-112"') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113"'-219"')];
dimer (229-228":232-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells

cévostamab	immunoglobuline G1-kappa anti-[*Homo sapiens* FCRL5 (récepteur Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] et anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-CD3 (1''-449'') [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), charnière 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')], (222''-219''')-disulfure avec la chaîne légère kappa anti-CD3 (1'''-219''') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dimère (229-228'':232-231'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO)
cevostamab	inmunoglobulina G1-kappa anti-[*Homo sapiens* FCRL5 (receptor Fc like 5, FCRH5, IRTA2, BXMAS1, CD307e)] y anti-[*Homo sapiens* CD3E (CD3 épsilon, Leu-4)], anticuerpo monoclonal, biespecífico tetravalente; cadena pesada gamma1 anti-FCRL5 (1-450) [VH (*Mus musculus* IGHV2-4*01 (77.1%) -(IGHD) -IGHJ3*01 (90.9%)/*Homo sapiens* IGHV4-4*08 (72.9%) -(IGHD) -IGHJ5*01 (85.7%)) CDR-IMGT [8.7.14] (26-33.51-57.96-109) (1-120) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v32 CH3 W22 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa anti-FCRL5 (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ1*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-CD3 (1''-449'') [VH (*Homo sapiens* IGHV1-3*01 (82.7%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.12] (26-33.51-58.97-108) (1''-119'') -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 G84.4, G1v33 S22, A24, V86 (CH1 R120>K (216) (120-217), bisagra 1-15 (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343-447), CHS (448-449)) (120''-449'')], (222''-219''')-disulfuro con la cadena ligera kappa anti-CD3 (1'''-219''') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (88.8%) -IGKJ1*01 (100%)) CDR-IMGT [12.3.8] (27-38.56-58.95-102) (1'''-112''') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'''-219''')]; dímero (229-228'':232-231'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO)

Heavy chain / Chaîne lourde / Cadena pesada (anti-FCRL5)

```
EVQLVESGPG LVKPSETLSL TCTVSGFSLT RFGVHWVRQP PGKGLEWLGV   50
IWRGGSTDYN AAFVSRLTIS KDNSKNQVSL KLSSVTAADT AVYYCSNHYY  100
GSSDYALDNW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK  150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT  200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP  250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG  300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ  350
VYTLPPSREE MTKNQVSLWC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV  400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK  450
```

Light chain / Chaîne légère / Cadena ligera (anti-FCRL5)

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVR NLVVWFQQKP GKAPKLLIYS   50
GSYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSPPYTFGQ  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3)

```
EVQLVQSGAE VKKPGASVKV SCKASGFTFT SYYIHWVRQA PGQGLEWIGW   50
IYPENDNTKY NEKFKDRVTI TADTSTSTAY LELSSLRSED TAVYYCARDG  100
YSRYYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD  150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY  200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK  250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS  300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV  350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL  400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK   449
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3)

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSRTRKNYLA WYQQKPGQSP   50
KLLIYWTSTR KSGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSFIL  100
RTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK  150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE  200
VTHQGLSSPV TKSFNRGEC                                    219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104)  22-95    147-203    264-324    370-428
                    22"-96'  146"-202"  263"-323"  369"-427"
Intra-L (C23-C104)  23'-88'  134'-194'
                    23'"-94'" 139'"-199'"
Inter-H-L (h 5-CL 126)  223-214'  222"-219'"
Inter-H-H (h 11, h 14)  229-228"  232-231"
```

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación:
H CH2 N84.4>G:
300, 299"

ciltacabtagenum autoleucelum

ciltacabtagene autoleucel

autologous peripheral blood mononuclear cell (PBMC)-derived T lymphocytes transduced *ex vivo* with a non-replicating, self-inactivating (SIN) lentiviral vector encoding a chimeric antigen receptor (CAR) targeting two epitopes of the human B cell maturation antigen (BCMA) under the control of a human elongation factor 1 alpha (EF1α) promoter

The coding sequence comprises a human CD8 alpha signal peptide (CD8α SP), a BCMA targeting domain consisting of two variable heavy chain-only antibodies (VHH1 and VHH2) targeting two distinct BCMA epitopes, a human CD8 alpha hinge and transmembrane domain (CD8α hinge + TM), a human CD137 cytoplasmic domain (4-1BB) and a human CD3 zeta cytoplasmic domain (CD3ζ).

The vector genome contains a chimeric Rous sarcoma virus (RSV)/truncated 5'LTR and a self-inactivating 3'LTR-SIN (Δ-U3).

ciltacabtagène autoleucel	lymphocytes T autologues dérivés de cellules mononuclées du sang périphérique (PBMC) transduits *ex vivo* avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant deux épitopes de l'antigène de maturation des lymphocytes B (BCMA) humains sous le contrôle d'un promoteur du facteur d'élongation 1-alpha humain (EF1α) La séquence code pour un peptide signal CD8 alpha humain (CD8α SP), un domaine ciblant le BCMA consistant en seulement la partie variable des chaînes lourdes (VHH1 and VHH2) de deux anticorps dirigés contre deux épitopes du BCMA, une charnière et un domaine transmembranaire du CD8 alpha humain, un domaine cytoplasmique du CD 137 humain (4-1BB) et un domaine cytoplasmique du CD3 zêta humain (CD3ζ). Le génome du vecteur contient en 5', une séquence LTR (terminale longue répétée) tronquée d'un virus du sarcome de Rous (RSV) chimérique et en 3', une séquence LTR-SIN (Δ-U3) auto-inactivante.
ciltacabtagén autoleucel	linfocitos T autólogos derivados de células mononucleares de sangre periférica (PBMC) transducidos *ex vivo* con un vector lentiviral no replicativo, auto inactivante (SIN), que codifica para un receptor de antígenos quimérico (CAR) dirigido a dos epítopos del antígeno de maduración de linfocitos B (BCMA) humano bajo el control de un promotor del factor de elongación 1 alfa humano (promotor EF1α) La secuencia codificante consta de un péptido señal del CD8 alfa humano, un dominio dirigido a BCMA consistente en sólo la parte variable de las cadenas pesadas (VHH1 y VHH2) de dos anticuerpos dirigidos a dos epítopos de BCMA, una bisagra y un dominio transmembrana del CD8 alfa humano, un dominio citoplásmico del CD137 humano (4-1BB) y un dominio citoplásmico del CD3 zeta humano (CD3ζ). El genoma del vector contiene un LTR 5' truncado/RSV (virus del sarcoma de Rous) quimérico y un LTR 3'-SIN auto inactivante (Δ-U3).

conendostatinum

conendostatin	L-methionyl-human endostatin [human collagen type XVIII α-1 (COL18A1) C-terminal (1572-1754)-fragment (1-183)], canonical D^{104}, R^{110}, S^{150} form, produced in *Escherichia coli*
conendostatine	L-méthionyl-endostatine humaine [fragment C-terminal (1572-1754) du collagène humain de type XVIII α-1 (COL18A1) (1-183)], forme canonique D^{104}, R^{110}, S^{150}, produit dans *Escherichia coli*
conendostatina	L-metionil-endostatina humana [fragmento C-terminal (1572-1754) del colágeno humano de tipo XVIII α-1 (COL18A1) (1-183)], forma canónica D^{104}, R^{110}, S^{150}, producido en *Escherichia coli*

Sequence / Séquence / Secuencia

```
M                                                                    0
HSHRDFQPVL HLVALNSPLS GGMRGIRGAD FQCFQQARAV GLAGTFRAFL   50
SSRLQDLYSI VRRADRAAVP IVNLKDELLF PSWEALFSGS EGPLKPGARI  100
FSFDGKDVLR HPTWPQKSVW HGSDPNGRRL TESYCETWRT EAPSATGQAS  150
SLLGGRLLGQ SAASCHHAYI VLCIENSFMT ASK                     183
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intra-chain 33-165 135-173

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
None / aucune / ninguna

cudarolimabum #

cudarolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfide with kappa light chain *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) - IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
cudarolimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (233-233'':236-236'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
cudarolimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal *Homo sapiens*;

cadena pesada gamma1 *Homo sapiens* (1-453) [VH (*Homo sapiens* IGHV3-30*03 (100%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 D12 (363), L14 (365) (348-452), CHS K>del (453)) (125-453)], (227-213')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (96.8%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (233-233'':236-236'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
ISYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGR 100
PWYSETGTSA FDIWGQGTMV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPG                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD  50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ SDHYPTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                          213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	151-207	268-328	374-432
	22"-96"	151"-207"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-88'	133'-193'		
	23'"-88'"	133'"-193'"		
Inter-H-L (h 5-CL 126)	227-213'	227"-213'"		
Inter-H-H (h 11, h 14)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

dapatifagenum navolactibacum #

dapatifagene navolactibac

A recombinant live attenuated *Lactococcus lactis,* subspecies *cremoris* (strain MG1363), expressing a fusion protein comprising lactococcal secretion leader SSusp45 and human trefoil factor protein 1 (hTFF1), driven by the promoter from the homologous *hllA* gene (*PhllA*); the transduced gene is located in the thymidylate synthase A (*thyA*) locus which has been deleted (930102-930469).

dapatifagène navolactibac

Lactococcus lactis, sous-espèce *cremoris,* recombinante (souche MG1363), vivante atténuée exprimant une protéine de fusion consistant en le leader de sécrétion lactoccique SSusp45 et le facteur en trèfle-1 humain (hTFF1), sous le contrôle du promoteur du gène homologue *hIIA* (*PhllA*); le gène transduit est localisé sur le locus de la thymidylate synthase A (*thyA*) qui a été supprimé (930102-930469).

dapatifagén navolactibac	*Lactococcus lactis*, subespecie *cremoris* (cepa MG1363), recombinante, viva atenuada, que expresa una proteína de fusión consistente en el leader de secreción lactocócica SSusp45 y la proteína 1 del factor trébol humano (hTFF1), dirigida por el promotor del gen homólogo *hIIA* (*PhIIA*); el gen transducido se localiza en el locus de la timidilato sintasa A (thyA), que ha sido delecionado (930102-930469).
datopotamabum #	
datopotamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
datopotamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

datopotamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membranario del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (230-230":233-233")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW  50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	224-214'	224"-214'"		
Inter-H-H (h 11, h 14)	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
451, 451"

datopotamabum deruxtecanum

datopotamab deruxtecan

immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to *deruxtecan*, comprising a linker and a camptothecin derivative;

	gamma1 heavy chain humanized (1-451) [VH (*Homo sapiens* IGHV1-3*01(79.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (230-230":233-233")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated, on an average of 4 cysteinyl, to *deruxtecan*, comprising a linker and a camptothecin derivative
datopotamab déruxtécan	immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé conjugué au *déruxtécan*, comprenant un linker et un dérivé de la camptothécine; chaîne lourde gamma1 humanisée (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (230-230":233-233")-bisdisulfure; produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, conjugué sur une moyenne de 4 cystéines au *déruxtécan*, comprenant un linker et un dérivé de la camptothécine
datopotamab deruxtecán	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membrana del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 del trofoblasto, glicoproteína Trop-2 en la superficie de las células, TROP2)], anticuerpo monoclonal humanizado conjugado con *deruxtecán*, que comprende un enlace y un derivado de la camptotecina;

cadena pesada gamma1 humanizada (1-451) [VH (*Homo sapiens* IGHV1-3*01 (79.6%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 E12 (360), M14 (362) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.2%) -IGKJ2*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (230-230'':233-233'')-bisdisulfuro; producido por células ováricas de hamster chino (CHO), forma glicosilada alfa, conjugado con una media de 4 cisteinas al *deruxtecán*, que comprende un enlace y un derivado de la camptotecina.

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT TAGMQWVRQA PGQGLEWMGW  50
INTHSGVPKY AEDFKGRVTI SADTSTSTAY LQLSSLKSED TAVYYCARSG 100
FGSSYWYFDV WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)*	224-214'	224"-214'"		
Inter-H-H (h 11, h 14)*	230-230"	233-233"		

*The four inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Les quatre ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan los cuatro puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

C-terminal lysine clipping:
H CHS K2:
451, 451"

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales



demupitamabum #

demupitamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
démupitamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé; chaîne lourde gamma1 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
demupitamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado; cadena pesada gamma1 *Homo sapiens* (1-449) [VH (*Homo sapiens* IGHV4-61*01 (89.9%) -(IGHD) - IGHJ3*02 (100%)) CDR-IMGT [10.7.11] (26-35.53-59.98-108) (1-119) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGGSVS SGDYYWTWIR QSPGKGLEWI  50
GHIYYSGNTN YNPSLKSRLT ISIDTSKTQF SLKLSSVTAA DTAIYYCVRD 100
RVTGAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPST LSASVGDRVT ITCQASQDIS NYLNWYQQKP GKAPKLLIYD  50
ASNLETGVPS RFSGSGSGTD FTFTISSLQP EDIATYFCQH FDHLPLAFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	146-202	263-323	369-427
	22"-97"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88"'	134'"-194"'		
Inter-H-L (h 5-CL 126)	222-214'	222"-214'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

docaravimabum #

docaravimab

immunoglobulin G2B-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III], *Mus musculus* monoclonal antibody;
gamma2b heavy chain *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), hinge 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfide with kappa light chain *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')];
dimer (228-228":231-231":234-234":237-237")-tetrakisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa

docaravimab

immunoglobuline G2B-kappa, anti-[ectodomaine épitope G-III glycoprotéine du virus de la rage souche ERA (Evelyn-Rockitniki-Abelseth)], anticorps monoclonal *Mus musculus*;
chaîne lourde gamma2b *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), charnière 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfure avec la chaîne légère kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')];
dimère (228-228":231-231":234-234":237-237")-tétrakisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa

docaravimab

inmunoglobulina G2B-kappa, anti-[ectodominio epítopo G-III glicoproteína del virus de la rabia cepa ERA (Evelyn-Rockitniki-Abelseth)], anticuerpo monoclonal *Mus musculus*;
cadena pesada gamma2b *Mus musculus* (1-455) [VH (*Mus musculus* IGHV2-6-7*01 (92.8%) -(IGHD) -IGHJ2*01 (100%)) CDR-IMGT [8.7.13] (26-33.51-57.96-108) (1-119) -*Mus musculus* IGHG2B*02 (CH1 (120-216), bisagra 1-22 (217-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (120-455)], (134-214')-disulfuro con la cadena ligera kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV10-96*01 (93.7%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.99-107) (1'-106') -*Mus musculus* IGKC*01 (100%) (108'-214')];
dímero (228-228":231-231":234-234":237-237")-tetrakisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLKESGPG LLAPSQSLSI TCTVSGFSLT GHGVNWVRQP PGKGLEWLGI  50
IWADGTTNYN SALKSRLSIS KDNSKSQVFL KMNSLQTDDT ASYYCAREGD 100
ISGYYFDYWG QGTTLTVSSA KTTPPSVYPL APGCGDTTGS SVTLGCLVKG 150
YFPESVTVTW NSGSLSSSVH TFPALLQSGL YTMSSSVTVP SSTWPSQTVT 200
CSVAHPASST TVDKKLEPSG PISTINPCPP CKECHKCPAP NLEGGPSVFI 250
FPPNIKDVLM ISLTPKVTCV VVDVSEDDPD VQISWFVNNV EVHTAQTQTH 300
REDYNSTIRV VSTLPIQHQD WMSGKEFKCK VNNKDLPSPI ERTISKIKGL 350
VRAPQVYILP PPAEQLSRKD VSLTCLVVGF NPGDISVEWT SNGHTEENYK 400
DTAPVLDSDG SYFIYSKLNM KTSKWEKTDS FSCNVRHEGL KNYYLKKTIS 450
RSPGK                                                   455
```

Light chain / Chaîne légère / Cadena ligera

```
DVQMTQTTSS LSASLGDRVT ITCRPSQDIN NYLSWYQQKP DGTVKLLIYY  50
TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ EDFATYFCQQ GNTLPPTFGG 100
GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	146-201	269-329	375-433
	22"-95"	146"-201"	269"-329"	375"-433"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 11-CL 126)		134-214'	134"-214'"	
Inter-H-H (h 12, h 15, h 18, h 21)	228-228"	231-231"	234-234"	237-237"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 305"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

ebopiprantum

ebopiprant

(3*S*)-3-[(2*S*)-3-([1,1'-biphenyl]-4-sulfonyl)-1,3-thiazolidine-2-carboxamido]-3-(4-fluorophenyl)propyl L-valinate


ébopiprant

L-valinate de (3*S*)-3-[(2*S*)-3-([1,1'-biphényl]-4-sulfonyl)-1,3-thiazolidine-2-carboxamido]-3-(4-fluorophényl)propyle

ebopiprant

L-valinato de (3*S*)-3-[(2*S*)-3-([1,1'-bifenil]-4-sulfonil)-1,3-tiazolidina-2-carboxamido]-3-(4-fluorofenil)propilo

$C_{30}H_{34}FN_3O_5S_2$



efanesoctocogum alfa #

efanesoctocog alfa	human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with replaced B-domain (746-1648)-sequence [FVIII domains A1-a1-A2-a2 (1-740) and N-terminal B-domain fragment (741-745), fused via a synthetic 291-peptide linker of 24 repeating 12-peptides (4 types) (746-1033) plus tripeptide ASS (1034-1036) to the FVIII C-terminal (1649-2332)-domains a3-A3-C1-C2 (1037-1720)], fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (1721-1946), (1726-663':1729-666')-bisdisulfide with the TIL3-D3-TIL4 domain-containing fragment 742-1218 of the human von Willebrand factor (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutant] fused via a synthetic 148-peptide linker of 12 repeating 12-peptides (4 types) plus tetrapeptide GASS (478'-625') to a thrombin cleavable FVIII fragment 712-743 (626'-657') [thrombin-cleavable acidic region 2 plus B3 domain (1-3)-peptide] fused to a human immunoglobulin G1 C-terminal K>del Fc fragment (658'-883'), produced in human embryonic kidney 293 (HEK293) cells, glycoform alfa
éfanésoctocog alfa	facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été remplacé (746-1648) [domaines A1-a1-A2-a2 du FVIII (1-740) et fragment N-terminal du domaine B (741-745), fusionné via un peptide synthétique de 291 acides aminés, fait de 24 peptides de 12 acides aminés chacun, se répétant (4 types) (746-1033), et d'un tripeptide ASS (1034-1036), à la partie C-terminale des domaines a3-A3-C1-C2 1649-2332 du FVIII (1037-1720)], fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (1721-1946), (1726-663':1729-666') lié par des ponts disulfure au fragment contenant le domaine TIL3-D3-TIL4 du facteur de von Willebrand humain 742-1218 (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutant] fusionné via un peptide synthétique de 148 acides aminés, fait de 12 peptides de 12 acides aminés chacun, se répétant (4 types), plus un tétrapeptide GASS (478'-625'), à un fragment du FVIII clivable par la thrombine 712-743 (626'-657') [région 2 acide clivable par la thrombine plus le (1-3)-peptide du domaine B3] fusionné au fragment Fc C-terminal K>del de l'immunoglobuline G1 humaine (658'-883'), produit dans des cellules rénales embryonnaires humaines 293 (HEK293), glycoforme alfa
efanesoctocog alfa	factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) en el dominio B reemplazado (746-1648) [dominios A1-a1-A2-a2 del FVIII (1-740) y fragmento N-terminal del dominio B (741-745), fusionado a través de un péptido sintético de 291 aminoácidos, hecho de 24 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos) (746-1033), y de un tripéptido ASS (1034-1036), con la parte C-terminal de los dominios a3-A3-C1-C2 1649-2332 del FVIII (1037-1720)], fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (1721-1946), (1726-663':1729-666') unido por puentes disulfuro con el fragmento que contiene el dominio TIL3-D3-TIL4 del factor de von Willebrand humano 742-1218 (1'-477') [(C^{1077}>$A^{336'}$,C^{1120}>$A^{379'}$)-mutante] fusionado a través de un péptido sintético de 148 aminoácidos, hecho de 12 péptidos de 12 aminoácidos cada uno, que se repiten (4 tipos), además un tetrapéptido GASS (478'-625'), con un fragmento del FVIII escindible por la trombina 712-743 (626'-657') [región 2 ácido escindible por la trombina además el (1-3)-péptido del dominio B3] fusionado con el fragmento Fc C-terminal K>del de la inmunoglobulina G1 humana (658'-883'), producido en las células renales embrionarias humanas 293 (HEK293), glicoforma alfa

Sequence / Séquence / Secuencia
(a) BddFVIII-Fc chain:

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV   80
YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS  160
HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR  240
SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL MDLGQFLLFC HISSHQHDGM  320
EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL  400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI  480
TDVRPLYSRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP LLICYKESVD  560
QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL  640
SIGAQTDFLS VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE  720
DSYEDISAYL LSKNNAIEPR SFSQNGTSES ATPESGPGSE PATSGSETPG TSESATPESG PGSEPATSGS ETPGTSESAT  800
PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG PGSEPATSGS ETPGTSESAT PESGPGSPAG SPTSTEEGSP  880
AGSPTSTEEG TSTEPSEGSA PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE PATSGSETPG SEPATSGSET  960
PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE PSEGSAPGSE PATSGSETPG TSESATPESG PGTSTEPSEG SAPASSEITR 1040
TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ KKTRHYFIAA VERLWDYGMS SSPHVLRNRA QSGSVPQFKK 1120
VVFQEFTDGS FTQPLYRGEL NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLISY EEDQRQGAEP RKNFVKPNET 1200
KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD LEKDVHSGLI GPLLVCHTNT LNPAHGRQVT VQEFALFFTI FDETKSWYFT 1280
ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL VMAQDQRIRW YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK 1360
MALYNLYPGV FETVEMLPSK AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ YGQWAPKLAR 1440
LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK FSSLYISQFI IMYSLDGKKW QTYRGNSTGT LMVFFGNVDS 1520
SGIKHNIFNP PIIARYIRLH PTHYSIRSTL RMELMGCDLN SCSMPLGMES KAISDAQITA SSYFTNMFAT WSPSKARLHL 1600
QGRSNAWRPQ VNNPKEWLQV DFQKTMKVTG VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1680
VVNSLDPPLL TRYLRIHPQS WVHQIALRME VLGCEAQDLY DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 1760
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 1840
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 1920
NVFSCSVMHE ALHNHYTQKS LSLSPG                                                          1946
```

(b) vWF fragment-FVIII a2-Fc chain:

```
SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG MVRHENRCVA LERCPCFHQG KEYAPGETVK   80
IGCNTCVCRD RKWNCTDHVC DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG CSHPSVKCKK  160
RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ  240
NNDLTSSNLQ VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ TMVDSSCRIL TSDVFQDCNK LVDPEPYLDV  320
CIYDTCSCES IGDCAAFCDT IAAYAHVCAQ HGKVVTWRTA TLCPQSCEER NLRENGYEAE WRYNSCAPAC QVTCQHPEPL  400
ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKKVT LNPSDPEHCQ ICHCDVVNLT CEACQEPGTS  480
ESATPESGPG SEPATSGSET PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG SPAGSPTSTE  560
EGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGSP AGSPTSTEEG SPAGSPTSTE EGASSDKNTG DYYEDSYEDI  640
SAYLLSKNNA IEPRSFSDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE  720
VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNQV  800
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL  880
SPG                                                                                   883
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
(a) 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, 1867-1925 (Cys-SH: 310, 692, 1388);
(b) 4'-45', 13'-41', 25'-36', 29'-64', 47'-58', 66'-88', 83'-100', 86'-95', 104'-233', 126'-268', 135'-230', 151'-158', 283'-326', 297'-321', 308'-348', 328'-334', 338'-363', 367'-410', 386'-406', 390'-402', 394'-433', 414'-427', 436'-464', 459'-474', 462'-471', 698'-758', 804'-862'
(a)-(b) intermolecular: 1726-663', 1729-666'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
N41, N239, N1198, N1506, N1797 and N94', N384', N734'

O-glycosylation sites / Sites de O-glycosylation / Posiciones de O-glicosilación
potentially each Ser and Thr in the linker peptides
746-1036 and 478'-625'

Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación
346, 718, 719, 723, 729, 1052, 1068 and 632', 633', 637', 643'

eflepedocokinum alfa

eflepedocokin alfa

human interleukin 22 (IL22, cytokine Zcyto18, IL10-related T-cell-derived inducible factor, IL-TIF) (1-146), fused via a $GSG_3S(G_4S)_2$ peptide linker (147-162) to a human immunoglobulin G2 C-terminal Fc fragment (163-385), P^{269}>S-mutant S^{316}>A-variant, dimer (165-165':168-168')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

eflépédocokine alfa

interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes T lié à IL10, IL-TIF) (1-146), fusionnée via un peptide liant $GSG_3S(G_4S)_2$ (147-162) au fragment Fc C-terminal de l'immunoglobuline G2 humaine (163-385), P^{269}>S-mutant S^{366}>A-variant, dimère (165-165':168-168')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

eflepedocokina alfa

interleukina 22 humana (IL22, citoquina Zcyto18, factor inducible derivado de los linfocitos T relacionado con IL10, IL-TIF) (1-146), fusionada a través de un péptido que se une a $GSG_3S(G_4S)_2$ (147-162) con el fragmento Fc C-terminal de la inmunoglobulina G2 humana (163-385), P^{269}>S-mutante S^{366}>A-variante, dímero (165-165':168-168')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV   50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH  100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIGSGG  150
GSGGGGSGGG GSVECPPCPA PPVAGPSVFL FPPKPKDTLM ISRTPEVTCV  200
VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD  250
WLNGKEYKCK VSNKGLPASI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ  300
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV  350
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK                  385
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 199-259 305-363
7'-99' 56'-145' 199'-259' 305'-363'
intermolecular: 165-165' 168-168'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N235 N21', N35', N64', N235'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 385, 385'

efmarodocokinum alfa #

efmarodocokin alfa

human interleukin 22 (IL22, cytokine Zcyto18, IL10-related T-cell-derived inducible factor, IL-TIF) (1-146), fused to a human immunoglobulin G4 C-terminal Fc fragment (147-377), S^{158}>P, N^{227}>G-mutant; dimer (156-156':159-159')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

efmarodocokine alfa

interleukine 22 humaine (IL22, cytokine Zcyto18, facteur inductible dérivé des lymphocytes lié à l'IL10, IL-TIF) (1-146), fusionnée au fragment Fc C-terminal de l'immunoglobuline G4 humaine (147-377), mutant S^{158}>P, N^{227}>G, dimère (156-156':159-159')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efmarodocokina alfa

interleukina 22 humana (IL22, citoquina Zcyto18, IL10-relacionada factor inducible derivado de células T, IL-TIF) (1-146), fusionada con el fragmento Fc C-terminal de la inmunoglobulina G4 humana (147-377), mutante S^{158}>P, N^{227}>G, dímero (156-156':159-159')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
APISSHCRLD KSNFQQPYIT NRTFMLAKEA SLADNNTDVR LIGEKLFHGV   50
SMSERCYLMK QVLNFTLEEV LFPQSDRFQP YMQEVVPFLA RLSNRLSTCH  100
IEGDDLHIQR NVQKLKDTVK KLGESGEIKA IGELDLLFMS LRNACIRVES  150
KYGPPCPPCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED  200
PEVQFNWYVD GVEVHNAKTK PREEQFGSTY RVVSVLTVLH QDWLNGKEYK  250
CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK  300
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG  350
NVFSCSVMHE ALHNHYTQKS LSLSLGK                           377
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intramolecular: 7-99 56-145 191-251 297-355
7'-99' 56'-145' 191'-251' 297'-355'
intermolecular: 156-156' 159-159'

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N21, N35, N64, N143 N21', N35', N64', N143'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 377, 377'


eliapixantum

eliapixant — 3-(5-methyl-1,3-thiazol-2-yl)-5-{[(3*R*)-oxolan-3-yl]oxy}-*N*-{(1*R*)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide

éliapixant — 3-(5-méthyl-1,3-thiazol-2-yl)-5-{[(3*R*)-oxolan-3-yl]oxy}-*N*-{(1*R*)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide

eliapixant — 3-(5-metil-1,3-tiazol-2-il)-5-{[(3*R*)-oxolan-3-il]oxi}-*N*-{(1*R*)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida

$C_{22}H_{21}F_3N_4O_3S$




elinzanetantum

elinzanetant — 2-[3,5-bis(trifluoromethyl)phenyl]-*N*-{4-(4-fluoro-2-methylphe-nyl)-6-[(7*S*,9a*S*)-7-(hydroxymethyl)hexahydropyrazino[2,1-*c*][1,4]oxazin-8(1*H*)-yl]pyridin-3-yl}-*N*,2-dimethylpropanamide

élinzanétant — 2-[3,5-bis(trifluorométhyl)phényl]-*N*-{4-(4-fluoro-2-méthylphényl)-6-[(7*S*,9a*S*)-7-(hydroxyméthyl)hexahydropyrazino[2,1-*c*][1,4]oxazin-8(1*H*)-yl]pyridin-3-yl}-*N*,2-diméthylpropanamide

elinzanetant — 2-[3,5-bis(trifluorometil)fenil]-*N*-{4-(4-fluoro-2-metilfenil)-6-[(7*S*,9a*S*)-7-(hidroximetil)hexahidropirazino[2,1-*c*][1,4]oxazin-8(1*H*)-il]piridin-3-il}-*N*,2-dimetilpropanamida

$C_{33}H_{35}F_7N_4O_3$




enflicoxibum

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1*H*-pyrazol-1-yl]benzene-1-sulfonamide

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorophényl)-3-(trifluorométhyl)-4,5-dihydro-1*H*-pyrazol-1-yl]benzène-1-sulfonamide

enflicoxib — *rac*-4-[(5*R*)-5-(2,4-difluorofenil)-3-(trifluorometil)-4,5-dihidro-1*H*-pirazol-1-il]benceno-1-sulfonamida

$C_{16}H_{12}F_5N_3O_2S$



and enantiomer
et énantiomère
y enantiómero


esamisulpridum

esamisulpride — 4-amino-5-(ethanesulfonyl)-*N*-{[(2*S*)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxybenzamide

ésamisulpride — 4-amino-5-(éthanesulfonyl)-*N*-{[(2*S*)-1-éthylpyrrolidin-2-yl]méthyl}-2-méthoxybenzamide

esamisulprida — 4-amino-5-(etanosulfonil)-*N*-{[(2*S*)-1-etilpirrolidin-2-il]metil}-2-metoxibenzamida

$C_{17}H_{27}N_3O_4S$



exalurenum


exaluren — 4-*O*-(2-amino-2,7-dideoxy-D-*glycero*-α-D-*gluco*-heptopyranosyl)-5-*O*-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-2-deoxy-D-streptamine

exalurène — 4-*O*-(2-amino-2,7-didésoxy-D-*glycéro*-α-D-*gluco*-heptopyranosyl)-5-*O*-(5-amino-5,6-didésoxy-α-L-talofuranosyl)-2-désoxy-D-streptamine

exalureno

4-*O*-(2-amino-2,7-didesoxi-D-*glicero*-α-D-*gluco*-heptopiranosil)-5-*O*-(5-amino-5,6-didesoxi-α-L-talofuranosil)-2-desoxi-D-estreptamina

$C_{19}H_{38}N_4O_{10}$



ezabenlimabum #

ezabenlimab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (226-226":229-229")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ézabenlimab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (226-226":229-229")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

ezabenlimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 humanizada (1-446) [VH (*Homo sapiens* IGHV3-23*04 (86.7%) -(IGHD) -IGHJ4*01 (100%)) [8.8.13] (1-120) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-218')-disulfuro con la cadena ligera kappa humanizada (1'-218') [V-KAPPA (*Homo sapiens* IGKV3D-11*01 (79.8%) -IGKJ2*02 (100%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')];
dímero (226-226":229-229")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVMLVESGGG LVQPGGSLRL SCTASGFTFS KSAMSWVRQA PGKGLEWVAY  50
ISGGGGDTYY SSSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARHS 100
NVNYYAMDYW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG     446
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT MSCRASENID VSGISFMNWY QQKPGQAPKL  50
LIYVASNQGS GIPARFSGSG SGTDFTLTIS RLEPEDFAVY YCQQSKEVPW 100
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (CH1 10-CL 126)	134-218'	134"-218'"		
Inter-H-H (h 8, h 11)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


ezeprogindum

ezeprogind — *N*-[3-(4-{3-[bis(2-methylpropyl)amino]propyl}piperazin-1-yl)propyl]-1*H*-benzimidazol-2-amine

ézéprogind — *N*-[3-(4-{3-[bis(2-méthylpropyl)amino]propyl}pipérazin-1-yl)propyl]-1*H*-benzimidazol-2-amine

ezeprogind — *N*-[3-(4-{3-[bis(2-metilpropil)amino]propil}piperazin-1-il)propil]-1*H*-benzimidazol-2-amino

$C_{25}H_{44}N_6$



feladilimabum #

feladilimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* ICOS (inducible T-cell costimulator, activation-inducible lymphocyte immunomediatory molecule, AILIM, CD278)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) -IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-12 S10>P (229)(220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
féladilimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* ICOS (costimulateur inductible du lymphocyte T, molécule immunomédiateur lymphocytaire inductible par activation, AILIM, CD278)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), charnière 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
feladilimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* ICOS (coestimulador inducible del linfocito T, molécula inmunomediadora linfocitaria inducible para activación, AILIM, CD278)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-448) [VH (*Homo sapiens* IGHV1-69*04 (84.7%) -(IGHD) - IGHJ6*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v3 CH2 E1.2 (CH1 (122-219), bisagra 1-12 S10>P (229) (220-231), CH2 L1.2>E (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ2*01 (100%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227'':230-230'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DYAMHWVRQA PGQGLEWMGL  50
ISIYSDHTNY NQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCGRNN 100
YGNYGWYFDV WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFEGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCSASSSVS YMHWYQQKPG QAPRLLIYDT  50
SKLASGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCFQG SGYPYTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	262-322	368-426
	22"-96"	148"-204"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (CH1 10-CL 126)	135-213'	135"-213'"		
Inter-H-H (h 8, h 11)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

felzartamabum #

felzartamab

immunoglobulin G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], humanized monoclonal antibody;
gamma1 heavy chain (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - *Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfide with lambda light chain (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')];
dimer (229-229":232-232")-bisdisulfide, produced in human cell line PER.C6, glycoform alfa

felzartamab

immunoglobuline G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosyl cyclase 1, ADP-ribose cyclique hydrolase 1, cADPr hydrolase 1, T10)], anticorps monoclonal humanisé ;
chaîne lourde gamma1 (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) - *Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfure avec la chaîne légère lambda (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')];
dimère (229-229":232-232")-bisdisulfure, produite dans des cellules humaines PER.C6, glycoforme alfa

felzartamab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD38 (ADP-ribosil ciclasa 1, ADP-ribosa cíclica hidrolasa 1, cADPr hidrolasa 1, T10)], anticuerpo monoclonal humanizado ;
cadena pesada gamma1 (1-450) [VH (*Homo sapiens* IGHV3-30*01 (90.8%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-212')-disulfuro con la cadena ligera lambda (1'-213') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (84.1%) -IGLJ3*02 (100%)) CDR-IMGT [6.3.10] (26-31.49-51.88-97) (1'-107') -*Homo sapiens* IGLC2*01 (100%) (108'-213')];
dímero (229-229'':232-232'')-bisdisulfuro, producida por células humanas PER.C6, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYYMNWVRQA PGKGLEWVSG  50
ISGDPSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDL 100
PLVYTGFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIELTQPPSV SVAPGQTARI SCSGDNLRHY YVYWYQQKPG QAPVLVIYGD  50
SKRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQTY TGGASLVFGG 100
GTKLTVLGQP KAAPSVTLFP PSSEELQANK ATLVCLISDF YPGAVTVAWK 150
ADSSPVKAGV ETTTPSKQSN NKYAASSYLS LTPEQWKSHR SYSCQVTHEG 200
STVEKTVAPT ECS                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	22'-87'	135'-194'		
	22'"-87'"	135'"-194'"		
Inter-H-L (h 5-CL 126)	223-212'	223"-212'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary PER.C6-type glycans / glycanes de type PER.C6 bi-antennaires complexes fucosylés / glicanos de tipo PER.C6 biantenarios complejos fucosilados

filapixantum

filapixant

3-{[(2*R*)-4-methylmorpholin-2-yl]methoxy}-5-(5-methyl-1,3-thiazol-2-yl)-*N*-{(1*R*)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide


filapixant

3-{[(2*R*)-4-méthylmorpholin-2-yl]méthoxy}-5-(5-méthyl-1,3-thiazol-2-yl)-*N*-{(1*R*)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}benzamide

filapixant

3-{[(2*R*)-4-metilmorfolin-2-il]metoxi}-5-(5-metil-1,3-tiazol-2-il)-*N*-{(1*R*)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamida


$C_{24}H_{26}F_3N_5O_3S$



fosciclopiroxum

fosciclopirox	[(6-cyclohexyl-4-methyl-2-oxopyridin-1(2*H*)-yl)oxy]methyl dihydrogen phosphate
fosciclopirox	dihydrogénophosphate de [(6-cyclohexyl-4-méthyl-2-oxopyridin-1(2*H*)-yl)oxy]méthyle
fosciclopirox	dihidrogenofosfato de [(6-ciclohexil-4-metil-2-oxopiridin-1(2*H*)-il)oxi]metilo


$C_{13}H_{20}NO_6P$



fosifidancitinibum

fosifidancitinib	(5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-yl)methyl dihydrogen phosphate
fosifidancitinib	dihydrogénophosphate de (5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-yl)méthyle
fosifidancitinib	dihidrogenofosfato de (5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin-4-il]amino}-2-oxo-1,3-benzoxazol-3(2*H*)-il)metilo


$C_{21}H_{21}FN_5O_7P$



genisteinum

genistein	5,7-dihydroxy-3-(4-hydroxyphenyl)-4*H*-chromen-4-one
génistéine	5,7-dihydroxy-3-(4-hydroxyphényl)-4*H*-chromén-4-one
genisteína	5,7-dihidroxi-3-(4-hidroxifenil)-4*H*-cromen-4-ona

$C_{15}H_{10}O_5$



giloralimabum #

giloralimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD40 (tumor necrosis factor receptor super family member 5, TNFRSF5)], monoclonal antibody; gamma1 heavy chain (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), hinge 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0%) -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (221-221":224-224")-bisdisulfide
giloralimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)], anticorps monoclonal; chaîne lourde gamma1 (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), charnière 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (221-221":224-224")-bisdisulfure
giloralimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de los receptores del TNF, TNFRSF5)], anticuerpo monoclonal; cadena pesada gamma1 (1-442) [VH (*Homo sapiens* IGHV4-59*01 (88.8%) -(IGHD) -IGHJ4*01 (85.7%)) CDR-IMGT [9.7.5] (26-34.52-58.97-101) (1-112) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (209) (113-210), bisagra 1-15 (211-225), CH2 V37>E (268) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-122*01 (89.0% -IGKJ4*01 (91.7%)/*Homo sapiens* IGKV2-29*02 (86.0%) -IGKJ2*02 (100%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVKPSETLSL TCTVSGYSIT SNYYWNWIRQ PPGKGLEWMG  50
YIRYDGSNNY NPSLKNRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARLD 100
YWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEEKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSQSLE NTNGNTFLNW YLQKPGQSPQ  50
LLIYRVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQVTHVP 100
FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	139-195	256-316	362-420
	22"-96"	139"-195"	256"-316"	362"-420"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	215-219'	215"-219'"		
Inter-H-H (h 11, h 14)	221-221"	224-224"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
292, 292"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:

H CHS K2:
442, 442"

giredestrantum

giredestrant

3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-1,3,4,9-tetrahydro-2*H*-pyrido[3,4-*b*]indol-2-yl]-2,2-difluoropropan-1-ol


girédestrant

3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azétidin-3-yl]amino}phényl)-3-méthyl-1,3,4,9-tétrahydro-2*H*-pyrido[3,4-*b*]indol-2-yl]-2,2-difluoropropan-1-ol

giredestrant

3-[(1*R*,3*R*)-1-(2,6-difluoro-4-{[1-(3-fluoropropil)azetidin-3-il]amino}fenil)-3-metil-1,3,4,9-tetrahidro-2*H*-pirido[3,4-*b*]indol-2-il]-2,2-difluoropropan-1-ol

$C_{27}H_{31}F_5N_4O$




icenticaftorum

icenticaftor — 3-amino-6-methoxy-*N*-[(2*S*)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide

icenticaftor — 3-amino-6-méthoxy-*N*-[(2*S*)-3,3,3-trifluoro-2-hydroxy-2-méthylpropyl]-5-(trifluorométhyl)pyridine-2-carboxamide

icenticaftor — 3-amino-6-metoxi-*N*-[(2*S*)-3,3,3-trifluoro-2-hidroxi-2-metilpropil]-5-(trifluorometil)piridina-2-carboxamida

$C_{12}H_{13}F_6N_3O_3$




icerguastatum

icerguastat — (2*E*)-2-[(2-chlorophenyl)methylidene]hydrazine-1-carboximidamide

icerguastat — (2*E*)-2-[(2-chlorophényl)méthylidène]hydrazine-1-carboximidamide

icerguastat — (2*E*)-2-[(2-clorofenil)metilideno]hidrazina-1-carboximidamida

$C_8H_9ClN_4$




idetrexedum

idetrexed — *N*-(4-{[(6*S*)-2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahydro-1*H*-cyclopenta[*g*]quinazolin-6-yl](prop-2-yn-1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamic acid

idétrexed — acide *N*-(4-{[(6*S*)-2-(hydroxyméthyl)-4-oxo-4,6,7,8-tétrahydro-1*H*-cyclopenta[*g*]quinazolin-6-yl](prop-2-yn-1-yl)amino}benzoyl)-L-γ-glutamyl-D-glutamique

idetrexed — ácido *N*-(4-{[(6*S*)-2-(hidroximetil)-4-oxo-4,6,7,8-tetrahidro-1*H*-ciclopenta[*g*]quinazolin-6-il](prop-2-in-1-il)amino}benzoil)-L-γ-glutamil-D-glutámico

$C_{32}H_{33}N_5O_{10}$




ifidancitinibum

ifidancitinib — 5-{[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3*H*)-one

ifidancitinib — 5-{[2-(4-fluoro-3-méthoxy-5-méthylanilino)-5-méthylpyrimidin-4-yl]amino}-1,3-benzoxazol-2(3*H*)-one

ifidancitinib — 5-{[2-(4-fluoro-5-metilanilino-3-metoxi)-5-metilpirimidin-4-il]amino}-1,3-benzoxazol-2(3*H*)-ona

$C_{20}H_{18}FN_5O_3$




imaradenantum

imaradenant — 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine

imaradénant — 6-(2-chloro-6-méthylpyridin-4-yl)-5-(4-fluorophényl)-1,2,4-triazin-3-amine

imaradenant — 6-(2-cloro-6-metilpiridin-4-il)-5-(4-fluorofenil)-1,2,4-triazin-3-amina

$C_{15}H_{11}ClFN_5$




inavolisibum

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazepin-9-yl}amino)propenamide

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluorométhyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazépin-9-yl}amino)propenamide

inavolisib — (2*S*)-2-({2-[(4*S*)-4-(difluorometil)-2-oxo-1,3-oxazolidin-3-il]-5,6-dihidroimidazo[1,2-*d*][1,4]benzoxazepin-9-il}amino)propanamida

$C_{18}H_{19}F_2N_5O_4$



insulinum efsitorum alfa #

insulin efsitora alfa

human insulin B-chain (1-30) variant (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fused via a G_2SG_4 peptide linker (31-37) to human insulin A-chain (38-58) variant (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) and via a $(G_4Q)_3G_5$ peptide linker (59-78) to a human immunoglobulin G2 C-terminal K>del Fc fragment (79-299), dimer (80-80':83-83')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

insuline efsitora alfa

chaîne B de l'insuline humaine (1-30) variant (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fusionné via un peptide liant G_2SG_4 (31-37) à la chaîne A de l'insuline humaine (38-58) variant (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) et via un peptide liant $(G_4Q)_3G_5$ (59-78) au fragment Fc C-terminal K>del de l'immunoglobuline G2 humaine (IgG2) (79-299), dimère (80-80':83-83')-bisdisulfure, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

insulina efsitora alfa

cadena B de la insulina humana (1-30) variante (Y^{16}>E, F^{25}>H, T^{27}>G, P^{28}>G, K^{29}>G, T^{30}>G) fusionada a través de un péptido que se une G_2SG_4 (31-37) a la cadena A de la insulina humana (38-58) variante (I^{10}>T^{47}, Y^{14}>D^{51}, N^{21}>G^{58}) y a través de un péptido que se une $(G_4Q)_3G_5$ (59-78) al fragmento Fc C-terminal K>del de la inmunoglobulina G2 humana (IgG2) (79-299), dímero (80-80':83-83')-bisdisulfuro, producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
FVNQHLCGSH LVEALELVCG ERGFHYGGGG GGSGGGGGIV EQCCTSTCSL   50
DQLENYCGGG GGQGGGGQGG GGQGGGGGEC PPCPAPPVAG PSVFLFPPKP  100
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN  150
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ  200
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM  250
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG   299
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

B-A	7-44	19-57	B'-A'	7'-44'	19'-57'
A-A	43-48		A'-A'	43'-48'	
Intra-Fc	114-174	220-278	114'-174'	220'-278'	
Inter-Fc	80-80'	83-83'			

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N150, N150'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados


iptacopanum

iptacopan

4-{(2*S*,4*S*)-4-ethoxy-1-[(5-methoxy-7-methyl-1*H*-indol-4-yl)methyl]piperidin-2-yl}benzoic acid

iptacopan	acide 4-{(2*S*,4*S*)-4-éthoxy-1-[(5-méthoxy-7-méthyl-1*H*-indol-4-yl)méthyl]pipéridin-2-yl}benzoïque
iptacopán	ácido 4-{(2*S*,4*S*)-4-etoxi-1-[(7-metil-5-metoxi-1*H*-indol-4-il)metil]piperidin-2-il}benzoico

$C_{25}H_{30}N_2O_4$



isecarosmabum #

isecarosmab	immunoglobulin single chain VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, THSD6, thrombospondin type I domain 6)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HSA)], *Lama glama* and humanized monoclonal antibody, bispecific bivalent; sc VH-VH'(1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-humanized VH anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), produced in Pichia pastoris yeast, non-glycosylated
isécarosmab	immunoglobuline single chaîne VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, thrombospondine type I domaine 6)] et anti-[*Homo sapiens* ALB (albumine, sérum albumine humaine, SAH)], anticorps monoclonal *Lama glama* et humanisé, bispécifique bivalent; sc VH-VH' (1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -35-mer (GGGGS)7 linker (125-159)-VH humanisé anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), produit dans la levure Pichia pastoris, non-glycosylé
isecarosmab	inmunoglobulina cadena simple VH-VH', anti-[*Homo sapiens* ADAMTSL5 (ADAMTS like 5, trombospondina tipo I dominio 6)] y anti-[*Homo sapiens* ALB (albúmina, sero albúmina humana, SAH)], anticuerpo monoclonal *Lama glama* y humanizado, biespecífico bivalente; sc VH-VH' (1-275) [*Lama glama* VH anti-ADAMTSL5 (*Lama glama* IGHV3S1*01 (81.4%) -(IGHD) -IGHJ2*01 (100%)/*Homo sapiens* IGHV3-23*04 (80.2%) -(IGHD) -IGHJ1*01 (100%) [8.8.17] (1-124)) -linker 35-mer (GGGGS)7 (125-159)-VH humanizado anti-ALB (*Homo sapiens* IGHV3-23*04 (87.5%) -(IGHD) -IGHJ1*01 (100%) [8.8.8] (160-275), producido en la levadura Pichia pastoris, no glicosilado

scVH-VH' chain / Chaîne scVH-VH' / Cadena scVH-VH'

```
DVQLVESGGG VVQPGGSLRL SCAASGRTVS SYAMGWFRQA PGKEREFVAG  50
ISRSAERTYY VDSLKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAADL 100
DPNRIFSREE YAYWGQGTLV TVSSGGGGSG GGGSGGGGSG GGGSGGGGSG 150
GGGSGGGGSE VQLVESGGGV VQPGNSLRLS CAASGFTFSS FGMSWVRQAP 200
GKGLEWVSSI SGSGSDTLYA DSVKGRFTIS RDNAKTTLYL QMNSLRPEDT 250
ALYYCTIGGS LSRSSQGTLV TVSSA                             275
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-single chain (C23-C104) 22-96 181-255

No N-glycosylation sites / pas de sites de N-glycosylation / ningún positión de N-glicosilación


itacnosertibum

itacnosertib — N^4-([2,2'-bipyridin]-3-yl)-N^2-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine

itacnosertib — N^4-([2,2'-bipyridin]-3-yl)-N^2-[3-méthoxy-4-(4-méthylpipérazin-1-yl)phényl]pyrimidine-2,4-diamine

itacnosertib — N^4-([2,2'-bipiridin]-3-il)-N^2-[4-(4-metilpiperazin-1-il)-3-metoxifenil]pirimidina-2,4-diamina

$C_{26}H_{28}N_8O$



itepekimabum #

itepekimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* IL33 (interleukin 33, interleukin-1 family member 11, IL1F11, nuclear factor for high endothelial venules, NF-HEV)], monoclonal antibody;
gamma4 heavy chain (1-449) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

itépékimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* IL33 (interleukine 33, membre 11 de la famille 1 d'interleukines, IL1F11, facteur nucléaire des veinules à haut endothélium, NF-HEV)], anticorps monoclonal;
chaîne lourde gamma4 (1-449)) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

itepekimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL33 (interleukina 33, miembro 11 de la familia 1 de interleukinas, IL1F11, factor nuclear de las vénulas del endotelio alto, NF-HEV)], anticuerpo monoclonal; cadena pesada gamma4 (1-449)) [VH (*Homo sapiens* IGHV3-23*04 (88.8%) -(IGHD) -IGHJ6*03 (91.0%)) [8.8.15] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230)(221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-12*01 (96.8%) -IGKJ5*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGN LEQPGGSLRL SCTASGFTFS RSAMNWVRRA PGKGLEWVSG  50
ISGSGGRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLSAED TAAYYCAKDS 100
YTTSWYGGMD VWGHGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIF SWLAWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFAIYYCQQ ANSVPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	263-323	369-427
	22"-96"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	136-214'	136"-214'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
449, 449"

izaflortaucipirum (^{18}F)

izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropyridin-4-yl)-9*H*-pyrrolo[2,3-*b*:4,5-*c*']dipyridine


izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropyridin-4-yl)-9*H*-pyrrolo[2,3-*b*:4,5-*c*']dipyridine

izaflortaucipir (^{18}F)

2-(2-(^{18}F)fluoropiridin-4-il)-9*H*-pirrolo[2,3-*b*:4,5-*c*']dipiridina

$C_{15}H_9{}^{18}FN_4$



izokibepum #

izokibep

fusion protein composed of 3 binding domains consisting of three-alpha-helix motifs, each derived from the immunoglobulin (Ig)-binding Z-domain of staphylococcal protein A (SpA), engineered for binding to two homodimer subunits of human interleukin 17A (IL17A) with the two identical N- and C-terminal domains (1-58, 116-173) and to the domain II of human serum albumin (HSA) with the central domain (59-110), connected via a G_4S peptide linker (111-115);
[IL17A-binding engineered SpA peptide (1-58)]-[HSA-binding engineered SpA peptide (59-110)]-[G_4S linker (111-115)]-[IL17A-binding engineered SpA peptide (116-173] fusion protein;
produced in *Escherichia coli*

izokibep

protéine de fusion composée de 3 domaines liants, chacun consistant en un motif à 3 hélices alpha dérivé du domaine Z de la protéine staphylococcique A (SpA) se liant à l'immunoglobuline (Ig), mis au point pour se lier aux deux homodimères des sous-unités de l'interleukine 17A humaine (IL17A) avec les deux domaines N- et C-terminaux identiques (1-58, 116-173), et au domaine II de l'albumine sérique humaine (ASH, HSA) avec le domaine central (59-110), connecté via un peptide liant G_4S (111-115);
protéine de fusion [peptide SpA mis au point pour se lier à l'IL17A (1-58)]-[peptide SpA mis au point pour se lier au HSA (59-110)]-[peptide liant G_4S (111-115)]-[peptide SpA mis au point pour se lier à l'IL17A (116-173)];
produite par *Escherichia coli*

izokibep

proteína de fusión compuesta de 3 dominios de unión, cada uno consistente en un motivo con 3 hélices alfa derivado del dominio Z de la proteína estafilocócica A (SpA) que se une a la inmunoglobulina (Ig), diseñado para unirse a los dos homodímeros de las sub-unidades de la interleukina 17A humana (IL17A) con los dos dominios N- y C-terminal idénticos (1-58, 116-173), y con el dominio II de la albúmina sérica humana (ASH, HSA) con el dominio central (59-110), conectado a través de un péptido que se une a G_4S (111-115);
proteína de fusión [péptido SpA diseñado para unirse a la IL17A (1-58)]-[péptido SpA diseñado para unirse al HSA (59-110)]-[G_4S linker (111-115)]-[péptido SpA diseñado para unirse a la IL17A (116-173)];
producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```
AEAKYAKEAD DAAVEIASLP NLTWDQWYAF IQKLRDDPSQ SSELLSEAKK   50
LNDSQAPKAS GSLAEAKEAA NAELDSYGVS DFYKRLIDKA KTVEGVEALK  100
DAILAALPGT GGGGSAEAKY AKEADDAAVE IASLPNLTWD QWYAFIQKLR  150
DDPSQSSELL SEAKKLNDSQ APK                               173
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales
None / aucune / ninguna


lazuvapagonum

lazuvapagon — (4*S*)-*N*-[(2*S*)-1-hydroxypropan-2-yl]-methyl-1-[2-methyl-4-(3-methyl-1*H*-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1*H*-1-benzazepine-4-carboxamide

lazuvapagon — (4*S*)-*N*-[(2*S*)-1-hydroxypropan-2-yl]-méthyl-1-[2-méthyl-4-(3-méthyl-1*H*-pyrazol-1-yl)benzoyl]-2,3,4,5-tétrahydro-1*H*-1-benzazépine-4-carboxamide

lazuvapagón — (4*S*)-*N*-[(2*S*)-1-hidroxipropan-2-il]-metil-1-[2-metil-4-(3-metil-1*H*-pirazol-1-il)benzoil]-2,3,4,5-tetrahidro-1*H*-1-benzazepina-4-carboxamida

$C_{27}H_{32}N_4O_3$



lecanemabum #

lecanemab — immunoglobulin G1-kappa, anti-[*Homo sapiens* APP (amyloid beta A4 precursor protein) soluble beta-amyloid protofibril], monoclonal antibody;
gamma1 heavy chain (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfide with kappa light chain (1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dimer (233-233":236-236")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

lécanémab — immunoglobuline G1-kappa, anti-[*Homo sapiens* APP (protéine précurseur amyloïde bêta A4) protofibrille bêta amyloïde soluble], anticorps monoclonal;
chaîne lourde gamma1 (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfure avec la chaîne légère kappa

(1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dimère (233-233'':236-236'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

lecanemab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* APP (proteína precusor amiloide beta A4) protofibrilla beta amiloide soluble], anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [VH (*Homo sapiens* IGHV3-48*01 (89.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.17] (26-33.51-58.97-113) (1-124) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01 (91%) -IGKJ1*02 (90.9%)/*Homo sapiens* IGKV2-30*02 (84.0%) -IGKJ2*01 (90.9%)) CDR-IMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (227'-219')];
dímero (233-233'':236-236'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCSASGFTFS SFGMHWVRQA PGKGLEWVAY  50
ISSGSSTIYY GDTVKGRFTI SRDNAKNSLF LQMSSLRAED TAVYYCAREG 100
GYYYGRSYYT MDYWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTPGAPAS ISCRSSQSIV HSNGNTYLEW YLQKPGQSPK  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLRI SRVEAEDVGI YYCFQGSHVP 100
PTFGPGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	151-207	268-328	374-432
	22"-96"	151"-207"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	227-219'	227"-219'"		
Inter-H-H (h 11, h 14)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2: 454, 454"

lorpucitinibum

lorpucitinib

2-{1-[*trans*-4-(cyanomethyl)cyclohexyl]-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl}-*N*-(2-hydroxy-2-methylpropyl)acetamide


lorpucitinib

2-{1-[*trans*-4-(cyanométhyl)cyclohexyl]-1,6-dihydroimidazo[4,5-*d*]pyrrolo[2,3-*b*]pyridin-2-yl}-*N*-(2-hydroxy-2-méthylpropyl)acetamide

lorpucitinib

2-{1-[*trans*-4-(cianometil)ciclohexil]-1,6-dihidroimidazo[4,5-*d*]pirrolo[2,3-*b*]piridin-2-il}-*N*-(2-hidroxi-2-metilpropil)acetamida

$C_{22}H_{28}N_6O_2$




luvadaxistatum

luvadaxistat — 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2*H*)-one

luvadaxistat — 4-hydroxy-6-{2-[4-(trifluorométhyl)phényl]éthyl}pyridazin-3(2*H*)-one

luvadaxistat — 4-hidroxi-6-{2-[4-(trifluorometil)fenil]etil}piridazin-3(2*H*)-ona

$C_{13}H_{11}F_3N_2O_2$



miptenalimabum #

miptenalimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], monoclonal antibody;
gamma4 heavy chain (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

mipténalimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* LAG3 (activateur 3 des lymhocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal;
chaîne lourde gamma4 (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), charnière 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

miptenalimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal;
cadena pesada gamma4 (1-448) [VH (*Homo sapiens* IGHV3-33*01 (77.0%) -(IGHD) -IGHJ4*01 (93.3%)) [10.7.14] (1-122) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (123-220), bisagra 1-12 S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (123-448)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17 (85.3%) -IGKJ2*03 (90.9%)/*Homo sapiens* IGKV1-39*01 (82.1%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLVESGGG VVQPGRSLRL SCAFSGFSLS TSDMGVGWIR QAPGKGLEWV  50
AHIWWDDVKR YNPALKSRFT ISRDNSKNTL YLQMNSLRAE DTAVYFCARI 100
EDYGVSYYFD YWGQGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSF LSASVGDRVS ITCKASQDVS TAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPD RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSIPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	149-205	263-323	369-427
	22"-97"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	136-214'	136"-214'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1: 1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mirdametinibum

mirdametinib

N-[(2*R*)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide


mirdamétinib

N-[(2*R*)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

mirdametinib

N-[(2*R*)-2,3-dihidroxipropoxi]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

$C_{16}H_{14}F_3IN_2O_4$



miromavimabum #

miromavimab	immunoglobulin G1-kappa, anti-[rabies virus strain ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-II], *Mus musculus* monoclonal antibody; gamma1 heavy chain *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), hinge 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfide with kappa light chain *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimer (225-225":228-228":230-230")-trisdisulfide, produced in mouse myeloma cell line SP2/0-Ag14, glycoform alfa
miromavimab	immunoglobuline G1-kappa, anti-[épitope G-II de l'ectodomaine de la glycoprotéine de la souche ERA (Evelyn-Rockitniki-Abelseth) du virus de la rage], anticorps monoclonal *Mus musculus*; chaîne lourde gamma1 *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), charnière 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfure avec la chaîne légère kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dimère (225-225":228-228":230-230")-trisdisulfure, produite dans la lignée cellulaire de myélome murin SP2/0-Ag14, glycoforme alfa
miromavimab	inmunoglobulina G1-kappa, anti-[epítopo G-II del ectodominio de la glicoproteína de la cepa ERA (Evelyn-Rockitniki-Abelseth) del virus de la rabia], anticuerpo monoclonal *Mus musculus*; cadena pesada gamma1 *Mus musculus* (1-445) [VH (*Mus musculus* IGHV1S130*01 (93.9%) -(IGHD) -IGHJ1*01 (88.2%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Mus musculus* IGHG1*02 (CH1 Q100>E (199) (122-218), bisagra 1-13 (219-231), CH2 K81>Q (288), I84.3>F (294) (232-338), CH3 N27>D (369) (339-443), CHS (444-445)) (122-445)], (223-214')-disulfuro con la cadena ligera kappa *Mus musculus* (1'-214') [V-KAPPA (*Mus musculus* IGKV6-17*01 (98.9%) -IGKJ1*02 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Mus musculus* IGKC*01 (100%) (108'-214')]; dímero (225-225":228-228":230-230")-trisdisulfuro, producida en la línea celular de mieloma murino SP2/0-Ag14, glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQPGSV LVRPGASVKL SCKTSGYAFT SSWMHWAKQR PGQGLEWIGQ  50
THPNSGYTNY NEKFKGKATL TVDTSSSTAY VDLSSLTSED SAVYYCARES 100
GDGPHWYFDV WGAGTAVTVS SAKTTPPSVY PLAPGSAAQT NSMVTLGCLV 150
KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS DLYTLSSSVT VPSSTWPSET 200
VTCNVAHPAS STKVDKKIVP RDCGCKPCIC TVPEVSSVFI FPPKPKDVLT 250
ITLTPKVTCV VVDISKDDPE VQFSWFVDDV EVHTAQTQPR EEQFNSTFRS 300
VSELPIMHQD WLNGKEFKCR VNSAAFPAPI EKTISKTKGR PKAPQVYTIP 350
PPKEQMAKDK VSLTCMITDF FPEDITVEWQ WNGQPAENYK NTQPIMDTDG 400
SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL HNHHTEKSLS HSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSHKF MSTSVGDRVS ITCKASQDVS TAVAWYQQKP GQSPKLLIYS  50
ASYRYTGVPD RFTGSGSGTD FTFTISSVQA EDLAVYYCQQ HYSSPHTFGG 100
GTKLETKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150
DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200
STSPIVKSFN RNEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-203	259-319	365-423
	22"-96"	148"-203"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	223-214'	223"-214'"		
Inter-H-H (h 7, h 10, h 12)	225-225"	228-228"	230-230"	

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex biantennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

modakafuspum alfa

modakafusp alfa

immunoglobulin G4-kappa, anti-[human ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, cell surface antigen CD38)], humanized monoclonal antibody, fused at each C-terminus of the heavy chains (1-447, 1"-447") to attenuated human interferon α-2b (IFNα2b) variant (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) (448-612, 448"-612"); gamma4 heavy chain humanized fused to IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), hinge 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fused to IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide;
produced in Chinese hamster ovary (CHO) K1SV cells, glycoform alfa

modakafusp alfa

immunoglobuline G4-kappa, anti-[ADP-ribosyl cyclase/ ADP cyclique - ribose hydrolase 1 humaine (EC:3.2.2.6) (ADPRC 1/cADRp hydrolase 1, antigène de surface cellulaire CD38)], anticorps monoclonal humain fusionné à chaque partie C-terminale des chaînes lourdes (1-447, 1"-447") à un variant (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) de l'interféron α-2b humain (IFNα2b) atténué, (448-612, 448"-612");
chaîne lourde gamma4 humanisée fusionnée à IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), charnière 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fusionné à IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dimère (226-226":229-229")-bisdisulfure ;
produit dans des cellules ovariennes de hamster chinois (CHO) K1SV, glycoforme alfa

modakafusp alfa

inmunoglobulina G4-kappa, anti-[ADP-ribosil ciclasa/ADP cíclica -ribosa hidrolasa 1 humana (EC:3.2.2.6) (ADPRC 1/cADRp hidrolasa 1, antígeno de superficie celular CD38)], anticuerpo monoclonal humano fusionado a cada parte C-terminal de las cadenas pesadas (1-447, 1''-447'') a una variante (K^{23}>R^{470}, T^{106}>A^{553}, A^{145}>D^{592}) del interferón α-2b humano (IFNα2b) atenuado, (448-612, 448''-612''); cadena pesada gamma4 humanizada fusionada al IFNα2b (1-612) [VH (*Homo sapiens* IGHV1-69-2*01 (90.7%) -(IGHD)- IGHJ4*01 (85.7%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (121-218), bisagra 1-12 S^{10}>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(121-447), fusionado con IFNα2b K^{23}>R (470), T^{106}>A (553), A^{145}>D (592) (448-612)],(134-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V^{101} (191) (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro ; producido en las células ováricas de hamster chino (CHO) K1SV, glicoforma alfa

Sequence / Séquence / Secuencia
Heavy chain / Chaîne lourde / Cadena pesada (anti-CD38 γ4-IFNα2b)

```
EVQLVQSGAE VKKPGATVKI SCKVSGYTFT DSVMNWVQQA PGKGLEWMGW   50
IDPEYGRTDV AEKFQGRVTI TADTSTDTAY MELSSLRSED TAVYYCARTK  100
YNSGYGFPYW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK  150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT  200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT  250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY  300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT  350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS  400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGKCDL  450
PQTHSLGSRR TLMLLAQMRR ISLFSCLKDR HDFGFPQEEF GNQFQKAETI  500
PVLHEMIQQI FNLFSTKDSS AAWDETLLDK FYTELYQQLN DLEACVIQGV  550
GVAETPLMKE DSILAVRKYF QRITLYLKEK KYSPCAWEVV RDEIMRSFSL  600
STNLQESLRS KE                                           612
```

Light chain / chaîne légère / cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQNVD SDVDWYQQKP GKAPKLLIYK   50
ASNDYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCMQ SNTHPRTFGG  100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	147-203	261-321	367-425
	22''-96''	147''-203''	261''-321''	367''-425''
Intra-IFN	448-545	476-585	448''-545''	476''-585''
Intra-L	23'-88'	134'-194'	23'''-88'''	134'''-194'''
Inter-H-L	134-214'	134''-214'''		
Inter-H-H	226-226''	229-229''		


Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
H CH2 N84.4: N297, N297''
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

murizatoclaxum
murizatoclax

(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-chloro-4-methoxy-8,9-dimethyl-4-{[(9a*R*)-octahydro-2*H*-pyrido[1,2-*a*]pyrazin-2-yl]methyl}-3',4'-dihydro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-1^{3},1'-naphthalene]-10,10,12-trione

murizatoclax	(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-chloro-4-méthoxy-8,9-diméthyl-4-{[(9a*R*)-octahydro-2*H*-pyrido[1,2-*a*]pyrazin-2-yl]méthyl}-3',4'-dihydro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazépina-3(1,2)-cyclobutanacyclododécaphan-5-ène-1^{3},1'-naphtalène]-10,10,12-trione
murizatoclax	(1^{3}*S*,3^{1}*R*,3^{2}*R*,4*R*,5*E*,8*S*,9*R*)-6'-cloro-4-metoxi-8,9-dimetil-4-{[(9a*R*)-octahidro-2*H*-pirido[1,2-*a*]pirazin-2-il]metil}-3',4'-dihidro-1^{2}*H*,1^{4}*H*,2'*H*-spiro[10λ^{6}-thia-11-aza-1(5,7)-[1,5]benzoxazepina-3(1,2)-ciclobutanaciclododecafan-5-eno-1^{3},1'-naftaleno]-10,10,12-triona

$C_{42}H_{57}ClN_4O_5S$



nadunolimabum #

nadunolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide
nadunolimab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide

nadunolimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1RAP (interleukin-1 receptor accessory protein)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-446) [VH (*Homo sapiens* IGHV1-69*02 (85.4%) -(IGHD) -IGHJ4*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.3%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (226-226":229-229")-bisdisulfide

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYAFT SSWMNWVRQA PGQGLEWMGR  50
IYPGDGNTHY AQKFQGRVTL TADKSTSTAY MELSSLRSED TAVYYCGEGY 100
LDPMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQGIN NYLNWYQQKP GKAPKLLIHY  50
TSGLHAGVPS RFSGSGSGTD YTLTISSLEP EDVATYYCQQ YSILPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfur
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 220-214' 220"-214'"
Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297'
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennai complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados.

nesolicaftorum

nesolicaftor

N-(*trans*-3-{5-[(1*R*)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide


nésolicaftor

N-(*trans*-3-{5-[(1*R*)-1-hydroxyéthyl]-1,3,4-oxadiazol-2-yl}cyclobutyl)-3-phenyl-1,2-oxazole-5-carboxamide

nesolicaftor

3-fenil-*N*-(*trans*-3-{5-[(1*R*)-1-hidroxietil]-1,3,4-oxadiazol-2-il}ciclobutil)-1,2-oxazolo-5-carboxamida

$C_{18}H_{18}N_4O_4$



nipocalimabum #

nipocalimab	immunoglobulin G1-lambda, anti-[*Homo sapiens* FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) -IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), hinge 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfide with lambda light chain *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
nipocalimab	immunoglobuline G1-lambda, anti-[*Homo sapiens* FCGRT (transporteur et récepteur du fragment Fc des IgG, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) -IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), charnière 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dimère (225-225'':228-228'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
nipocalimab	inmunoglobulina G1-lambda, anti-[*Homo sapiens* FCGRT (transportador y receptor del fragmento Fc de las IgG, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-445) [VH (*Homo sapiens* IGHV3-23*01 (90.8%) -(IGHD) -IGHJ3*01 (100%)) CDR-IMGT [8.8.9] (26-33.51-58.97-105) (1-116) -*Homo sapiens* IGHG1*03 G1m3>G1m17, nG1m1, G1v29 CH2 A84.4 (CH1 R120>K (213) (117-214), bisagra 1-15 (215-229), CH2 N84.4>A (296) (230-339), CH3 E12 (355), M14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-215')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-216') [V-LAMBDA (*Homo sapiens* IGLV2-23*01 (94.8%) -IGLJ1*01 (100%)) CDR-IMGT [9.3.10] (26-34.52-54.91-100) (1'-110') -*Homo sapiens* IGLC3*03 (100%) (111'-216')]; dímero (225-225'':228-228'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS TYAMGWVRQA PGKGLEWVSS  50
IGASGSQTRY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARLA 100
IGDSYWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYASTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPASV SGSPGQSITI SCTGTGSDVG SYNLVSWYQQ HPGKAPKLMI  50
YGDSERPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYAGSGIYV 100
FGTGTKVTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHKSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	143-199	260-320	366-424
	22"-96"	143"-199"	260"-320"	366"-424"
Intra-L (C23-C104)	22'-90'	138'-197'		
	22'"-90'"	138'"-197'"		
Inter-H-L (h 5-CL 126)	219-215'	219"-215'"		
Inter-H-H (h 11, h 14)	225-225"	228-228"		

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación
H CH2 N84.4>A:
296, 296"

olverembatinibum

olverembatinib

4-methyl-*N*-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-[(1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)ethynyl]benzamide


olvérembatinib

4-méthyl-*N*-{4-[(4-méthylpipérazin-1-yl)méthyl]-3-(trifluorométhyl)phényl}-3-[(1*H*-pyrazolo[3,4-*b*]pyridin-5-yl)éthynyl]benzamide

olverembatinib

4-metil-*N*-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}-3-[(1*H*-pirazolo[3,4-*b*]piridin-5-il)etinil]benzamide

$C_{29}H_{27}F_3N_6O$



olvimulogenum nanivacirepvecum

olvimulogene nanivacirepvec

A recombinant replication-competent oncolytic vaccinia virus (strain LIVP) comprising the genes encoding a Renilla luciferase - green fluorescent protein fusion protein (ruc-gfp) and enzymes beta-galactosidase (lacZ) and beta-glucuronidase (gusA), inserted into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively. Expression of the three proteins is driven by a synthetic early/late promoter (pSEL), a vaccinia virus strain Western Reserve early/late p7.5 promoter and a vaccinia virus strain Western Reserve late p11 promoter, respectively. A human transferrin receptor gene has also been inserted in the J2R locus but is not expressed.

olvimulogène nanivacirépvec	virus de la vaccine recombinant répliquant oncolytique (souche LIVP) contenant les gènes codant pour une protéine de fusion luciférase de Renilla - protéine fluorescente verte (ruc-gfp) et des enzymes galactosidase bêta (lacZ) et glucuronidase bêta (gusA), insérés dans les loci F14.5L, J2R (thymidine kinase) and A56R (hémagglutinine), respectivement. L'expression des trois protéines est sous le contrôle d'un promoteur synthétique précoce/tardif (pSEL), d'un promoteur p7.5 précoce/tardif du virus de la vaccine souche Western Reserve et d'un promoteur p11 tardif du virus de la vaccine souche Western Reserve, respectivement. Un gène du récepteur de transférine humain a aussi été inséré dans le locus J2R mais n'est pas exprimé.
olvimulogén nanivacirepvec	Un virus vaccinia recombinante (cepa LIVP) competente para replicación, oncolítico, que contiene los genes que codifican para una proteína de fusión de la luciferasa de Renilla y la proteína fluorescente verde (ruc-gfp) y para las enzimas beta-galactosidasa (LacZ) y beta-glucuronidasa (gusA), insertados en los loci F14.5L, J2R (timidina quinasea) y A56R (hemaglutinina), respectivamente. La expresión de las tres proteínas está dirigida por un promotor temprano/tardío sintético (pSEL), un promotor p7.5 precoz/tardío de la cepa Western Reserve del virus vaccinia y un promotor p11 tardío de la cepa Western Reserve del virus vaccinia, respectivamente. Se ha insertado también un gen del receptor de transferrina humano en el locus J2R pero éste no se expresa.

omfiloctocogum alfa #

omfiloctocog alfa	human coagulation factor VIII (FVIII, antihemophilic factor, AHF, procoagulant component) with deleted B-domain (746-1639)-sequence: single-chain recombinant FVIII composed of domains A1-a1-A2-a2 (1-740), the B-domain N- and C-terminal fragments (741-745) and 1640-1648 (746-754) and domains a3-A3-C1-C2 1649-2332 (755-1438), produced in Chinese hamster ovary (CHO) cells, glycoform alfa
omfiloctocog alfa	facteur de coagulation VIII humain (FVIII, facteur antihémophilique, AHF, composant procoagulant) dont le domaine B a été supprimé (746-1639): chaîne unique du FVIII humain recombinant composé des domaines A1-a1-A2-a2 (1-740), des fragments N- and C-terminaux du domaine B (741-745) et 1640-1648 (746-754) et des domaines a3-A3-C1-C2 1649-2332 (755-1438), produit par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
omfiloctocog alfa	factor de coagulación VIII humano (FVIII, factor antihemofílico, AHF, componente procoagulante) con el dominio B que ha sido suprimido (746-1639):

cadena única del FVIII humano recombinante compuesto de los dominios A1-a1-A2-a2 (1-740), de los fragmentos N- y C-terminal del dominio B (741-745) y 1640-1648 (746-754) y de los dominios a3-A3-C1-C2 1649-2332 (755-1438), producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL    50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA   100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD   150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA   200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR   250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL   300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL   350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL   400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG   450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD   500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP   550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG   600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS   650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR   700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNPPVLK   750
RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK   800
TRHYFIAAVE RLWDYGMSSS PHVLRNRAQS GSVPQFKKVV FQEFTDGSFT   850
QPLYRGELNE HLGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLISYEE   900
DQRQGAEPRK NFVKPNETKT YFWKVQHHMA PTKDEFDCKA WAYFSDVDLE   950
KDVHSGLIGP LLVCHTNTLN PAHGRQVTVQ EFALFFTIFD ETKSWYFTEN  1000
MERNCRAPCN IQMEDPTFKE NYRFHAINGY IMDTLPGLVM AQDQRIRWYL  1050
LSMGSNENIH SIHFSGHVFT VRKKEEYKMA LYNLYPGVFE TVEMLPSKAG  1100
IWRVECLIGE HLHAGMSTLF LVYSNKCQTP LGMASGHIRD FQITASGQYG  1150
QWAPKLARLH YSGSINAWST KEPFSWIKVD LLAPMIIHGI KTQGARQKFS  1200
SLYISQFIIM YSLDGKKWQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPPI  1250
IARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMESKA ISDAQITASS  1300
YFTNMFATWS PSKARLHLQG RSNAWRPQVN NPKEWLQVDF QKTMKVTGVT  1350
TQGVKSLLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVFQ GNQDSFTPVV  1400
NSLDPPLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLY               1438
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179, 248-329, 528-554, 630-711, 938-964, 1005-1009, 1127-1275, 1280-1432
(Cys-SH: 310, 692, 1106)

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N41, N239, N916, N1224
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

Tyr-sulfation sites / Sites de Tyr-sulfation / Posiciones de Tyr-sulfación
346, 718, 719, 723, 770, 786


onatasertibum

onatasertib — 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(*trans*-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one

onatasertib — 7-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-(*trans*-4-méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one

onatasertib — 7-[6-(2-hidroxipropan-2-il)piridin-3-il]-1-(*trans*-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-*b*]pirazin-2(1*H*)-ona

$C_{21}H_{27}N_5O_3$



ongericimabum #

ongericimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)], humanized monoclonal antibody; gamma4 heavy chain (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) -IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), hinge 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfide with kappa light chain (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) - IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (217-217'':220-220'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ongéricimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9, convertase 1 régulée par l'apoptose neuronale, NARC1, NARC-1, proprotéine convertase 9, PC9)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), charnière 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (217-217'':220-220'')-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
ongericimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* PCSK9 (proproteína convertasa subtilisina/kexina tipo 9, convertasa 1 regulada por la apoptosa neuronal, NARC1, NARC-1, proproteína convertasa 9, PC9)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-438) [VH (*Homo sapiens* IGHV4-59*01 (79.2%) -(IGHD) - IGHJ1*01 (100%)) CDR-IMGT [8.7.5] (26-33.51-57.96-100) (1-111) - *Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (112-209), bisagra 1-12 S10>P (219) (210-221), CH2 (222-331), CH3 (332-436), CHS (437-438)) (112-438)], (125-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.1%) -IGKJ1*01 (100%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (217-217'':220-220'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGFSIS SYGIHWIRQS PGKGLEWIGV  50
IWRGGITDYN APFMSRVTIS KDNSKNQVSF KLSSVTAADT AVYYCANHRD 100
WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV 150
SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP 200
SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD TLMISRTPEV 250
TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL 300
HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT 350
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR 400
LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK              438
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCQASQDIN KYIDWYQHKP GKAPKLLIHY  50
ASTLQPGVPS RFSGSGSGRD YTFTISSLQP EDIATYYCLQ YDDLWTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	138-194	252-312	358-416
	22"-95"	138"-194"	252"-312"	358"-416"
Intra-L (C23-C104)	23'-88'	133'-193'		
	23'"-88"'	133'"-193'"		
Inter-H-L (CH1 10-CL 126)	125-213'	125"-213'"		
Inter-H-H (h 8, h 11)	217-217"	220-220"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
288, 288"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ontorpaceptum #

ontorpacept — human signal-regulatory protein alpha (SIRPα, tyrosine-protein phosphatase non-receptor type substrate 1, inhibitory receptor SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variant, N-terminal (1-118)-fragment [binding domain for CD47 (inhibitor of phagocytosis by macrophages)], fused to a human immunoglobulin G1 C-terminal Fc fragment (119-345), dimer (124-124':127-127')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ontorpacept — protéine régulatoire de signal alpha, humaine (SIRPα, substrat 1 de type non-récepteur de la tyrosine-protéine phosphatase, récepteur inhibitoire SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variant, fragment N-terminal (1-118) [domaine se liant au CD47 (inhibiteur de la phagocytose par les macrophages)], fusionnée au fragment Fc C-terminal de l'immunoglobuline G1 (119-345), dimère (124-124':127-127')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

ontorpacept — proteína reguladora de señal alfa, humana (SIRPα, sustrato 1 de tipo no-receptor de la tirosina-proteína fosfatasa, receptor inhibidor SHPS-1), (L^{14}>S, T^{20}>S, T^{22}>I, R^{24}>H, A^{27}>V, G^{45}>A, D^{65}>E, L^{66}>S, N^{70}>E, R^{77}>S, G^{79}>S, D^{101}>del, V^{102}>T^{101})-variante, fragmento N-terminal (1-118) [dominio unido al CD47 (inhibidor de la fagocitosis por los macrófagos)], fusionado con el fragmento Fc C-terminal de la inmunoglobulina G1 (119-345), dímero (124-124':127-127')-bisdisulfuro, producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
EEELQVIQPD KSVSVAAGES AILHCTVTSL IPVGPIQWFR GAGPARELIY   50
NQKEGHFPRV TTVSESTKRE NMDFSISISN ITPADAGTYY CVKFRKGSPD  100
TEFKSGAGTE LSVRAKPSDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM  150
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV  200
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP  250
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG  300
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK       345
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

intra-chain	25-91	159-219	265-323
	25'-91'	159'-219'	265'-323'
inter-chain:	124-124'	127-127'	

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N80, N195, N80', N195'
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping / Coupure de la lysine C-terminale / supresión de lisina C-terminal
H CHS K2: 345, 345'

opucolimabum #

opucolimab — immunoglobulin G1-lambda, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], monoclonal antibody;
gamma1 heavy chain (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), hinge 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with lambda light chain humanized (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')];
dimer (232-232":235-235")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells

opucolimab — immunoglobuline G1-lambda, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal;
chaîne lourde gamma1 (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), charnière 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')];
dimère (232-232":235-235")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO)

opucolimab — inmunoglobulina G1-lambda, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal;

cadena pesada gamma1 (1-453) [VH (*Homo sapiens* IGHV3-21*01 (94.9%) -(IGHD) -IGHJ3*01 (93.3%)) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (220) (124-221), bisagra 1-15 (222-236), CH2 N84.4>A (303) (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera lambda (1'-214') [V-LAMBDA (*Homo sapiens* IGLV1-51*01 (82.3%) -IGLJ2*01 (100%)) [8.3.10] (1'-109') -*Homo sapiens* IGLC3*03 (98.1%) K119>R (207), P123>L (211) (110'-214')]; dímero (232-232":235-235")-bisdisulfuro, producido por células ováricas de hamster chino (CHO)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYTMNWVRQA PGKGLEWVSS  50
ISSGSDYLYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARNE 100
LRWYPQAGAF DRWGQGTMVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYASTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
QSVVTQPPSM SAAPGQRVTI SCSGSSSYIE SSYVGWYQQL PGTAPRLLIY  50
DDDMRPSGIP DRFSGSKSGT SATLAITGLQ TGDEADYYCE IWRSGLGGVF 100
GGGTKLTVLS QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HKSYSCQVTH 200
EGSTVERTVA LTEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L (C23-C104)	22'-89'	137'-196'		
	22'"-89'"	137'"-196'"		
Inter-H-L (h 5-CL 126)	226-214'	226"-214'"		
Inter-H-H (h 11, h 14)	232-232"	235-235"		

No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación:
H CH2 N84.4>A:
303, 303"

C-terminal lysine clipping:
H CHS K2:
453, 453"


orelabrutinibum

orelabrutinib — 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridine-3-carboxamide

orélabrutinib — 2-(4-phénoxyphényl)-6-[1-(prop-2-énoyl)pipéridin-4-yl]pyridine-3-carboxamide

orelabrutinib — 2-(4-fenoxifenil)-6-[1-(prop-2-enoil)piperidin-4-il]piridina-3-carboxamida

$C_{26}H_{25}N_3O_3$




orvacabtagenum autoleucelum #

orvacabtagene autoleucel	autologous CD4+ and CD8+ T lymphocytes obtained from peripheral blood mononuclear cells (PBMC), transduced *ex vivo* with a replication-incompetent, self-inactivating (SIN) lentiviral vector, encoding a chimeric antigen receptor (CAR) consisting of the human B cell maturation antigen (BCMA)-specific scFv, an IgG4-CH2-CH3 hinge region, CD28 transmembrane domain, CD137 (4-1BB) co-stimulatory domain and CD3 zeta signalling domain, under the control of a hybrid Elongation Factor 1 alpha (EF1α) / Human T cell Leukemia Virus (HTLV) R element promoter. The vector also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CAR on the cell surface.
orvacabtagène autoleucel	lymphocytes T autologues CD4+ and CD8+ obtenus de cellules mononuclées du sang périphérique (PBMC), transduits *ex vivo* avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour un récepteur d'antigène chimérique (CAR) ciblant l'antigène spécifique du scFv de maturation des lymphocytes B (BCMA) humain, une région charnière IgG4-CH2-CH3, un domaine transmembranaire du CD28, un domaine co-stimulateur du CD137 (4-1BB), et un domaine de signalisation CD3 zêta, sous le contrôle d'un promoteur hybride du facteur d'élongation 1-alpha humain (EF1α) / élément R du virus du lymphome humain à cellules T (HTLV). Le vecteur exprime un récepteur du facteur de croissance des cellules épidermiques humain tronqué (EGFRt) qui est exprimé séparément du CAR à la surface de la cellule.
orvacabtagén autoleucel	linfocitos T CD4+ y CD8+ autólogos obtenidos de células mononucleares de sangre periférica, transducidos con un vector lentiviral auto inactivante e incompetente para replicación, que codifica un receptor para antígenos quimérico (CAR) consistente en un ssFv específico del antígeno de maduración de linfocitos B humano (BCMA), una región bisagra IgG4-CH2-CH3, un dominio transmembrana de CD28, un domino coestimulador de CD137 (4-1BB) y un dominio de señalización de CD3 zeta, bajo el control de un promotor híbrido del Factor de Elongación 1 alfa (EF1a) / elemento R del virus de la leucemia de células T (HTLV) humana. El vector también codifica para una forma truncada del receptor del factor de crecimiento epidérmico (EGFRt) humano que se expresa separado del CAR en la superficie celular.

osoresnontrinum

osoresnontrine	1-(oxan-4-yl)-6-[(pyridin-2-yl)methyl]-1,5-dihydro-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one
osoresnontrine	1-(oxan-4-yl)-6-[(pyridin-2-yl)méthyl]-1,5-dihydro-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one
osoresnontrina	1-(oxan-4-il)-6-[(piridin-2-il)metil]-1,5-dihidro-4*H*-pirazolo[3,4-*d*]pirimidin-4-ona

$C_{16}H_{17}N_5O_2$



pelacarsenum

pelacarsen

all-P-ambo-5'-*O*-(28-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)guanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)guanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine


pélacarsen

tout-P-ambo-5'-*O*-(28-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy]méthyl}-1-hydroxy-1,10,14,21-tétraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-phosphaoctacosan-1-yl)-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)guanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine

pelacarsén

todo-P-ambo-5'-*O*-(28-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis{[3-({6-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]hexil}amino)-3-oxopropoxi]metil}-1-hidroxi-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ^5-fosfaoctacosan-1-il)-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)guanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridilil-(3'→5')-2'-*O*-(2-metoxietil)guanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidina

$C_{296}H_{439}N_{71}O_{163}P_{20}S_{13}$



pelcitoclaxum

pelcitoclax

(3-{[(10*R*)-1^4-chloro-3^5-fluoro-2^4-(methanesulfonyl)-2^5-methyl-7,7-dioxo-10-[(phenylsulfanyl)methyl]-2^1-(propan-2-yl)-8^3-(trifluoromethanesulfonyl)-2^1*H*-7λ^6-thia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-tetrabenzenatridecaphane-13^4-carbonyl]oxy}propyl)phosphonic acid


pelcitoclax

acide (3-{[(10*R*)-1^4-chloro-3^5-fluoro-2^4-(méthanesulfonyl)-2^5-méthyl-7,7-dioxo-10-[(phénylsulfanyl)méthyl]-2^1-(propan-2-yl)-8^3-(trifluorométhanesulfonyl)-2^1*H*-7λ^6-thia-6,9-diaza-4(1,4)-pipérazina-13(1)-pipéridina-2(2,3)-pyrrola-1(1),3(1,3),5,8(1,4)-tétrabenzenatridécaphane-13^4-carbonyl]oxy}propyl)phosphonique

pelcitoclax

ácido (3-{[(10*R*)-1^4-cloro-10-[(fenilsulfanil)metil]-3^5-fluoro-2^4-(metanosulfonil)-2^5-metil-7,7-dioxo-2^1-(propan-2-il)-8^3-(trifluorometanosulfonil)-2^1*H*-7λ^6-tia-6,9-diaza-4(1,4)-piperazina-13(1)-piperidina-2(2,3)-pirrola-1(1),3(1,3),5,8(1,4)-tetrabencenatridecafano-13^4-carbonil]oxi}propil)fosfónico


$C_{57}H_{66}ClF_4N_6O_{11}PS_4$



pexopiprantum

pexopiprant	({8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethylquinolin-5-yl}oxy)acetic acid
pexopiprant	acide ({8-chloro-3-[(4-chlorophényl)méthyl]-4-(difluorométhoxy)-2-éthylquinolin-5-yl}oxy)acétique
pexopiprant	ácido ({8-cloro-3-[(4-clorofenil)metil]-4-(difluorometoxi)-2-etilquinolin-5-il}oxi)acético

$C_{21}H_{17}Cl_2F_2NO_4$



pimurutamabum #

pimurutamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
pimurutamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé;

chaîne lourde gamma1 humanisée (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), charnière 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (228-228":231-231")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

pimurutamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-449) [VH (*Homo sapiens* IGHV3-48*03 (78.6%) -(IGHD) -IGHJ3*01 (85.7%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), bisagra 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.3%) -IGKJ4*01 (90.9%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (228-228":231-231")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFSLT NYGVHWVRQA PGKGLEWLGV  50
IWSGGNTDYG NEFTSRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARALD 100
YYDYEFAYWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIKY  50
ASESISGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ NNNWPTSFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	146-202	263-323	369-427
	22"-95"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
449, 449"


posenacaftorum

posenacaftor — 8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1*R*)-1-(oxan-4-yl)ethoxy]quinoline-4-carboxylic acid

posénacaftor — acide 8-méthyl-2-(3-méthyl-1-benzofuran-2-yl)-5-[(1*R*)-1-(oxan-4-yl)éthoxy]quinoléine-4-carboxylique

posenacaftor — ácido 8-metil-2-(3-metil-1-benzofuran-2-il)-5-[(1*R*)-1-(oxan-4-il)etoxi]quinolina-4-carboxílico

$C_{27}H_{27}NO_5$




pudexacianinii chloridum

pudexacianinium chloride — 3-(3-{[3-(cyclomaltoheptaos-2^I-*O*-yl)propyl]amino}-3-oxopropyl)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(cyclomaltoheptaos-2^I-*O*-yl)propyl]amino}-3-oxopropyl)-1,1-dimethyl-1,3-dihydro-2*H*-benzo[*e*]indol-2-ylidene]ethylidene}-2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1*H*-benzo[*e*]indol-3-ium chloride

chlorure de pudexacianinium — chlorure de 3-(3-{[3-(cyclomaltoheptaos-2^I-*O*-yl)propyl]amino}-3-oxopropyl)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(cyclomaltoheptaos-2^I-*O*-yl)propyl]amino}-3-oxopropyl)-1,1-diméthyl-1,3-dihydro-2*H*-benzo[*e*]indol-2-ylidène]éthylidène}-2-méthoxycyclohex-1-en-1-yl]éthèn-1-yl}-1,1-diméthyl-1*H*-benzo[*e*]indol-3-ium

cloruro de pudexacianinio — cloruro de 3-(3-{[3-(ciclomaltoheptaos-2^I-*O*-il)propil]amino}-3-oxopropil)-2-{(1*E*)-2-[(3*E*)-3-{(2*E*)-2-[3-(3-{[3-(ciclomaltoheptaos-2^I-*O*-il)propil]amino}-3-oxopropil)-1,1-dimetil-1,3-dihidro-2*H*-benzo[*e*]indol-2-ilideno]etilideno}-2-metoxiciclohex-1-en-1-il]eten-1-il}-1,1-dimetil-1*H*-benzo[*e*]indol-3-ium

$C_{135}H_{197}ClN_4O_{73}$



quavonlimabum #

quavonlimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

quavonlimab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CTLA4 (protéine 4 associée aux lymphocytes T cytotoxiques, CD152)], anticorps monoclonal humanisé;
chaîne lourde gamma1 humanisée (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfure avec la chaîne légère kappa humanisée (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

quavonlimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CTLA4 (proteína 4 asociada a los linfocitos T citotóxicos, CD152)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 humanizada (1-445) [VH (*Homo sapiens* IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfuro con la cadena ligera kappa humanizada (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DNWMNWVRQA PGKGLEWLAQ  50
IRNKPYNYET YYSASVKGRF TISRDDSKNS VYLQMNSLKT EDTGVYYCTA 100
QFAYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRTSENIY GGLNWYQRKP GKSPKLLIYG  50
ATNLASGVSS RFSGSGSGTD YTLTISSLQP EDVATYYCQN VLRSPFTFGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	142-198	259-319	365-423
	22"-98"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	218-214'	218"-214'"		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
445, 445"

ragifilimabum #

ragifilimab — immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF18 (tumor necrosis factor receptor (TNFR) superfamily member 18, activation-inducible TNFR family receptor, AITR, glucocorticoid-induced TNFR-related, GITR, CD375)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-447) [VH (*Homo sapiens* IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ragifilimab — immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF18 (membre 18 de la superfamille des récepteurs du TNF, récepteur de la famille TNFR induit par activation, AITR, récepteur apparenté au TNFR et induit par les glucocorticoïdes, GITR, CD375), anticorps monoclonal humanisé;
chaîne lourde gamma1 humanisée (1-447) [VH (*Homo sapiens* IGHV1-2*02 (80.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfure avec la chaîne légère kappa humanisée (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')];
dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

ragifilimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF18 (miembro 18 de la superfamilia de los receptores del TNF, receptor de la familia TNFR inducido por activación, AITR, receptor relacionado con el TNFR e inducido por los glucocorticoides, GITR, CD375), anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-447) [VH (*Homo sapiens* IGHV1-2*02 (80.6%) -(IGHD) - IGHJ4*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS K>del (447)) (119-447)], (221-220')-disulfuro con la cadena ligera kappa humanizada (1'-220') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.1%) -IGKJ2*01 (100%)) CDR-IMGT [12.3.9] (27-38.56-58.95-103) (1'-113') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKGSGYTFT DYAMYWVRQA PGQGLEWIGV  50
IRTYSGDVTY NQKFKDRATM TVDKSISTAY MELSRLRSDD TAVYYCAKSG 100
TVRGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLT WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYHCQNDYSY 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                  220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-94'	140'-200'		
	23'"-94'"	140'"-200'"		
Inter-H-L (h 5-CL 126)	221-220'	221"-220'"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1:
1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

reciferceptum #

recifercept

human fibroblast growth factor receptor 3 (FGFR-3, CD333) (1-336)-(401-413) fragment (1-349) [soluble isoform (337-400>del, 414-784>del)-sFGFR3], produced in Chinese hamster ovary (CHO) cells, glycoform alfa

récifercept

fragment (1-336)-(401-413) du récepteur 3 du facteur de croissance des fibroblastes humain (FGFR-3, CD333) (1-349) [isoforme soluble (337-400>del, 414-784>del)-sFGFR3], produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

recifercept

fragmento (1-336)-(401-413) del receptor 3 del factor de crecimiento de los fibroblastos humanos (FGFR-3, CD333) (1-349) [isoforma soluble (337-400>del, 414-784>del)-sFGFR3], producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
ESLGTEQRVV GRAAEVPGPE PGQQEQLVFG SGDAVELSCP PPGGGPMGPT   50
VWVKDGTGLV PSERVLVGPQ RLQVLNASHE DSGAYSCRQR LTQRVLCHFS  100
VRVTDAPSSG DDEDGEDEAE DTGVDTGAPY WTRPERMDKK LLAVPAANTV  150
RFRCPAAGNP TPSISWLKNG REFRGEHRIG GIKLRHQQWS LVMESVVPSD  200
RGNYTCVVEN KFGSIRQTYT LDVLERSPHR PILQAGLPAN QTAVLGSDVE  250
FHCKVYSDAQ PHIQWLKHVE VNGSKVGPDG TPYVTVLKTA GANTTDKELE  300
VLSLHNVTFE DAGEYTCLAG NSIGFSHHSA WLVVLPVSLE SNASMSSNT   349
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
intra-chain 39-97 154-206 253-317
(Cys-SH: 87)

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
N76, N203, N240, N272, N293, N306, N342
Fucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes fucosylés / Glicanos de tipo CHO biantenarios complejos fucosilados

relzomostatum

relzomostat

(3*R*,4*S*,5*S*,6*R*)-5-methoxy-4-[(2*R*,3*R*)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 6-(2,2-difluoroethyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate


relzomostat

6-(2,2-difluoroéthyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate de (3*R*,4*S*,5*S*,6*R*)-5-méthoxy-4-[(2*R*,3*R*)-2-méthyl-3-(3-méthylbut-2-én-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yle

relzomostat

6-(2,2-difluoroetil)-2,6-diazaspiro[3.3]heptano-2-carboxilato de (3*R*,4*S*,5*S*,6*R*)-5-metoxi-4-[(2*R*,3*R*)-2-metil-3-(3-metilbut-2-en-1-il)oxiran-2-il]-1-oxaspiro[2.5]octan-6-ilo

$C_{24}H_{36}F_2N_2O_5$



resiquimodum pegolum

resiquimod pegol

2,2',2'',2'''-{methanetetrayltetrakis[methylenepoly(oxyethylene)oxy]}tetrakis[*N*-(2-{[2-(ethoxymethyl)-1-(2-hydroxy-2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-yl]amino}-2-oxoethyl)acetamide]


résiquimod pégol

2,2',2'',2'''-{méthanetétrayltétrakis[méthylènepoly(oxyéthylène)oxy]}tétrakis[*N*-(2-{[2-(éthoxyméthyl)-1-(2-hydroxy-2-méthylpropyl)-1*H*-imidazo[4,5-*c*]quinoléin-4-yl]amino}-2-oxoéthyl)acétamide]

resiquimod pegol

2,2',2'',2'''-{metanotetrailtetrakis[metilenepoli(oxietileno)oxi]}tetrakis[*N*-(2-{[2-(etoximetil)-1-(2-hidroxi-2-metilpropil)-1*H*-imidazo[4,5-*c*]quinolin-4-il]amino}-2-oxoetil)acetamida]

$C_{89}H_{112}N_{20}O_{20} . (C_2H_4O)_{4n}$



revdofilimabum #

revdofilimab — immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], monoclonal antibody;
gamma1 heavy chain (1-450) [VH (*Mus musculus* IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/*Homo sapiens* IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-218')-disulfide with kappa light chain (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (83.8%) -IGKJ1*01 (90.9%)/*Homo sapiens* IGKV4-1*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dimer (229-229":232-232")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

revdofilimab — immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal;
chaîne lourde gamma1 (1-450) [VH (*Mus musculus* IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/*Homo sapiens* IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (83.8%) -IGKJ1*01 (90.9%)/*Homo sapiens* IGKV4-1*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')];
dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

revdofilimab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal;

cadena pesada gamma1 (1-450) [VH (*Mus musculus* IGHV5-6-3*01 (88.8%) -IGHJ4*01 (93.8%)/*Homo sapiens* IGHV3-7*01 (88.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.13] (26-33.51-58.97-109) (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (83.8%) -IGKJ1*01 (90.9%)/*Homo sapiens* IGKV4-1*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (229-229":232-232")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYGMSWVRQA PGKGLELVAT  50
INSNGGRTYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100
ITTAYAMDYW GQGTTVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKASQSVD YDGDSYMHWY QQKPGQPPKL  50
LIYAASILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSNEDPR 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (h 5-CL 126)	223-218'	223"-218'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
450, 450"


rezivertinibum

rezivertinib — *N*-(2-[2-(dimethylamino)ethoxy]-4-methoxy-5-{[4-(1-methyl-1*H*-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide

rézivertinib — *N*-(2-[2-(diméthylamino)éthoxy]-4-méthoxy-5-{[4-(1-méthyl-1*H*-indol-3-yl)pyrimidin-2-yl]amino}phényl)prop-2-énamide

rezivertinib — *N*-(2-[2-(dimetilamino)etoxi]-5-{[4-(1-metil-1*H*-indol-3-il)pirimidin-2-il]amino}fenil)-4-metoxiprop-2-enamida


$C_{27}H_{30}N_6O_3$



rilematovirum

rilematovir	3-({5-chloro-1-[3-(methanesulfonyl)propyl]-1*H*-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2*H*-imidazo[4,5-*c*]pyridin-2-one
rilématovir	3-({5-chloro-1-[3-(méthanesulfonyl)propyl]-1*H*-indol-2-yl}méthyl)-1-(2,2,2-trifluoroéthyl)-1,3-dihydro-2*H*-imidazo[4,5-*c*]pyridin-2-one
rilematovir	3-({5-cloro-1-[3-(metanosulfonil)propil]-1*H*-indol-2-il}metil)-1-(2,2,2-trifluoroetil)-1,3-dihidro-2*H*-imidazo[4,5-*c*]piridin-2-ona

$C_{21}H_{20}ClF_3N_4O_3S$



ripafollitropinum alfa (bovinum) #

ripafollitropin alfa (bovine)	bovine follicle-stimulating hormone (synthetic analog): [follitropin (*Bos taurus*) subunit β (1-109)]-[human chorionic gonadotropin (hCG) C-terminal 28-peptide linker (110-137)]-[glycoprotein hormones α chain (follitropin subunit α) (*Bos taurus*) (138-233)] fusion protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
ripafollitropine alfa (bovine)	hormone folliculostimulante bovine (analogue synthétique): protéine de fusion [follitropine (*Bos taurus*) sous-unité β (1-109)]-[peptide liant: 28-peptide C-terminal de la gonadotrophine chorionique humaine (hCG) (110-137)]-[chaîne α des hormones glycoprotéiques (follitropine sous-unité α) (*Bos taurus*) (138-233)], produit par des cellules ovariennes de hamster chinois (CHO), forme glycosylée alfa
ripafolitropina alfa (bovina)	hormona estimulante del folículo bovina (análogo sintético): proteína de fusión [folitropina (*Bos taurus*) subunidad β (1-109)]-[conector: 28-péptido C-terminal de la gonadotropina coriónica humana (hCG) (110-137)]-[cadena α de las hormonas glicoproteicas (folitropina subunidad α) (*Bos taurus*) (138-233)], producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Sequence / Séquence / Secuencia:
CELTNITITV EKEECGFCIS INTTWCAGYC YTRDLVYRDP ARPNIQKTCT 5(
FKELVYETVK VPGCAHHADS LYTYPVATEC HCSKCDSDST DCTVRGLGPS 1(
YCSFREIKES SSSKAPPPSL PSPSRLPGPS DTPILPQFPD GEFTMQGCPE 1!
CKLKENKYFS KPDAPIYQCM GCCFSRAYPT PARSKKTMLV PKNITSEATC 2(
CVAKAFTKAT VMGNVRVENH TECHCSTCYY HKS 2:

Disulfide bridge location / Position de la pont disulfure / Posición del puente disulfu
(predicted): 1-49, 15-64, 18-102, 26-80, 30-82, 85-92, 148-172,
151-201, 169-223, 173-225, 200-228

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
potential N-glycosylation: N5, N22, N193, N219
potential O-glycosylation: S113, S119, S124, S130

Other post-translational modifications:
potential deamidation: N5, N22, N44, Q46, Q137, Q146,
N156, Q168, N193, N214, N219
potential S-oxidation: M145, M170, M188, M212

ripertamabum #

ripertamab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], chimeric monoclonal antibody; gamma1 heavy chain chimeric (1-451) [VH (*Mus musculus* IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfide with kappa light chain chimeric (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dimer (230-230":233-233")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ripertamab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal chimérique;
chaîne lourde gamma1 chimérique (1-451) [VH (*Mus musculus* IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), charnière 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfure avec la chaîne légère kappa chimérique (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dimère (230-230":233-233")-bisdisulfure, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

ripertamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 quimérica (1-451) [VH (*Mus musculus* IGHV1-12*01 (91.8%) -(IGHD) -IGHJ1*01 (87.5%)) CDR-IMGT [8.8.14] (26-33.51-58.97-110) (1-121) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (218) (122-219), bisagra 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfuro con la cadena ligera kappa quimérica (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (95.8%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (230-230'':233-233'')-bisdisulfuro, producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQPGAE LVKPGASVKM SCKASGYTFT SYNMHWVKQT PGRGLEWIGA  50
IYPGNGDTSY NQKFKGKATL TADKSSSTAY MQLSSLTSED SAVYYCARST 100
YYGGDWYFNV WGAGTTVTVS AASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIHWFQQKPG SSPKPWIYAT  50
SNLASGVPVR FSGSGSGTSY SLTISRVEAE DAATYYCQQW TSNPPTFGGG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                          213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'''-87'''	133'''-193'''		
Inter-H-L (h 5-CL 126)	224-213'	224"-213'''		
Inter-H-H (h 11, h14)	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

rocakinogenum sifuplasmidum

rocakinogene sifuplasmid	A DNA plasmid encoding both subunits of human interleukin-12 (IL12), subunit alpha (IL12A, IL-12 subunit p35) and subunit beta (IL12B; IL-12 subunit p40), under the control of a human cytomegalovirus (CMV) immediate-early 1 (IE1) promoter and a simian cytomegalovirus (sCMV) promoter, respectively.
rocakinogène sifuplasmide	plasmide dont l'ADN code pour les deux sous-unités de l'interleukine 12 humaine (IL-12), sous-unité alpha (IL12A, sous-unité p35 de l'IL-12) et sous-unité bêta (IL12B; sous-unité p40 de l'IL-12), sous le contrôle d'un activateur/promoteur immédiat-précoce 1 (IE1) du cytomégalovirus (CMV) et d'un promoteur du cytomégalovirus simiesque (sCMV), respectivement
rocakinogén sifuplasmida	Un plásmido de DNA que codifica para ambas subunidades de la interleucina 12 (IL12) humana, la subunidad alfa (IL12A, IL-12 subunidad p35) y la subunidad beta (IL12B; IL-12 subunidad p40), bajo el control de un promotor inmediato-temprano 1 (IE1) del citomegalovirus (CMV) humano y un promotor del citomegalovirus de simio (sCMV), respectivamente.

rosopatamabum #

rosopatamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)], monoclonal antibody; gamma1 heavy chain (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
rosopatamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)], anticorps monoclonal; chaîne lourde gamma1 (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA *Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
rosopatamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* FOLH1 (folato hidrolasa, antígeno membranario específico de la próstata, PSMA)], anticuerpo monoclonal; cadena pesada gamma1 (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA *Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGPE VKKPGATVKI SCKTSGYTFT EYTIHWVKQA PGKGLEWIGN  50
INPNNGGTTY NQKFEDKATL TVDKSTDTAY MELSSLRSED TAVYYCAAGW 100
NFDYWGQGTL LTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSTSVGDRVT LTCKASQDVG TAVDWYQQKP GPSPKLLIYW  50
ASTRHTGIPS RFSGSGSGTD FTLTISSLQP EDFADYYCQQ YNSYPLTFGP 100
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	142-198	259-319	365-423
	22"-96"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88"'	134'"-194'"		
Inter-H-L (h 5-CL 126)	218-214'	218"-214'"		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

rosopatamabum tetraxetanum #

rosopatamab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)], monoclonal antibody, *tetraxetan* conjugate; gamma1 heavy chain (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dimer (224-224":227-227")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa, *tetraxetan* (DOTA) conjugate (on an average of 3 to 5 lysyl, linked to the chelator by their N6)

rosopatamab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)], anticorps monoclonal, conjugué au *tétraxétan*;
chaîne lourde gamma1 (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), charnière 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA *Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];

dimère (224-224":227-227")-bisdisulfure; produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, conjugué au *tétraxétan* (DOTA) (avec une moyenne de 3 à 5 lysyl liés au chélateur par leur N6)

rosopatamab tetraxetán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* FOLH1 (folato hidrolasa, antígeno membranario específico de la próstata, PSMA)], anticuerpo monoclonal, conjugado con *tetraxetán* ;
cadena pesada gamma1 (1-445) [VH (*Mus musculus* IGHV1-26*01 (78.4%) -(IGHD) -IGHJ2*01 (92.9%)/*Homo sapiens* IGHV1-69-2*01 (76.3%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), bisagra 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA *Mus musculus* IGKV6-23*01 (80.9%) -IGKJ2*03 (72.7%)/(*Homo sapiens* IGKV1-13*02 (78.7%) -IGKJ3*01 (91.7%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (224-224":227-227")-bisdisulfuro; producido por células ováricas de hamster chino (CHO), forma glicosilada alfa, conjugado con *tetraxetán* (DOTA) (con una media de 3 a 5 restos lisil unidos al quelante por sus respectivos N6)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGPE VKKPGATVKI SCKTSGYTFT EYTIHWVKQA PGKGLEWIGN  50
INPNNGGTTY NQKFEDKATL TVDKSTDTAY MELSSLRSED TAVYYCAAGW 100
NFDYWGQGTL LTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSTSVGDRVT LTCKASQDVG TAVDWYQQKP GPSPKLLIYW  50
ASTRHTGIPS RFSGSGSGTD FTLTISSLQP EDFADYYCQQ YNSYPLTFGP 100
GTKVDIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


Intra-H (C23-C104)	22-96	142-198	259-319	365-423
	22"-96"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	218-214'	218"-214'"		
Inter-H-H (h 11, h 14)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

3 to 5 lysyl (K)
3 à 5 lysyl (K)
3 a 5 lisil (K)

N^6-(tetraxetan)-L-lysyl



sabatolimabum #

sabatolimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* HAVCR2 (hepatitis A virus cellular receptor 2, T-cell immunoglobulin mucin family member 3, Tim-3, TIM3, TIMD3, CD366)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-444) [VH (*Homo sapiens* IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118)-*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (224-224":227-227")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
sabatolimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* HAVCR2 (récepteur cellulaire 2 du virus de l'hépatite A, CD366, membre 3 de la famille mucine immunoglobuline des cellules T, Tim-3, TIM3, TIMD3, CD366)], anticorps monoclonal humanisé; chaîne lourde gamma4 humanisée (1-444) [VH (*Homo sapiens* IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), charnière 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfure avec la chaîne légère kappa humanisée (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (224-224":227-227")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
sabatolimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* HAVCR2 (receptor celular 2 del virus de la hepatitis A, CD366, miembro 3 de la familia mucina inmunoglobulina de las células T, Tim-3, TIM3, TIMD3, CD366)], anticuerpo monoclonal humanizado; cadena pesada gamma4 humanizada (1-444) [VH (*Homo sapiens* IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), bisagra 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfuro con la cadena ligera kappa humanizada (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (224-224":227-227")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYNMHWVRQA PGQGLEWMGD  50
IYPGNGDTSY NQKFKGRVTI TADKSTSTVY MELSSLRSED TAVYYCARVG 100
GAFPMDYWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLG       444
```

Light chain / Chaîne légère / Cadena ligera

```
AIQLTQSPSS LSASVGDRVT ITCRASESVE YYGTSLMQWY QQKPGKAPKL  50
LIYAASNVES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY FCQQSRKDPS 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	259-319	365-423
	22"-96"	145"-201"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (CH1 10-CL 126)	132-218'	132"-218'"		
Inter-H-H (h 8, h 11)	224-224"	227-227"		

N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1: 1, 1"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


samelisantum

samelisant — *N*-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-2-(morpholin-4-yl)acetamide

samélisant — *N*-{4-[(1-cyclobutylpipéridin-4-yl)oxy]phényl}-2-(morpholin-4-yl)acetamide

samelisant — *N*-{4-[(1-ciclobutilpiperidin-4-il)oxi]fenil}-2-(morfolin-4-il)acetamida

$C_{21}H_{31}N_3O_3$




samuraciclibum

samuraciclib — (3*R*,4*R*)-4-({[7-(benzylamino)-3-(propan-2-yl)pyrazolo[1,5-*a*]pyrimidin-5-yl]amino}methyl)piperidin-3-ol

samuraciclib — (3*R*,4*R*)-4-({[7-(benzylamino)-3-(propan-2-yl)pyrazolo[1,5-*a*]pyrimidin-5-yl]amino}méthyl)pipéridin-3-ol

samuraciclib — (3*R*,4*R*)-4-({[7-(benzilamino)-3-(propan-2-il)pirazolo[1,5-*a*]pirimidin-5-il]amino}metil)piperidin-3-ol


$C_{22}H_{30}N_6O$



seralutinibum

seralutinib	*N*-{3-[(1*S*)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide
séralutinib	*N*-{3-[(1*S*)-1-{[6-(3,4-diméthoxyphényl)pyrazin-2-yl]amino}éthyl]phényl}-5-méthylpyridine-3-carboxamide
seralutinib	*N*-{3-[(1*S*)-1-{[6-(3,4-dimetoxifenil)pirazin-2-il]amino}etil]fenil}-5-metilpiridina-3-carboxamida

$C_{27}H_{27}N_5O_3$



simoladagenum autotemcelum #

simoladagene autotemcel	autologous CD34+ hematopoietic stem cells (HSC), obtained by leukapheresis or from bone marrow, transduced *ex vivo* with a non-replicating, self-inactivating (SIN) lentiviral vector encoding codon optimised human adenosine deaminase (ADA) under the internal control of elongation factor 1α short promoter (EFS)
simoladagène autotemcel	cellules souches hématopoïétiques CD34+ autologues obtenues par leucophérèse ou de la moëlle osseuse, transduites *ex vivo* avec un vecteur lentiviral non-répliquant, auto-inactivant (SIN) codant pour l'adénosine déaminase (ADA) humaine codon optimisé sous le contrôle interne d'un promoteur court du facteur d'élongation 1α (EFS)
simoladagén autotemcel	células madre hematopoyéticas CD34+ autólogas obtenidas por leucoaféresis o de médula ósea, transducidas *ex vivo* con un vector lentiviral no replicativo y auto inactivante (SIN), que codifica para la adenosina deaminasa (ADA) humana con codones optimizados bajo el control interno del promotor corto del factor de elongación 1α (EFS)

sisunatovirum

sisunatovir	1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1*H*-benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'*H*)-one


sisunatovir

1'-{[5-(aminométhyl)-1-(4,4,4-trifluorobutyl)-1*H*-benzimidazol-2-yl]méthyl}-6'-fluoro-spiro[cyclopropane-1,3'-[3*H*]indol]-2'(1'*H*)-one

sisunatovir

1'-{[5-(aminometil)-1-(4,4,4-trifluorobutil)-1*H*-benzimidazol-2-il]metil}-6'-fluoro-spiro[ciclopropano-1,3'-[3*H*]indol]-2'(1'*H*)-ona

$C_{23}H_{22}F_4N_4O$



sovesudilum

sovesudil

propyl 2'-(aminomethyl)-5'-[(3-fluoropyridin-4-yl)carbamoyl][1,1'-biphenyl]-3-carboxylate


sovésudil

2'-(aminométhyl)-5'-[(3-fluoropyridin-4-yl)carbamoyl][1,1'-biphényl]-3-carboxylate de propyle

sovesudil

2'-(aminometil)-5'-[(3-fluoropiridin-4-il)carbamoil][1,1'-bifenil]-3-carboxilato de propilo

$C_{23}H_{22}FN_3O_3$



sugemalimabum #

sugemalimab

immunoglobulin G4-lambda, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with lambda light chain *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')];
dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

sugémalimab

immunoglobuline G4-lambda, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], anticorps monoclonal *Homo sapiens*;

chaîne lourde gamma4 *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (122-219), charnière 1-12 S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfure avec la chaîne légère lambda *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')];
dimère (227-227'':230-230'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

sugemalimab

inmunoglobulina G4-lambda, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal *Homo sapiens*;
cadena pesada gamma4 *Homo sapiens* (1-448) [VH (*Homo sapiens* IGHV3-23*01 (98.0%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (122-219), bisagra 1-12 S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfuro con la cadena ligera lambda *Homo sapiens* (1'-214') [V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100%) - IGLJ2*01 (100%)) [6.3.11] (1'-108') -*Homo sapiens* IGLC2*01 (100%) (109'-214')];
dímero (227-227'':230-230'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSG  50
ISGSGGFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPP 100
RGYNYGPFDY WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD  50
SDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	262-322	368-426
	22"-96"	148"-204"	262"-322"	368"-426"
Intra-L (C23-C104)	22'-87'	136'-195'		
	22'"-87'"	136'"-195'"		
Inter-H-L (CH1 10-CL 126)	135-213'	135"-213'"		
Inter-H-H (h 8, h 11)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Deamidation sites / Sites de déamidation / Posiciones de desamidación
H CH3 N44: 385, 385"
H CH3 N114: 435, 435"
Oxidation sites / Sites de oxydation / Posiciones de oxidación
H CH2 M15.1: 253, 253"
H CH3 M107: 429, 429"


suvecaltamidum

suvecaltamide — 2-[4-(propan-2-yl)phenyl]-*N*-{(1*R*)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide

suvécaltamide — 2-[4-(propan-2-yl)phényl]-*N*-{(1*R*)-1-[5-(2,2,2-trifluoroéthoxy)pyridin-2-yl]éthyl}acetamide

suvecaltamida — 2-[4-(propan-2-il)fenil]-*N*-{(1*R*)-1-[5-(2,2,2-trifluoroetoxi)piridin-2-il]etil}acetamida

$C_{20}H_{23}F_3N_2O_2$



tebotelimabum #

tebotelimab — immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)] and anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody, bispecific tetravalent;
gamma4 heavy chain scFv-h-CH2-CH3 humanized (1-496) [V-KAPPA anti-LAG3 (*Homo sapiens* IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -8-mer linker (108-115)-VH anti-PDCD1 (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-mer diglycyl-cysteinyl-triglycyl linker (235-240)-E-coil motif (241-268) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (hinge 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))], (237-240':245-248')-bisdisulfide with kappa light chain humanized (1'-271')[V-KAPPA anti-PDCD1 (*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti LAG3 (*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -6-mer diglycyl-cysteinyl-triglycyl linker (238'-243') -K-coil motif (244'-271')];
dimer (276-276":279-279")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

tébotélimab — immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)] et anti-[*Homo sapiens* LAG3 (activateur 3 des lymphocytes, lymphocyte-activation 3, CD223)], anticorps monoclonal humanisé, bispécifique tétravalent;
chaîne lourde gamma4 scFv-h-CH2-CH3 humanisée (1-496) [V-KAPPA anti-LAG3 (*Homo sapiens* IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -8-mer linker (108-115) -VH anti-PDCD1 (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-mer diglycyl-cystéinyl-triglycyl linker (235-240)-E-coil motif (241-268) -*Homo sapiens* IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (charnière 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))],(237-240':245-248')-bisdisulfure avec la chaîne légère kappa humanisée (1'-271') [V-KAPPA anti-PDCD1 (*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -8-mer linker (112'-119')-VH anti-LAG3(*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -6-mer diglycyl-cystéinyl-triglycyl linker (238'-243') -K-coil motif (244'-271')];
dimère (276-276":279-279")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

tebotelimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)] y anti-[*Homo sapiens* LAG3 (activador 3 de los linfocitos, linfocito-activación 3, CD223)], anticuerpo monoclonal humanizado, biespecífico tetravalente;
cadena pesada gamma4 scFv-h-CH2-CH3 humanizada (1-496) [V-KAPPA anti-LAG3 (*Homo sapiens* IGKV1-39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -conector octámero (108-115) -VH anti-PDCD1 (Homo sapiens IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -conector sexámero diglicil-cisteinil-triglicil (235-240) -E-coil motif (241-268) -Homo sapiens IGHG4*01, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (bisagra 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>del (496) (269-496))],(237-240':245-248')-bisdisulfuro con la cadena ligera kappa humanizada (1'-271') [V-KAPPA anti-PDCD1 (*Homo sapiens* IGKV3D-11*02 (77.7%) -IGKJ4*01 (100%)) [10.3.9] (1'-111') -conector octámero (112'-119')-VH anti-LAG3(*Homo sapiens* IGHV1-18*01 (86.7%) -(IGHD) -IGHJ4*01 (82.7%)) [8.8.11] (120'-237') -conector sexámero diglicil-cisteinil-triglicil (238'-243') -K-coil motif (244'-271')];
dímero (276-276":279-279")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
DIQMTQSPSS LSASVGDRVT ITCRASQDVS SVVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100
GTKLEIKGGG SGGGGQVQLV QSGAEVKKPG ASVKVSCKAS GYSFTSYWMN 150
WVRQAPGQGL EWIGVIHPSD SETWLDQKFK DRVTITVDKS TSTAYMELSS 200
LRSEDTAVYY CAREHYGTSP FAYWGQGTLV TVSSGGCGGG EVAACEKEVA 250
ALEKEVAALE KEVAALEKES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 300
LYITREPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 350
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 400
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 450
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG     496
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL  50
LIHAASNQGS GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY FCQQSKEVPY 100
TFGGGTKVEI KGGGSGGGGQ VQLVQSGAEV KKPGASVKVS CKASGYTFTD 150
YNMDWVRQAP GQGLEWMGDI NPDNGVTIYN QKFEGRVTMT TDTSTSTAYM 200
ELRSLRSDDT AVYYCAREAD YFYFDYWGQG TTLTVSSGGC GGGKVAACKE 250
KVAALKEKVA ALKEKVAALK E                                 271
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	23-88	137-211	311-371	417-475
	23"-88"	137"-211"	311"-371"	417"-475"
Intra-L (C23-C104)	23'-92'	141'-215'		
	23'"-92'"	141'"-215'"		
Inter-H-L	237-240'	245-248'		
	237"-240'"	245"-248'"		
Inter-H-H (h 8, h 11)	276-276"	279-279"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
347, 347"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

telazorlimabum #

telazorlimab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, ACT35, OX40, CD134)], humanized monoclonal antibody;
gamma1 heavy chain humanized (1-448) [VH (*Homo sapiens* IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-35.53-59.98-107) (1-118) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.38-46) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')];
dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

télazorlimab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF4 (membre 4 de la superfamille des récepteurs du facteur de nécrose tumorale, ACT35, OX40, CD134)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-448) [VH (*Homo sapiens* IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-35.53-59.98-107) (1-118) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.38-46) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
telazorlimab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF4 (miembro 4 de la superfamilia de los receptores del factor de necrosis tumoral, ACT35, OX40, CD134)], anticuerpo monoclonal humanizado; cadena pesada gamma1 humanizada (1-448) [VH (*Homo sapiens* IGHV2-70*10 (93.0%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [10.7.10] (26-35.53-59.98-107) (1-118) -*Homo sapiens* IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (87.4%) -IGKJ1*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.38-46) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVTLKESGPA LVKPTQTLTL TCSFSGFSLS TSGMGVGWIR QPPGKALEWI  50
AHIWWDDDKY YNTALKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI 100
DWDGFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASSSVS YMHWYQQKPG QAPRPWIYAT  50
SNRATGIPAR FSGSGSGTDY TLTISSLEPE DFAVYYCQQW SSNPWTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	145-201	262-322	368-426
	22"-97"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (h 5-CL 126)	221-213'	221"-213'"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping:
H CHS K2:
448, 448"

tesnatilimabum

tesnatilimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* KLRK1 (killer cell lectin like receptor K1, NKG2D, KLR, NKG2-D, CD314)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-57.96-104) (1-115) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-215')-disulfide with kappa light chain *Homo sapiens* (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (27-33.51-53.90-98) (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (221-221'':224-224'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
tesnatilimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* KLRK1 (récepteur lectine like K1 de cellule tueuse, NKG2D, KLR, NKG2-D, CD314)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma1 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-57.96-104) (1-115) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-215')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (21-33.51-53.90-98) (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (221-221'':224-224'')-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
tesnatilimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* KLRK1 (receptor lectina like K1 de célula asesina, NKG2D, KLR, NKG2-D, CD314)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 *Homo sapiens* (1-442) [VH (*Homo sapiens* IGHV4-59*01 (93.8%) -(IGHD) - IGHJ3*02 (93.8%)) CDR-IMGT [8.7.9] (26-33.51-57.96-104) (1-115) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-215')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (100%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (21-33.51-53.90-98) (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (221-221'':224-224'')-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVHLQESGPG LVKPSETLSL TCTVSDDSIS SYYWSWIRQP PGKGLEWIGH  50
ISYSGSANYN PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCANWDD 100
AFNIWGQGTM VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	142-198	256-316	362-420
	22"-95"	142"-198"	256"-316"	362"-420"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	129-215'	129"-215'"		
Inter-H-H (h 8, h 11)	221-221"	224-224"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
292, 292"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados


tezatabepum matraxetanum

tezatabep matraxetan	three-alpha-helix binding protein, derived from an immunoglobulin G (IgG)-binding domain of a staphylococcal protein A (SpA), designed to bind receptor tyrosine-protein kinase erbB-2 (ERBB2, Neu, HER2), produced by peptide synthesis, conjugated at the C-terminal Cys^{61} to one (3*RS*)-2,5-dioxo-1-(2-{2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetamido}ethyl)pyrrolidin-3-yl (*matraxetan*) group
tézatabep matraxétan	protéine à trois hélices alpha, dérivée du domaine de l'immunoglobuline G (IgG) se liant à la protéine staphylococcique A (SpA), mise au point pour se lier au récepteur tyrosine-protéine kinase erbB-2 (ERBB2, Neu, HER2), produite par synthèse peptidique, conjuguée sur la Cys^{61} en sa partie C-terminale à un groupe (3*RS*)-2,5-dioxo-1-(2-{2-[4,7,10-tris(carboxyméthyl)-1,4,7,10-tétraazacyclododécan-1-yl]acétamido}éthyl)pyrrolidin-3-yle (*matraxétan*)
tezatabep matraxetán	proteína de tres hélices alfa, derivada del dominio de la inmunoglobulina G (IgG) que se une a la proteína estafilocócica A (SpA), diseñada para unirse al receptor tirosina-proteína kinasa erbB-2 (ERBB2, Neu, HER2), producida por síntesis peptídica, conjugada con la Cys^{61} en su parte C-terminal a un grupo (3*RS*)-2,5-dioxo-1-(2-{2-[4,7,10-tris(carboximetil)-1,4,7,10-tetraazaciclododecan-1-il]acetamido}etil)pirrolidin-3-ilo (*matraxetán*)

Sequence / Séquence / Secuencia

```
AEAKYAKEMR NAYWEIALLP NLTNQQKRAF IRKLYDDPSQ SSELLSEAKK  50
LNDSQAPKVD C*                                           61
```

Potential modified residues / résidus modifiés potentiels / restos modificados pote



tifalibepum #

tifalibep

fusion protein composed of 3 binding domains, each consisting of a three-alpha-helix motif derived from the immunoglobulin (Ig)-binding Z-domain of staphylococcal protein A (SpA), engineered for binding to the human neonatal Fc receptor (FcRn) with the two identical N- and C-terminal domains (1-58, 116-173), and for binding to the domain II of human serum albumin (HSA) with the central domain (59-110), connected via a G_4S peptide linker (111-115); [FcRn-binding engineered SpA peptide (1-58)]-[HSA-binding engineered SpA peptide (59-110)]-[G_4S linker (111-115)]-[FcRn-binding engineered SpA peptide (116-173] fusion protein;
produced in *Escherichia coli*

tifalibep

protéine de fusion composée de 3 domaines liants, chacun consistant en un motif à 3 hélices alfa dérivé du domaine Z de la protéine staphylococcique A (SpA) se liant à l'immunoglobuline (Ig), mis au point pour se lier au récepteur Fc néonatal humain (FcRn) avec les deux domaines N- et C-terminaux identiques (1-58, 116-173), et au domaine II de l'albumine sérique humaine (ASH, HSA) avec le domaine central (59-110), connecté via un peptide liant G_4S (111-115) ; protéine de fusion [peptide SpA mis au point pour se lier au FcRn (1-58)]-[peptide SpA mis au point pour se lier au HSA (59-110)]-[peptide liant G_4S (111-115)]-[peptide SpA mis au point pour se lier au FcRn (116-173)];
produite par *Escherichia coli*

tifalibep

proteína de fusión compuesta de 3 dominios de unión, cada uno consistente en un motivo con 3 hélices alfa derivado del dominio Z de la proteína estafilocócica A (SpA) que se une a la inmunoglobulina (Ig), diseñada para unirse al receptor Fc neonatal humano (FcRn) con los dos dominios N- y C-terminal idénticos (1-58, 116-173), y con el dominio II de la albúmina sérica humana (ASH, HSA) con el dominio central (59-110), conectado a través de un péptido linker G_4S (111-115) ;
proteína de fusión [péptido SpA diseñado para unirse al FcRn (1-58)]-[péptido SpA diseñado para unirse al HSA (59-110)]-[G_4S linker (111-115)]-[péptido SpA diseñado para unirse al FcRn (116-173)];
producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```
AEAKFAKEWQ QAAHEIRWLP NLTFDQRVAF IHKLRDDPSQ SSELLSEAKK   50
LSESQAPKAS GSLAEAKEAA NAELDSYGVS DFYKRLIDKA KTVEGVEALK  100
DAILAALPGT GGGGSAEAKF AKEWQQAAHE IRWLPNLTFD QRVAFIHKLR  150
DDPSQSSELL SEAKKLSESQ APK                                173
```

Post-translational modifications / Modifications post-traductionnelles / Modificaciones postraduccionales
None / aucune / ninguna

tilogotamabum #

tilogotamab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-447) [VH (*Homo sapiens* IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfide with kappa light chain humanized (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (227-227":230-230")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
tilogotamab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), récepteur de mort 5, DR5, TRAILR2, TRAIL-R2, TR-2, CD262)], anticorps monoclonal humanisé; chaîne lourde gamma1 humanisée (1-447) [VH (*Homo sapiens* IGHV1-3*01 (84.7%) -(IGHD) -IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-216), charnière 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfure avec la chaîne légère kappa humanisée (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (227-227":230-230")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
tilogotamab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF10B (miembro 10B de la superfamilia de los receptores del factor de necrosis tumoral (TNFR), receptor de muerte 5, DR5, TRAILR2, TRAIL-R2, TR-2, CD262)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 humanizada (1-447) [VH (*Homo sapiens* IGHV1-3*01 (84.7%) -(IGHD) - IGHJ4*01 (93.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1, G1v34 CH3 G109 (CH1 R120 (215) (119-216), bisagra 1-15 (217-231), CH2 (232-341), CH3 E12 (357), M14 (359), E109>G (431) (342-446), CHS K>del (447)) (119-447)], (221-213')-disulfuro con la cadena ligera kappa humanizada (1'-213') [V-KAPPA (*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ4*01 (100%)) CDR-IMGT [5.3.9] (27-31.49-51.88-96) (1'-106') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (227-227":230-230")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGFNIK DTHMHWVRQA PGQRLEWIGR  50
IDPANGNTEY DQKFQGRVTI TVDTSASTAY MELSSLRSED TAVYYCARWG 100
TNVYFAYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH GALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT ITCSASSSVS YMYWYQQKPG KAPKPWIYRT  50
SNLASGVPSR FSGSGSGTDF TLTISSLQPE DFATYYCQQY HSYPPTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (h 5-CL 126)	221-213'	221"-213'"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		


N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tolebrutinibum

tolebrutinib — 4-amino-3-(4-phenoxyphenyl)-1-[(3*R*)-1-(prop-2-enoyl)piperidin-3-yl]-1,3-dihydro-2*H*-imidazo[4,5-*c*]pyridin-2-one

tolébrutinib — 4-amino-3-(4-phénoxyphényl)-1-[(3*R*)-1-(prop-2-énoyl)pipéridin-3-yl]-1,3-dihydro-2*H*-imidazo[4,5-*c*]pyridin-2-one

tolebrutinib — 4-amino-3-(4-fenoxifenil)-1-[(3*R*)-1-(prop-2-enoil)piperidin-3-il]-1,3-dihidro-2*H*-imidazo[4,5-*c*]piridin-2-ona




tovinontrinum

tovinontrine — 6-{(3*S*,4*S*)-4-methyl-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-*a*]pyrazin-8(7*H*)-one

tovinontrine — 6-{(3*S*,4*S*)-4-méthyl-1-[(pyrimidin-2-yl)méthyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-*a*]pyrazin-8(7*H*)-one

tovinontrina — 6-{(3*S*,4*S*)-4-metil-1-[(pirimidin-2-il)metil]pirrolidin-3-il}-3-(oxan-4-il)imidazo[1,5-*a*]pirazin-8(7*H*)-ona

$C_{21}H_{26}N_6O_2$




udonitrectagum

udonitrectag — (1*S*,4*R*,5*R*,7*S*)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid

udonitrectag — acide (1*S*,4*R*,5*R*,7*S*)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylique

udonitrectag — ácido (1*S*,4*R*,5*R*,7*S*)-3,4-dibencil-2-oxo-6,8-dioxa-3-azabiciclo[3.2.1]octano-7-carboxílico

$C_{20}H_{19}NO_5$



upifitamabum #

upifitamab — immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC34A2 (solute carrier family 34 (sodium phosphate) member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b)], monoclonal antibody;
gamma1 heavy chain (1-449) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -glycyl (120) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (*Mus musculus* IGKV10-94*01 (84.2%) -IGKJ5*01 (91.7%)/*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginyl (108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
dimer (229-229":232-232")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

upifitamab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC34A2 (membre 2 de la famille 34 (phosphate de sodium) de transporteurs de solutés, cotransporteur 2B de sodium/phosphate, NaPi2b, NaPi3b)], anticorps monoclonal; chaîne lourde gamma1 (1-449) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -glycyl (120) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), charnière 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA (*Mus musculus* IGKV10-94*01 (84.2%) -IGKJ5*01 (91.7%)/*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginyl (108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
dimère (229-229":232-232")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

upifitamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC34A2 (miembro 2 de la familia 34 (fosfato de sodio) de transportadores de solutos, cotransportador 2B de sodio/fosfato, NaPi2b, NaPi3b)], anticuerpo monoclonal; cadena pesada gamma1 (1-449) [VH (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (1-119) -glicil (120) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (217) (121-218), bisagra 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K>del (449)) (121-449)], (223-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA (*Mus musculus* IGKV10-94*01 (84.2%) -IGKJ5*01 (91.7%)/*Homo sapiens* IGKV1-16*01 (83.2%) -IGKJ2*01 (90.9%)) [6.3.9] (1'-107') -arginil (108') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (154), V101 (192) (109'-215')];
dímero (229-229":232-232")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VVKPGASVKM SCKASGYTFT GYNIHWVKQA PGQGLEWIGA  50
IYPGNGDTSY KQKFRGRATL TADTSTSTVY MELSSLRSED SAVYYCARGE 100
TARATFAYWG QGTLVTVSSG ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSASQDIG NFLNWYQQKP GKTVKVLIYY  50
TSSLYSGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCQQ YSKLPLTFGQ 100
GTKLELKRRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-88'	135'-195'		
	23'"-88'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	223-215'	223"-215'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

urabrelimabum #

urabrelimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* CD47 (integrin associated protein, IAP, MER6, OA3)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain *Homo sapiens* (1-452) [VH (*Homo sapiens* IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-58.97-114) (1-125)-*Homo sapiens* IGHG4*01 (CH1 (126-223), hinge 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-212')-disulfide with kappa light chain *Homo sapiens* (1'-212') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (94.7%) - IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dimer (231-231":234-234")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
urabrélimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* CD47 (protéine associée à l'intégrine, IAP, MER6, OA3)], anticorps monoclonal *Homo sapiens*; chaîne lourde gamma4 *Homo sapiens* (1-452) [VH (*Homo sapiens* IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-58.97-114) (1-125)-*Homo sapiens* IGHG4*01 (CH1 (126-223), charnière 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-212')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-212') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dimère (231-231":234-234")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa
urabrelimab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD47 (proteína asociada a la integrina, IAP, MER6, OA3)], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma4 *Homo sapiens* (1-452) [VH (*Homo sapiens* IGHV4-4*02 (94.9%) -(IGHD) - IGHJ6*01 (94.7%)) CDR-IMGT [9.7.18] (26-34.52-58.97-114) (1-125)-*Homo sapiens* IGHG4*01 (CH1 (126-223), bisagra 1-12 (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-212')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-212') [V-KAPPA (*Homo sapiens* IGKV3-11*01 (94.7%) -IGKJ4*01 (91.7%)) CDR-IMGT [6.3.8] (27-32.50-52.89-96) (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (151), V101 (189) (107'-212')]; dímero (231-231":234-234")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSGTLSL TCAVSGVSIR SINWWNWVRQ PPGKGLEWIG  50
EIYHSGSTNY NPSLKSRVTI SVDKSKNQFS LKLNSVTAAD TAVYYCARDG 100
GIAVTDYYYY GLDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPSCPAPEFL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESVS SNLAWYQQKP GQAPRLLIYG  50
AFNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSDWFTFGGG 100
TKVEIKTVAA PSVFIFPPSD EQLKSGTASV VCLLNNFYPR EAKVQWKVDN 150
ALQSGNSQES VTEQDSKDST YSLSSTLTLS KADYEKHKVY ACEVTHQGLS 200
SPVTKSFNRG EC                                           212
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	152-208	266-326	372-430
	22"-96"	152"-208"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-88'	132'-192'		
	23'"-88'"	132'"-192'"		
Inter-H-L (CH1 10-CL 126)	139-212'	139"-212'"		
Inter-H-H (h 8, h 11)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

uzansertibum

uzansertib

N-{(7*R*)-4-[(3*R*,4*R*,5*S*)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5*H*-cyclopenta[*b*]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide


uzansertib

N-{(7*R*)-4-[(3*R*,4*R*,5*S*)-3-amino-4-hydroxy-5-méthylpipéridin-1-yl]-7-hydroxy-6,7-dihydro-5*H*-cyclopenta[*b*]pyridin-3-yl}-6-(2,6-difluorophényl)-5-fluoropyridine-2-carboxamide

uzansertib

N-{(7*R*)-4-[(3*R*,4*R*,5*S*)-3-amino-4-hidroxi-5-metilpiperidin-1-il]-7-hidroxi-6,7-dihidro-5*H*-ciclopenta[*b*]piridin-3-il}-6-(2,6-difluorofenil)-5-fluoropiridina-2-carboxamida

$C_{26}H_{26}F_3N_5O_3$



vebicorvirum

vebicorvir

5,5,11-trioxo-*N*-{[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl}-10,11-dihydro-5*H*-5λ^6-dibenzo[*b*,*f*][1,4]thiazepine-8-carboxamide


vébicorvir

5,5,11-trioxo-*N*-{[2-(trifluorométhyl)-1,3-thiazol-5-yl]méthyl}-10,11-dihydro-5*H*-5λ^6-dibenzo[*b*,*f*][1,4]thiazépine-8-carboxamide

vebicorvir

5,5,11-trioxo-*N*-{[2-(trifluorometil)-1,3-tiazol-5-il]metil}-10,11-dihidro-5*H*-5λ^6-dibenzo[*b*,*f*][1,4]tiazepina-8-carboxamida

$C_{19}H_{12}F_3N_3O_4S_2$



velmupressinum

velmupressin

1,5-anhydro{4-chloro-L-phenylalanyl-3-(thiophen-2-yl)-L-alanyl-L-valyl-L-asparaginyl-*S*-(3-carboxypropyl)-L-cysteinyl-*N*-[4-(carbamimidoylamino)butyl]-L-prolinamide}


velmupressine

1,5-anhydro{4-chloro-L-phénylalanyl-3-(thiophén-2-yl)-L-alanyl-L-valyl-L-asparaginyl-*S*-(3-carboxypropyl)-L-cystéinyl-*N*-[4-(carbamimidoylamino)butyl]-L-prolinamide}

velmupresina

1,5-anhidro{4-cloro-L-fenilalanil-3-(tiofen-2-il)-L-alanil-L-valil-L-asparaginil-*S*-(3-carboxipropil)-L-cisteinil-*N*-[4-(carbamimidoilamino)butil]-L-prolinamida}

$C_{42}H_{60}ClN_{11}O_8S_2$



velufenacinum

velufenacin

[(3*R*)-1-methylpyrrolidin-3-yl]methyl (3'-chloro-4'-fluoro[1,1'-biphenyl]-2-yl)carbamate


vélufénacine

(3'-chloro-4'-fluoro[1,1'-biphényl]-2-yl)carbamate de [(3*R*)-1-méthylpyrrolidin-3-yl]méthyle

velufenacina

(3'-cloro-4'-fluoro[1,1'-bifenil]-2-il)carbamato de [(3*R*)-1-metilpirrolidin-3-il]metilo

$C_{19}H_{20}ClFN_2O_2$



verbrinacogenum setparvovecum #

verbrinacogene setparvovec	A recombinant non-replicating adeno-associated virus of a modified liver-tropic serotype (S3) (rAAVS3) vector, encoding a gain-of-function variant (R338L; Padua) of codon-optimised human coagulation factor IX (hFIX) under the control of a liver-specific promoter (FRE1) comprising a truncated version of the human apolipoprotein E locus control region (i.e. enhancer) with a truncated version of the human alpha-1-antitrypsin promoter.
verbrinacogène setparvovec	vecteur viral adéno-associé recombinant, non-répliquant, d'un sérotype hépatotropique modifié (S3) (rAAVS3), codant pour le variant Padua (R338L) du facteur de coagulation IX humain (F9, Facteur IX, FIX) dont les codons sont optimisés, sous le contrôle du promoteur spécifique du foie (FRE1) comprenant une version tronquée de la région de contrôle du locus de l'apoprotéine E humaine (c.-à-d. amplificateur) avec une version tronquée du promoteur de l'antitrypsine alpha-1 humaine.
verbrinacogén setparvovec	Un vector de virus adeno-asociado recombinante, no replicativo, de un serotipo hepatotrópico modificado (S3) (rAAVS3), que codifica una variante de ganancia de función (R338L; Padua) del factor de coagulación IX humano (hFIX) con codones optimizados, bajo el control de un promotor específico de hígado (FRE1) que consta de una versión truncada de la región de control del locus de la apolipoproteína E humana (es decir, potenciador) con una versión truncada del promotor de la alfa-1-antitripsina humana.

vilobelimabum #

vilobelimab	immunoglobulin G4-kappa, anti-[*Homo sapiens* C5 (complement 5) anaphylatoxin (C5a, C5 Pr678-751)], chimeric monoclonal antibody; gamma4 heavy chain chimeric (1-446) [VH (*Mus musculus* IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/*Homo sapiens* IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), hinge 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfide with kappa light chain chimeric (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (98.0%) -IGKJ2*01 (100%)/*Homo sapiens*IGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225":228-228")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
vilobélimab	immunoglobuline G4-kappa, anti-[*Homo sapiens* C5 (complément 5) anaphylatoxine (C5a, C5 Pr678-751)], anticorps monoclonal chimérique;

chaîne lourde gamma4 chimérique (1-446) [VH (*Mus musculus* IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/*Homo sapiens* IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), charnière 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfure avec la chaîne légère kappa chimérique (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (98.0%) -IGKJ2*01 (100%)/*Homo sapiens*IGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (225-225":228-228")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

vilobelimab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* C5 (complemento 5) anafilatoxina (C5a, C5 Pr678-751)], anticuerpo monoclonal quimérico;
cadena pesada gamma4 quimérica (1-446) [VH (*Mus musculus* IGHV1-61*01 (81.6%) -(IGHD) -IGHJ3*01 (92.9%)/*Homo sapiens* IGHV1-46*01 (62.2%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.13] (1-119) -*Homo sapiens* IGHG4*01 (CH1 (120-217), bisagra 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133-218')-disulfuro con la cadena ligera kappa quimérica (1'-218') [V-KAPPA (*Mus musculus* IGKV3-4*01 (98.0%) -IGKJ2*01 (100%)/*Homo sapiens*IGKV3D-11*02 (69.1%) -IGKJ2*01 (91.7%)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (225-225":228-228")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPQ LVRPGTSVKI SCKASGYSFT TFWMDWVKQR PGQGLEWIGR  50
IDPSDSESRL DQRFKDRATL TVDKSSSTVY MQLSSPTSED SAVYYCARGN 100
DGYYGFAYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPSCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSYMKWY QQKPGQPPKL  50
LIYAASNLQS GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPY 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	260-320	366-424
	22"-96"	146"-202"	260"-320"	366"-424"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (CH1 10-CL 126)	133-218'	133"-218'"		
Inter-H-H (h 8, h 11)	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
446, 446"


vonafexorum

vonafexor — 4-chloro-5-[4-(2,6-dichlorobenzene-1-sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid

vonafexor — acide 4-chloro-5-[4-(2,6-dichlorobenzène-1-sulfonyl)pipérazin-1-yl]-1-benzofuran-2-carboxylique

vonafexor — ácido 4-cloro-5-[4-(2,6-diclorobenceno-1-sulfonil)piperazin-1-il]-1-benzofuran-2-carboxílico

$C_{19}H_{15}Cl_3N_2O_5S$




vosilasarmum

vosilasarm — 2-chloro-4-({(1*R*,2*S*)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl}amino)-3-methylbenzonitrile

vosilasarm — 2-chloro-4-({(1*R*,2*S*)-1-[5-(4-cyanophényl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl}amino)-3-méthylbenzonitrile

vosilasarm — 4-({(1*R*,2*S*)-1-[5-(4-cianofenil)-1,3,4-oxadiazol-2-il]-2-hidroxipropil}amino)-2-cloro-3-metilbenzonitrilo

$C_{20}H_{16}ClN_5O_2$



vulinacimabum #

vulinacimab — immunoglobulin G1-kappa, anti-[*Homo sapiens* VEGFR2 (vascular endothelial growth factor receptor 2, KDR, kinase insert domain receptor, FLK1, CD309)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfide with kappa light chain *Homo sapiens* (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (226-226":229-229")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

vulinacimab

immunoglobuline G1-kappa, anti-[*Homo sapiens* VEGFR2 (récepteur 2 du facteur de croissance endothélial vasculaire, KDR, récepteur à domaine insert kinase, FLK1, CD309)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), charnière 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfure avec la chaîne légère kappa *Homo sapiens* (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')];
dimère (226-226":229-229")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

vulinacimab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* VEGFR2 (receptor 2 del factor de crecimiento endotelial vascular, KDR, receptor con dominio inserto kinasa, FLK1, CD309)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 *Homo sapiens* (1-447) [VH (*Homo sapiens* IGHV3-23*04 (90.8%) -(IGHD) -IGHJ1*01 (100%)) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (214) (118-215), bisagra 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-457)) (118-447)], (220-219')-disulfuro con la cadena ligera kappa *Homo sapiens* (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-30*01 (83.0%) -IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (100%) Km3 A45.1 (158), V101 (196) (113'-219')];
dímero (226-226":229-229")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGGG LVQPGGSLRL SCAASGFSFS TYAMSWVRQA PGKGLEWVSG  50
ISGSGGTTHY ADSVKGRFTI SRDNSKNTVN LQMNSLRAED TAVYYCAKGL 100
WFGEGLWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLY YRSGYTFLDW YVQKPGQSPQ  50
LLIYQSSKRD SGVPDRISGS GSGTDFTLRI SRVEAEDVGV YYCFQGTHWP 100
YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	220-219'	220"-219'"		
Inter-H-H (h 11, h 14)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

C-terminal lysine clipping:
H CHS K2:
447, 447"


xevinapantum

xevinapant — (5*S*,8*S*,10a*R*)-*N*-(diphenylmethyl)-5-[(2*S*)-2-(methylamino)propanamido]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamide

xévinapant — (5*S*,8*S*,10a*R*)-*N*-(diphénylméthyl)-5-[(2*S*)-2-(méthylamino)propanamido]-3-(3-méthylbutanoyl)-6-oxodécahydropyrrolo[1,2-*a*][1,5]diazocine-8-carboxamide

xevinapant — (5*S*,8*S*,10a*R*)-*N*-(difenilmetil)-5-[(2*S*)-2-(metilamino)propanamido]-3-(3-metilbutanoil)-6-oxodecahidropirrolo[1,2-*a*][1,5]diazocina-8-carboxamida

$C_{32}H_{43}N_5O_4$




zandelisibum

zandelisib — 4-[2-(difluoromethyl)-1*H*-benzimidazol-1-yl]-*N*-{2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine

zandélisib — 4-[2-(difluorométhyl)-1*H*-benzimidazol-1-yl]-*N*-{2-méthyl-1-[2-(1-méthylpipéridin-4-yl)phényl]propan-2-yl}-6-(morpholin-4-yl)-1,3,5-triazin-2-amine

zandelisib — 4-[2-(difluorometil)-1*H*-benzimidazol-1-il]-*N*-{2-metil-1-[2-(1-metilpiperidin-4-il)fenil]propan-2-il}-6-(morfolin-4-il)-1,3,5-triazin-2-amina

$C_{31}H_{38}F_2N_8O$



zoligratinibum


zoligratinib — [5-amino-1-(2-methyl-1*H*-benzimidazol-5-yl)-1*H*-pyrazol-4-yl](1*H*-indol-2-yl)methanone

zoligratinib — [5-amino-1-(2-méthyl-1*H*-benzimidazol-5-yl)-1*H*-pyrazol-4-yl](1*H*-indol-2-yl)méthanone

zoligratinib

[5-amino-1-(2-metil-1*H*-benzimidazol-5-il)-1*H*-pirazol-4-il](1*H*-indol-2-il)metanona

$C_{20}H_{16}N_6O$



zotiraciclibum

zotiraciclib

(8*E*)-6-methyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene


zotiraciclib

(8*E*)-6-méthyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-1,4(1,3)-dibenzénacyclododécaphan-8-ène

zotiraciclib

(8*E*)-6-metil-12-oxa-3,6-diaza-2(4,2)-pirimidina-1,4(1,3)-dibencenaciclododecafan-8-eno

$C_{23}H_{24}N_4O$



zuberitamabum #

zuberitamab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MS4A1 (membrane spanning 4-domains subfamily A member 1, CD20)], chimeric monoclonal antibody; gamma1 heavy chain chimeric (1-452) [VH (*Mus musculus* IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/*Homo sapiens* IGHV1-46*01 (70.4%) -(IGHD) -IGHJ1*03 (85.7%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain chimeric (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (96.8%) -IGKJ1*01 (90.9 %)/*Homo sapiens* IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dimer (231-231":234-234")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

zubéritamab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal chimérique;

chaîne lourde gamma1 chimérique (1-452) [VH (*Mus musculus* IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/*Homo sapiens* IGHV1-46*01 (70.4%) -(IGHD) -IGHJ1*03 (85.7%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220), charnière 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfure avec la chaîne légère kappa chimérique (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (96.8%) -IGKJ1*01 (90.9 %)/*Homo sapiens* IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dimère (231-231":234-234")-bisdisulfure, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

zuberitamab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 quimérica (1-452) [VH (*Mus musculus* IGHV1-12*01 (96.9%) -(IGHD) -IGHJ1*03 (100%)/*Homo sapiens* IGHV1-46*01 (70.4%) -(IGHD) -IGHJ1*03 (85.7%)) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 (100%) G1m17,1 (CH1 K120 (219) (123-220), bisagra 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfuro con la cadena ligera kappa quimérica (1'-213') [V-KAPPA (*Mus musculus* IGKV4-72*01 (96.8%) -IGKJ1*01 (90.9 %)/*Homo sapiens* IGKV3-11*01 (64.9%) -IGKJ2*01 (90.9%)) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (231-231":234-234")-bisdisulfuro, producido por células ováricas de hamster chino (CHO), forma glicosilada alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQSGAE LVRPGASVKM SCKASGYTFT SYNMHWVKQT PRQGLEWIGA  50
IYPGNGDTSY NQKFKGKATL TVDKSSSTAY MQLSSLTSED SAVYFCARVV 100
YYSNSYWYFD VWGTGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIELSQSPAI LSASPGEKVT MTCRASSSVS YMHWYQQKPG SSPKPWIYAP  50
SNLASGVPAR FSGSGSGTSY SLTISRVEAE DAATYYCQQW SFNPPTFGAG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                          213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	149-205	266-326	372-430
	22"-96"	149"-205"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (h5-CL 126)	225-213'	225"-213'"		
Inter-H-H (h 11, h 14)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
C-terminal lysine clipping:
H CHS K2:
452, 452"

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 63
Dénominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p.45 **bardoxolonum**


bardoxolone	*replace the molecular formula by the following one*
bardoxolone	*remplacer la formule moléculaire brute par la suivante*
bardoxolona	*sustitúyase la fórmula molecular por la siguiente*

$C_{31}H_{41}NO_4$

Recommended International Nonproprietary Names (Rec. INN): List 79
Dénominations communes internationales recommandées (DCI Rec.): Liste 79
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 79
(WHO Drug Information, Vol. 32, No. 1, 2018)

p.112 **davamotecanum pegadexamerum**

davamotecan pegadexamer	*replace the structure by the following one*
davamotécan pégadexamère	*remplacer la structure par la suivante*
davamotecán pegadexámero	*sustitúyase la estructura por la siguiente*



p.123 **ianalumabum #**
-124

ianalumab	*replace the description and the structure by the following ones*
ianalumab	*remplacer la description et la structure par les suivantes*
ianalumab	*sustitúyase la descripción y la estructura por las siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide;
produced in Chinese hamster ovary (CHO) cells, glycoform alfa

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B, CD268], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (233-233":236-236")-bisdisulfure,
produit dans des cellules de hamster chinois (CHO), glycoforme alfa

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B, CD268], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (233-233":236-236")-bisdisulfuro,
producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPG LVKPSQTLSL TCAISGDSVS SNSAAWGWIR QSPGRGLEWL  50
GRIYYRSKWY NSYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA 100
RYDWVPKIGV FDSWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAT LSLSPGERAT LSCRASQFIS SSYLSWYQQK PGQAPRLLIY  50
GSSSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QLYSSPMTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                        215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-99	151-207	268-328	374-432
	22"-99"	151"-207"	268"-328"	374"-432"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	227-215'	227"-215'"		
Inter-H-H (h 11, h 14)	233-233"	236-236"		


N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados
N-terminal glutaminyl cyclization to pyroglutamyl (pE, 5-oxoprolyl)
H VH Q1: 1, 1"

C-terminal lysine clipping
H CHS K2:
454, 454"

Recommended International Nonproprietary Names (Rec. INN): List 81
Dénominations communes internationales recommandées (DCI Rec.): Liste 81
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 81
(WHO Drug Information, Vol. 33, No. 1, 2019)

p.128 **vutrisiranum**

vutrisiran	*replace the structure by the following one*
vutrisiran	*remplacer la structure par la suivante*
vutrisirán	*sustitúyase la estructura por la siguiente*



Recommended International Nonproprietary Names (Rec. INN): List 82
Dénominations communes internationales recommandées (DCI Rec.): Liste 82
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 82
(WHO Drug Information, Vol. 33, No. 3, 2019)

p.606-607 **adlinacogenum civaparvovecum #**

adlinacogene civaparvovec	*replace the description by the following one*
adlinacogène civaparvovec	*remplacer la description par la suivante*
adlinacogén civaparvovec	*sustitúyase la descripción por la siguiente*

a recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, which contains a promoter-less human coagulation factor IX (hF9, Factor IX or FIX) transgene cassette, encoding exons 2-8 and splice acceptor site sequence (SA) from hF9 exon 2, flanked by a sequence homologous to the zinc-finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1

vecteur viral adéno-associé de type 2/6 recombinant (**rAAV6**), non-répliquant, contenant la cassette avec le transgène du facteur de coagulation IX humain (hF9, Facteur IX, FIX) sans promoteur, codant pour les exons 2-8 et la séquence du site accepteur (SA) d'épissage de l'exon 2 de hF9, flanqué par une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 l'albumine humaine (hALB).

un vector de virus adeno asociado tipo 2/6 recombinante (**rAAV6**), no replicativo, que contiene un casete con el transgen del factor de coagulación IX (hF9, Factor IX o FIX) humano sin promotor, que codifica para los exones 2-8 y la secuencia del sitio aceptor (SA) del splicing del exon 2 de hf9, flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB)

p.625 **devafidugenum civaparvovecum #**
-626 devafidugene civaparvovec *replace the description by the following one*
devafidugène civaparvovec *remplacer la description par la suivante*
devafidugén civaparvovec *sustitúyase la descripción por la siguiente*

a recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, which contains a promoter-less human alpha-L-iduronidase (hIDUA) transgene cassette, encoding partial exon 1 and full exons 2-14 with the first 28 amino acids removed, and splice acceptor site sequence (SA) from hIDUA exon 2, flanked by a sequence homologous to the zinc-finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1

vecteur viral adéno-associé de type 2/6 recombinant (**rAAV6**), non-répliquant, contenant la cassette du transgène de l'alpha-L-iduronidase humaine (hIDUA) sans promoteur, codant partiellement l'exon 1 et entièrement les exons 2-14 dont la partie correspondant aux 28 premiers acides aminés a été retirée, et la séquence du site accepteur (SA) d'épissage de l'exon 2 de l'hIDUA, flanqué d'une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 de l'albumine humaine (hALB)

un vector de virus adeno asociado tipo 2/6 recombinante (**rAAV6**), no replicativo, que contiene un casete con el transgen de la alfa-L-iduronidasa humana (hIDUA) sin promotor, que codifica para el exón 1 parcial y los exones 2-14 completos con los primeros 28 amino ácidos eliminados, y la secuencia del sitio aceptor (SA) del splicing del exón 2 de hIDUA, flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB)

p.645 **inlezifigenum civaparvovecum #**
inlezifigene civaparvovec *replace the description by the following one*
inlezifigène civaparvovec *remplacer la description par la suivante*
inlezifigén civaparvovec *sustitúyase la descripción por la siguiente*

a recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, expressing a cDNA that targets 447-461 bp of the albumin locus (relative to the transcription initiation site), fused to the obligate heterodimeric FokI nuclease domain ELD, under the control of an apolipoprotein E hepatic control region and human alpha-1-antitrypsin promoter (ApoE/hAAT)

vecteur viral adéno-associé de type 2/6 recombinant (**rAAV6**), non-répliquant, exprimant un ADNc ciblant les paires de bases 447-461 du locus de l'albumine (en relation avec le site initial de transcription), fusionné au domaine hétérodimérique ELD de la nucléase FokI, sous le contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE) spécifique du foie et du promoteur de l'alpha1-antitrypsine humaine (ApoE/hAAT)

un vector de virus adeno asociado tipo 2/6 recombinante (**rAAV6**), no replicativo, que expresa un cDNA dirigido a unirse a los pares de bases 447-461 (en relación al sitio de iniciación de la transcripción) del locus de la albúmina, fusionado al dominio heterodimérico ELD de la nuclease FokI, bajo el control de una región de control hepático de la apolipoproteína E y el promotor de la alfa 1 antitripsina humana (ApoE/hAAT)

p.669 **ranuzifigenum civaparvovecum #**
-670 ranuzifigene civaparvovec *replace the description by the following one*
ranuzifigène civaparvovec *remplacer la description par la suivante*
ranuzifigén civaparvovec *sustitúyase la descripción por la siguiente*

a recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, expressing a cDNA that targets 468-485 bp of the albumin locus (relative to the transcription initiation site), fused to the obligate heterodimeric FokI nuclease domain ELD, under the control of an apolipoprotein E hepatic control region and human alpha-1-antitrypsin promoter (ApoE/hAAT)

vecteur viral adéno-associé de type 2/6 recombinant (**rAAV6**), non-répliquant, exprimant un ADNc ciblant les paires de bases 468-485 du locus de l'albumine (en relation avec le site initial de transcription), fusionné au domaine hétérodimérique ELD de la nucléase FokI, sous le contrôle d'une région de contrôle de l'apolipoprotéine E (ApoE) spécifique du foie et du promoteur de l'alpha1-antitrypsine humaine (ApoE/hAAT)

un vector de virus adeno asociado tipo 2/6 recombinante (**rAAV6**), no replicativo, que expresa un cDNA dirigido a unirse a los pares de bases 468-485 (en relación al sitio de iniciación de la transcripción) del locus de la albúmina, fusionado al dominio heterodimérico ELD de la nuclease FokI, bajo el control de una región de control hepático de la apolipoproteína E y el promotor de la alfa 1 antitripsina humana (ApoE/hAAT)

p.676 **selitrectinibum**
selitrectinib *replace the chemical name by the following one*
sélitrectinib *remplacer le nom chimique par le suivant*
selitrectinib *sustitúyase el nombre químico por el siguiente*

(2^2R,6*R*)-3^5-fluoro-6-methyl-**7-aza-**1(5,3)-pyrazolo[1,5-*a*]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one

(2^2R,6*R*)-3^5-fluoro-6-méthyl-**7-aza-**1(5,3)-pyrazolo[1,5-*a*]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one

(2^2R,6*R*)-3^5-fluoro-6-metil-**7-aza-**1(5,3)-pirazolo[1,5-*a*]pirimidina-3(3,2)-piridina-2(1,2)-pirrolidinaciclooctafan-8-ona

p.688 **tefidsogenum civaparvovecum #**
-689 tefidsogene civaparvovec *replace the description by the following one*
téfidsogène civaparvovec *remplacer la description par la suivante*
tefidsogén civaparvovec *sustitúyase la descripción por la siguiente*

a recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, which contains a promoter-less human iduronate 2-sulfatase (hIDS) transgene cassette, encoding parts of exon 1 plus exons 2-9 from hIDS and a splice acceptor site (SA) derived from human coagulation factor IX (hF9, factor IX or FIX) exon 2, flanked by a sequence homologous to the zinc-finger nuclease (ZFN) cleavage site of the human albumin (hALB) intron 1

vecteur viral adéno-associé de type 2/6 recombinant (**rAAV6**), non-répliquant, contenant la cassette du transgène de l'iduronate 2-sulfatase humaine (hIDS) sans promoteur, codant partiellement l'exon 1 et les exons 2-9 de hIDS, et la séquence du site accepteur (SA) d'épissage dérivé de l'exon 2 du facteur de coagulation IX humain (hF9, facteur IX, FIX), flanqué d'une séquence homologue au site de clivage de la nucléase à doigts de zinc (ZFN) de l'intron 1 de l'albumine humaine (hALB)

un vector de virus adeno asociado tipo 2/6 recombinante (**rAAV6**), no replicativo, que contiene un casete con el transgen de la iduronato 2-sulfatasa humana (hIDS) sin promotor, que codifica para partes del exón 1 más los exones 2-9 de hIDS y un sitio aceptor del splicing derivado del exón 2 del factor de coagulación IX humano (hF9, factor IX o FIX), flanqueado por una secuencia homóloga al sitio de rotura por la nuclease con dedos de zinc (ZFN) del intron 1 de la albúmina humana (hALB)

Recommended International Nonproprietary Names (Rec. INN): List 83
Dénominations communes internationales recommandées (DCI Rec.): Liste 83
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 83
(WHO Drug Information, Vol. 34, No. 1, 2020)

p.25 -26 **avalotcagenum ontaparvovecum #**
avalotcagene ontaparvovec *replace the description by the following one*
avalotcagène ontaparvovec *remplacer la description par la suivante*
avalotcagén ontaparvovec *sustitúyase la descripción por la siguiente*

A recombinant non-replicating adeno-associated virus type 2/8 (**rAAV8**) vector, encoding codon-optimized, wild-type human ornithine transcarbamylase (OTC) under the control of a hybrid human thyroxine-binding globulin (TBG) / human alpha 1-microglobulin/bikunin precursor (AMBP) promoter/enhancer. The vector genome is a head-to-head dimer, with the vector genome cassette located 5' of the mutated internal inverted terminal repeat (ITR) in a reverse orientation and the vector genome cassette located 3' of the mutated internal ITR in a forward orientation.

vecteur viral adéno-associé de type 2/8 recombinant non-répliquant (**rAAV8**), codant pour l'ornithine transcarbamylase humaine sauvage (OTC) avec des codons optimisés, sous le contrôle de l'activateur/promoteur hybride de la globuline liant la thyroxine (TBP) humaine /précurseur de microglobuline alpha 1 / bikunine (AMBP). Le génome du vecteur est un dimère en tête à tête avec la cassette contenant le génome du vecteur en position 5´ de la séquence inverse terminale répétée (ITR) interne et mutée dont l'orientation est inverse et la cassette contenant le vecteur du génome en position 3´ de l'ITR interne et mutée dont l'orientation est vers l'avant

Un vector de virus adenoasociado recombinante no replicativo del serotipo 2/8 (**rAAV8**), que codifica para la ornitina transcarbamilasa silvestre humana (OTC) con codones optimizados, bajo el control de un promotor/potenciador híbrido de la globulina fijadora de tiroxina humana (TBG) / precursor de microglobulina alfa 1 humana/bicunina (AMBP). El genoma del vector es un dímero de cabeza con cabeza, con el casete del genoma del vector en posición 5' a la repetición terminal invertida (ITR) interna y mutada localizado en orientación inversa. y el casete del genoma del vector en posición 3' a la ITR localizado en orientación hacia adelante.

p.49 **epcoritamabum #**

epcoritamab *replace the structure by the following one*
épcoritamab *remplacer la structure par la suivante*
epcoritamab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVKLVESGGG LVQPGGSLRL SCAASGFTFN TYAMNWVRQA PGKGLEWVAR  50
IRSKYNNYAT YYADSVKDRF TISRDDSKSS LYLQMNNLKT EDTAMYYCVR 100
HGNFGNSYVS WFAYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP EFEGGPSVFL 250
FPPKPKDTLM ISRTPEVTCV VVAVSHEDPE VKFNWYVDGV EVHNAKTKPR 300
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ 350
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFLLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS 450
LSPG                                                    454
```

Light chain / Chaîne légère / Cadena ligera (anti-CD**3**E)

```
QAVVTQEPSF SVSPGGTVTL TCRSSTGAVT TSNYANWVQQ TPGQAFRGLI  50
GGTNKRAPGV PARFSGSLIG DKAALTITGA QADDESIYFC ALWYSNLWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS                                        215
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-**MS4A1**)

```
EVQLVESGGG LVQPDRSLRL SCAASGFTFH DYAMHWVRQA PGKGLEWVST  50
ISWNSGTIGY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKDI 100
QYGNYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEFE GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVA VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera (anti-**MS4A1**)

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ 100
GTRLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-98 152-208 269-329 375-433
22"-96" 149"-205" 266"-326" 372"-430"
Intra-L (C23-C104) 22'-90' 137'-196'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 228-214' 225"-214'"
Inter-H-H (h 11, h 14) 234-231" 237-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
305, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

p.55 **giroctocogenum fitelparvovecum #**

giroctocogene fitelparvovec *replace the description by the following one*
giroctocogène fitelparvovec *remplacer la description par la suivante*
giroctocogén fitelparvovec *sustitúyase la descripción por la siguiente*

A recombinant non-replicating adeno-associated virus type 2/6 (**rAAV6**) vector, encoding human B-domain-deleted blood coagulation factor VIII (hF8, FVIII) under the control of a synthetic liver-specific promoter.

Vecteur viral adéno-associé de type 2/6 recombinant non-répliquant (**rAAV6**), codant pour le facteur de coagulation sanguine VIII humain (hF8, FVIII), dont le domaine B a été supprimé, sous le contrôle d'un promoteur synthétique spécifique du foie.

Un vector de virus adenoasociado recombinante no replicativo del tipo 2/6 (**rAAV6**), que codifica para el factor de coagulación sanguíneo VIII humano (hF8, FVIII) con el dominio B delecionado, bajo el control de un promotor sintético específico del hígado.

p.63

supprimer	*insérer*
lététresgéne autoleucel	lététresgène autoleucel

p.132 **zildistrogenum varoparvovecum #**

zildistrogene varoparvovec	*replace the description by the following one*
zildistrogène varoparvovec	*remplacer la description par la suivante*
zildistrogén varoparvovec	*sustitúyase la descripción por la siguiente*

A recombinant non-replicating adeno-associated virus type 2/9 (**rAAV9**) vector, encoding human microdystrophin 5 (h-μD5) under control of CK8 muscle creatine kinase promoter and enhancer elements

vecteur viral adéno-associé de type 2/9 recombinant non-répliquant (**rAAV9**) codant pour la microdystrophine 5 humaine (h-mD5) sous le contrôle de l'activateur/promoteur de la créatine kinase musculaire CK8

Un vector de virus adenoasociado recombinante no replicativo del tipo 2/9 (**rAAV9**), que codifica para la microdistrofina 5 humana (h-mD5) bajo el control del promotor y elementos potenciadores (enhancer) de la creatina quinasa CK8 de músculo.

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.

<table>
<tr><td>化学名・別名</td><td>ダトポタマブ　デルクステカンは、抗体薬物複合体（分子量：約 152,000）であり、遺伝子組換えモノクローナル抗体の平均 4 個のシステイン残基に、カンプトテシン誘導体とリンカーからなるデルクステカン（(3RS)-1-[(10S)-10-ベンジル-1-{[(1S,9S)-9-エチル-5-フルオロ-9-ヒドロキシ-4-メチル-10,13-ジオキソ-2,3,9,10,13,15-ヘキサヒドロ-1H,12H-ベンゾ[de]ピラノ[3',4':6,7]インドリジノ[1,2-b]キノリン-1-イル]アミノ}-1,6,9,12,15,18-ヘキサオキソ-3-オキサ-5,8,11,14,17-ペンタアザトリコサン-23-イル]-2,5-ジオキソピロリジン-3-イル基（$C_{52}H_{57}FN_9O_{13}$；分子量：1,035.06））が結合している。抗体部分は抗細胞表面糖タンパク質 Trop-2 モノクローナル抗体であり、その相補性決定部はマウス抗体に、その他はヒト IgG1 に由来し、CHO 細胞により産生される。タンパク質部分は、451 個のアミノ酸残基からなる H 鎖（γ1 鎖）2 本及び 214 個のアミノ酸残基からなる L 鎖（κ 鎖）2 本で構成される糖タンパク質（分子量：約 148,000）である。

別名：ダトポタマブ　デルクステカン（遺伝子組換え）とその製剤</td></tr>
<tr><td>構造式</td><td>別紙のとおり</td></tr>
<tr><td>効能・効果</td><td>化学療法歴のあるホルモン受容体陽性かつ HER2 陰性の手術不能又は再発乳癌</td></tr>
<tr><td>用法・用量</td><td>通常、成人にはダトポタマブ　デルクステカン（遺伝子組換え）として 1 回 6 mg/kg（体重）を 90 分かけて 3 週間間隔で点滴静注する。初回投与の忍容性が良好であれば 2 回目以降の投与時間は 30 分間まで短縮できる。なお、患者の状態により適宜減量する。</td></tr>
<tr><td>劇薬等の指定</td><td></td></tr>
<tr><td>市販名及び有効成分・分量</td><td>原体：ダトポタマブ　デルクステカン（遺伝子組換え）
製剤：ダトロウェイ点滴静注用 100 mg
（1 バイアル中、ダトポタマブ　デルクステカン（遺伝子組換え）108 mg 含有）</td></tr>
<tr><td>毒性</td><td>急性毒性：
反復投与毒性試験で急性毒性情報を得られるため、ICH M3（R2）に準拠して、ダトポタマブ　デルクステカンの単回投与毒性試験は実施していない。

亜急性毒性、慢性毒性：
<table>
<tr><th>動物種</th><th>投与期間</th><th>投与経路</th><th>投与量 (mg/kg)</th><th>主な所見</th></tr>
<tr><td>ラット</td><td>3 ヵ月（1 回／3 週）</td><td>静脈内</td><td>20, 60, 200</td><td>いずれの投与量でも、死亡及び瀕死例は認められなかった。20 mg/kg 以上で胸腺、60 mg/kg 以上で腎臓、消化管、切歯、200 mg/kg で肺、皮膚、生殖器、リンパ造血器に毒性所見が認められた。いずれも重篤ではなく、精巣の変化を除き、可逆性が示されたことから、STD10[a] は 200 mg/kg より大きいと判断された。</td></tr>
<tr><td>サル</td><td>3 ヵ月（1 回／3 週）</td><td>静脈内</td><td>10, 30, 80</td><td>いずれの投与量でも、死亡及び瀕死例は認められなかった。10 mg/kg 以上で消化管、30 mg/kg 以上で肺、角膜、皮膚、胸腺、肝臓、80 mg/kg で腎臓、股関節軟骨に毒性所見が認められた。肺、角膜、皮膚の一部所見を除き、可逆性が示された。重篤な肺毒性が 30 mg/kg 以上で観察されたことから、HNSTD[b] は 10 mg/kg と判断された。</td></tr>
<tr><td colspan="5">a: severely toxic dose in 10% of the animals（10%の動物に重篤な毒性が発現する投与量）、b: highest non-severely toxic dose（重篤な毒性が発現しない最大投与量）</td></tr>
</table></td></tr>
<tr><td>副作用</td><td>＜化学療法歴のあるホルモン受容体陽性かつ HER2 陰性の手術不能又は再発乳癌＞
○国際共同第 III 相試験（TROPION-Breast01 試験［6.0 mg/kg（体重）投与］）
副作用（臨床検査値異常を含む）発現率: 93.6%（337/360 名）
副作用（臨床検査値異常を含む）の種類: 悪心（184/360 名）、口内炎（180/360 名）、脱毛症（131/360 名）、疲労（85/360 名）、ドライアイ（78/360 名）</td></tr>
</table>